|
|
·|û¡Ghung120110149413 µoªí®É¶¡:2020/6/24 ¤U¤È 02:11:23
|
¥«³õº¨£·sÃÄ(¥þ²y¥«³õ¨C¦~¬ù350-400»õ¬ü¤¸) Àø®Ä¤ÀªR p=0.009 6634 ªYÄ£ ªÑ¥»: 3.832»õ ¥Dn·~°È: ¨xŦ¯e¯fªvÀø¤Î¯kµhªvÀø¬ÛÃöÃĪ«¬ã¨s¤Î¶}µo ¸³ºÊ«ùªÑ¤ñ¨Ò: 21.7%(¼W¥[¤¤) ¥~¸ê«ùªÑ¤ñ¨Ò: 0.22%(¼W¥[¤¤) Ä~Äò©¹¤U¬Ý...! ============================================================================= ²£«~01¡GSNP-610 (ªvÀø¯×ªÕ¨x¯e¯f·sÃÄ) ¾AÀ³¯g: «D°sºë©Ê¯×ªÕ¨xª¢ ²£«~Àu¶Õ: 1.¥Ø«e©|µL¼Ð·ÇªvÀøÃĪ« 2.¥«³õº¨£·sÃÄ(First-in-class) 3.¦P®É¥i¥Î©ó°sºë©Ê©M«D°sºë©Ê¯×ªÕ¨x 4.µL¦w¥þ©Ê°ÝÃD ¥«³õ: «D°sºë©Ê¯×ªÕ¨xª¢¥þ²y¥«³õ¨C¦~¬ù350-400»õ¬ü¤¸¡C Ävª§¤O: 1.¦h«§@¥Î¾÷Âà:ªvÀø¤Î¹w¨¾¯×ªÕ¨xª¢ 2.ª½±µ§@¥Î©ó¨xŦ¡AªvÀø¯×ªÕ¨xª¢¡A°§C¨x¯× 3.¥i´£¥X¨uÃĥӽСAÀ³¥Î©óªvÀø§³®W«æ©Ê¯×ªÕ¨x ¬ãµo¶¥¬q: 1.¤w³q¹LUSFDA¤ÎTFDA¼f¬d¶i¤JÁ{§É¤G´Á 2.Á{§ÉÀø®Ä¤Î·sªvÀø¾÷ÂàÅçÃÒ Àø®Ä¤ÀªR¡G 1.²Ä¤@´ÁÁ{§É¸ÕÅç¡Gµ²ªGÅã¥Ü¤HÅé¨Ï¥Î¦w¥þ¡A©Ê½è¨}¦n 2.²Ä¤G´ÁÁ{§É¸ÕÅç¨ä¤¤¤ÀªR¡G17¦ìNASH ¯f¤H (p=0.009) ============================================================================= ²£«~02¡GSNP-630 ¾AÀ³¯g:«D°sºë©Ê¯×ªÕ¨xª¢ ²£«~Àu¶Õ: 1.¬°Àu¤Æ(Optimized)¤§·s¤Æ¾Ç¹êÅé(NCE) 2.¥«³õº¨£·sÃÄ(First-in-class) 3.¦P®É¥i¥Î©ó°sºë©Ê©M«D°sºë©Ê¯×ªÕ¨x 4.§@¬°²Ä¤@¥N²£«~¤W¥««áªº±µÄò¦û¦³¥«³õ¤§²£«~ ¥«³õ: «D°sºë©Ê¯×ªÕ¨xª¢¥þ²y¥«³õ¨C¦~¬ù350-400»õ¬ü¤¸¡C Ävª§¤O: 1.¦h«§@¥Î¾÷Âà:ªvÀø¤Î¹w¨¾¯×ªÕ¨xª¢ 2.ª½±µ§@¥Î©ó¨xŦ¡AªvÀø¯×ªÕ¨xª¢¡A°§C¨x¯× 3.Àu¤ÆªºÀø®Ä±j«×¡B§@¥Î®É¶¡ 4.µL¦w¥þ©Ê°ÝÃD ¬ãµo¶¥¬q: 1.Á{§É«e 2.¹w©w¥Ó½Ð¬ü°êFDAIND¡B§Ö³t³q¹D(fasttrack)¡C 3.¥Ó½Ð¬ü°ê¬ð¯}©ÊªvÀø(breakthrough therapy)ªº»{©w¡C Àø®Ä¤ÀªR¡G 1. ¥Ø«e¦b°Êª«¤W¥H¤£¦P¾¯¶q¶i¦æ¸ÕÅç¡Aµ²ªGÅã¥Ü p<0.05 ============================================================================= ²£«~03¡GSNP-810 (µL¨x¬r©Ê¤îµh·sÃÄ¡B¸Ñ¬r¾¯) ¾AÀ³¯g: µL¨x¬r©Ê¤AñQÓi×ô¤îµhÃÄ (¸Ñ¼öÂíµh¾¯) ²£«~Àu¶Õ: 1.¦w¥þ¤Æ¦Xª«·s²Õ¦X¡BµL¨x¬r©Ê 2.¸Ñ¨M¢¤ÁÂåÀø»Ý¨D (Important urgent unmet medical needs) 3.¦³¾¯«¬±M§Q¡A¦w¥þ½d³ò¤j¡A¥iקï©Î§R°£FDA¨x¬rĵ»y¥i¼W¥[¾¯¶q ¥«³õ: ¤AñQÓi×ô¶È¦b¬ü°ê¤@¦~´N¦³40»õ¬ü¤¸ªº¥«³õ Ävª§¤O: 1.¥«³õ¤WµLÃþ¦üµL¨x¬r©Ê¤§Ävª§ÃĪ« 2.¥i§ð¦û¼s¤j¥«³õ¡]NSAID, COX-2 §í¨î¾¯¡BOpioidsÃþ¤îµhÃÄ¥«³õ¡^ 3.¥i¬Ù°£¶D³^¶O¡B±Ð¨|°V½m¶O ¬ãµo¶¥¬q: 1.¤w§¹¦¨§C¾¯¶q¡B°ª¾¯¶qÁ{§É¸ÕÅç 2.¤w¥Ó½ÐUSFDA¼Ï纽Á{§É¸ÕÅç¡B±N¥Ó½Ð¬ð¯}©Ê¼f¬d/§Ö³t³q¹D 3.µL¨x¬r©Ê¤AñQÓi×ô¸Ñ¬r¾¯¦¨¤À¡A¤w¥Ó½Ð¬dÅçµn°O¥Î¤§Á{§É¸ÕÅç ============================================================================= ²£«~04¡GSNP-830/ SNP-840 ¾AÀ³¯g: µL¨x¬r©Ê¤AñQÓi×ô¤îµhÃĽƤè(ªvÀø¤¤¡B««×¯kµh) ²£«~Àu¶Õ: 1.µL¨x¬r©Ê¤AñQÓi×ôªº½Æ¤è 2.¦³¾¯«¬±M§Q¡A¦w¥þ½d³ò¤j¡A¥iקï©Î§R°£FDA¨x¬rĵ»y¡A¥i¼W¥[¾¯¶q ¥«³õ: ¤AñQÓi×ô³B¤èÃĦb¬ü°ê¤@¦~´N¦³27»õ¬ü¤¸ªº¥«³õ Ävª§¤O: 1.¥«³õ¤WµLÃþ¦üµL¨x¬r©Ê¤§Ävª§ÃĪ«½Æ¤è 2.½Æ¤è¤w¥Ñ¬ü°êFDAn¨D°¾¯¶q§C©ó325²@§J¡A±N¼vÅTÀø®Ä 3.¦³¨Ï¥Î±M§Q¡A¥iקï©Î§R°£FDA¨x¬rĵ»y 4.¥i¼W¥[¤AñQÓi×ô¾¯¶q ¡]¥Ñ325mg ¦^´_¦Ü500 mg¬Æ¦Ü§ó°ª¡A·|¸û¦³®Ä¡^¥H¼W¥[Àø®Ä¡A©Î´î¤ÖOpioids¾¯¶q¡A°§C¦¨Å}°Æ§@¥Î 5.¤GªÌ¾Ü¤@±ÂÅv 6.¥i¼W¥[¥«¦û²v ¬ãµo¶¥¬q: 1.SNP-810¨ú±oÃÄÃÒ«á¡A¶i¦æÁ{§É¸ÕÅç§t¬Ûµ¥©Ê¸ÕÅç SNP-830 ¤£¬O ·s¦¨¤À ªº·sÃÄ¡A©Ò¥H¤£»Ýn¶i¦æ²Ä¤@¡A¤G¤Î¤T´ÁÁ{§É´úÅç µ¥ SNP-810 ®³¨ìÃÄÃÒ«á¡A¥H ·sÀø®Ä½Æ¤è¶i¦æÁ{§É¸ÕÅç§t¬Ûµ¥©Ê´úÅç ´N¥i¥HÀò±oÃÄÃÒ ============================================================================= ***************************************************************************** SNP-8 ¨t¦C Àø®Ä¤ÀªR¡G 1. ¦b°Êª«¤W¥H¤£¦P¾¯¶q¶i¦æ¸ÕÅç¡Aµ²ªGÅã¥Ü p<0.005 1. ¤w¸g§¹¦¨¤§¤HÅé¸ÕÅç¡Aµ²ªGÅã¥Ü p<0.005 ============================================================================= ***************************************************************************** ¥¼¨Ó¥Ø¼Ð±ÂÅv¥D¤O²£«~¡G 1. ¯×ªÕ¨xÃÄ¡GSNP-610 ©M SNP-630 ¦U¦³ÀuÂI¡A¥Ø¼Ð¬°¥þ²y±ÂÅv 2. ¤îµhÃÄ(OTC): SNP-810, ¥Ø¼Ð¬°¬ü°ê¤Î¥þ²y±ÂÅv 3. ¤îµhÃÄ(³B¤èÃÄ): SNP-830 ¤Î SNP-840, ¦b°Êª«¤W¬Ò¦³¥¿±ªºµ²ªG¡A¥Ø¼Ð¬°¥þ²y±ÂÅv ============================================================================= ***************************************************************************** ¥Ø«e¤½¥q»P°ê»Ú¤j«¬Ãļt¥¿¦b½Í§Þ³N±ÂÅv©M¦X§@p¹º §Ú¬Ý¹L¤½¥q©xºô©M©Ò´£¨Ñªº¸ê®Æ¡Aı±o¤½¥q«Ü¥Î¤ß¦b¸gÀç¡A¦Ó¥B¸ê®Æ¤]«Ü¸Ô²Ó ¹ï¤½¥qµo®i«Ü¦³¦Û«H¡A¥¼¨ÓªÑ»ùȱo´Á«Ý¡A¦³¾÷·|¬O ¤U¤@Ó ¦X¤@ ÄÆªÑ ----------------------------------------------------------------------------- ¥H¤W¸ê®Æ ³£°Ñ¦Ò ªÑªF·|ij¨Æ¿ý.pdf ©M ¤½¥q©xºô (¦³¿³½ìµÛÅwªï¦A²`¤J¬ã¨s»P°Q½×) |
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/28 ¤W¤È 09:00:43²Ä 613 ½g¦^À³
|
2020-12-29ºô¸ôÁ¿®y§ó·s¡uÅé¥~¿zÀËÃĪ«©Ê¨xŦ·l¶Ëªº¤èªk¡G´î¤ÖÃĪ«¶}µo¦´Á¤§·l¯Ó¡v ÃĪ«¤Þ°_ªº¨xŦ·l¶Ë(drug-induced Liver Injury, DILI)¬OÁ{§É¸ÕÅ礤¾ÉPÃĪ«¥¢±Ñªºì¦]¤§¤@¡A¤]¬OÃĪ«°h¥X¥«³õªº¥Dnì¦]¡C nehrc.nhri.org.tw/taat/news.php?cat=knowledge&id=112 |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/28 ¤W¤È 08:26:34²Ä 612 ½g¦^À³
|
¤jÃļt¤â¤W¤@°ï¦]ÃĪ«©Ê¨x·l¶Ë¢Ò¢×¢Ú¢×¡^¦Ó¤¤Â_©Î²×¤îªºÃĪ«¡C ¬JµM[ªYÄ£ªº§Þ³N¥¥x]¯à¸Ñ¨M§x´o60¦h¦~ªºÃøÃD¡A¤jÃļt¥i¯à¤£·|·Qn[ªYÄ£¥¥x]¸Ñ¨M¨ä¥LÃĪ«ªº¨x¬r©Ê? ªYÄ£¥H[¨xŦ¥NÁÂ酶]»P[°ò¦]½Õ±±§Þ³N]¶}µoÃĪ«¡A¦¹ºØ§Þ³N¥iÀ³¥Î©ó¥i¯à¾ÉP¨x¬r©Ê¤§ÃĪ«¥H¤Î¨xŦ¯e¯f(NASH)¤§ªvÀø¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/27 ¤U¤È 11:28:50²Ä 611 ½g¦^À³
|
ªYÄ£ªº§Þ³N¥¥x¤£¬O«]¦b¸Ñ¨M¤AñQÓi×ô¡]Acetaminophen¡^ªº¨x¬r©Ê¡A ¦Ó¬OÂX¤Î¨ä¥LÃĪ«! ¢Ò¢×¢Ú¢×¤w ¦¨ 为 过 ¥h¢´¢¯¦~药ª«¦]¦w¥þ©Ê问题ºM¥«ªº³Ì±`见ì¦]! ¸U¤@°ê»Ú¤jÃļt¤£¥un±ÂÅvSNP-810¦Ó¬O³s§Þ³N¥¥x¤@¨Ö±ÂÅv¡A¨º»ò±ÂÅvª÷? -------------------------------------------------- -------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2020/7/27 ¤U¤È 11:03:07²Ä 219 ½g¦^À³ ¤w¬¢¸ß©Î¬¢°Ó¤¤¤§¥i¯à¦X§@±ÂÅv¹ï¶Hwww.sinewpharma.com/upload/userfiles/file/About%20us/About+Us.pdf .................................................. .............................. ¥¼¨Ó®i±æ 37/43 6. ±´°Q¡B×¹¢¦]¨x¬r©Ê¦Ó¨î¨Ï¥Î©Î°±¤î¶}µoªº¦UÃþ«n·sÃÄÃD ---------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2020/7/28 ¤W¤È 11:46:12²Ä 224 ½g¦^À³ 药ª«©Ê¨x损伤¡]¢Ò¢×¢Ú¢×¡^Á¬B¬Ò¬O! ¢Ò¢×¢Ú¢×¤w ¦¨ 为 过 ¥h¢´¢¯¦~药ª«¦]¦w¥þ©Ê问题ºM¥«ªº³Ì±`见ì¦] ¢±¢¯¢°¢²¦~¬ü国¢Ô¢Ò¢Ï 药ª«©Ê¨x损伤«ü«n¤¶绍 ¤@¡B«e¨¥ ¥»«ü«n¥Nªí¬ü国¹«~药«~监·þºÞ²z§½¡]¢Ô¢Ò¢Ï¡^当 «e 对 药 ª«©Ê¨x损伤¡]¢Ò¢×¢Ú¢×¡^问题ªº观点¡A¦®¦bûñ§U医药产业©M¨ä¥L进¦æ·s药¬ã发¤H员评¦ô药ª«¤Þ°_严«¨x损伤¡]P©R©Î»Ý±µ¨ü¨x²¾´Óªº¤£¥i°fªº¨x°IºÜ¡^ªºýͦb风险¡C ¤G¡BI´º¡G药ª«©Ê¨x损伤 ¢Ò¢×¢Ú¢×¤w ¦¨ 为 过 ¥h¢´¢¯¦~药ª«¦]¦w¥þ©Ê问题ºM¥«ªº³Ì±`见ì¦]¡]¦pÉݤþ肼¡B´À¥§»Ä¡B¥» 恶 ¬¥ ªâ¡B·Í ªâ »Ä¡B¦± ®æ ¦C ଡB¥§ ªk Ðüଵ¥¡^¡C药ª«¤W¥«¦Z发现ªº¨x脏¬r©Ê¤]会¨î«Ü¦h药ª«ªº¨Ï¥Î¡A¦pÉÝýç肼¡B©Ô贝¬¥ûØ¡B¦±¥ï¨F¬P¡B¦«¥dªB¡B«DûØ®ò¯×µ¥¡C¦³¨Ç药ª«¦b欧¬w¤W¥«¦Z发现¤F¨ä¨x¬r©Ê¡]¦pÉݤBªâ»Ä¡B哌§J©õªL¡Bªüým©Z¡^¦Ó¥¼获¬ü国§åã¡C¤@¨Ç药ª«¦b¤W¥««e¬ã¨s¤¤¥X现¤F¥i导Pýͦb严« ¢Ò¢×¢Ú¢×ªº证Õu¡]¦p¦a来¬¥ûØ¡A¥L¯Á¨F©Z¡A§Æ¬ü¥[¸s¡^¦Ó¥¼获¦U国§åã¤W¥«¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/27 ¤U¤È 11:15:36²Ä 610 ½g¦^À³
|
¨È·à±dªºASLAN003¦b¦PÃþDHODH§í»s¾¯¤¤ªí²{³Ì§Cªº¨x¬r©Ê¡A¬Q¤Ñº¦20%+¡C ÃĪ«»¤µoªº¨x·l¶Ë¡]DILI¡^¬O¤W¥««e©M¤W¥««áÃĪ«®ø¯Óªº¥DnÅX°Ê¤O¡A³q±`·|ªýê¥iªvÀø¤Æ¦Xª«ªº¶}µo¡C --------------------------------------------------------------------------------------------- ¨È´µÄõ»sÃĦ³¤½¥q 2021¦~1¤ë26¤é¡A¬P´Á¤G¡A±ß¤W8:30 ¡X ³Ì·s¬ã¨sªí©ú¡AASLAN003¾¨ºÞ¬O³Ì¦³®ÄªºDHODH§í»s¾¯¤§¤@¡A¦ý¨ä¨x¬r©Ê¼ç¤O³Ì§C¡C ¡X ¼Æ¾Ú¨ÏASLAN003»P²Ä¤@¥NDHODH§í»s¾¯©M¦PÃþ¤¤ªº¨ä¥LÃĪ«°Ï¤À¶}¨Ó¡A¤ä«ù¨ä¦¨¬°ªvÀø¦Û¨§K¬Ì©Ê¯e¯fªº¦PÃþ³Ì¨ÎDHODH§í»s¾¯ªº¼ç¤O 2021¦~1¤ë26¤é¡A·s¥[©Y·s¥[©Y-¥þ²y»â¥ýªºÁ{§É¶¥¬q§K¬Ì¾Ç¥Íª«»sÃĤ½¥qASLAN Pharmaceuticals¡]¯Ç´µ¹F§JªÑ²¼¥N½X¡GASLN¡^¤µ¤Ñ«Å¥¬¡A¥Ñ¤j¾Ç¶i¦æªº¤@¶µ¬ã¨sªº·s¼Æ¾Ú^°ê§Qª«®úªº¡mÅé¥~¬r²z¾ÇÂø»x¡n¤Wµoªíªº½×¤åªí©ú¡A¦b´ú¸Õªº¤»ºØ¤G²B¨Å²M»Ä²æ²B酶¡]DHODH¡^§í»s¾¯¤¤¡AASLAN003¾¨ºÞ¬O³Ì¦³®ÄªºDHODH§í»s¾¯¤§¤@¡A«o¨ã¦³³Ì§Cªº¨x¬r©Ê¼ç¤O¡C ÃĪ«»¤µoªº¨x·l¶Ë¡]DILI¡^¬O¤W¥««e©M¤W¥««áÃĪ«®ø¯Óªº¥DnÅX°Ê¤O¡A³q±`·|ªýê¥iªvÀø¤Æ¦Xª«ªº¶}µo¡Cªñ¦~¨Ó¡A¦³Ãö¨Ï¥Î²Ä¤@¥NDHODH§í»s¾¯¡]¨Ó¬t¦Ì¯S©M¯S¬t¦Ì¯S¡^ªº¦w¥þ©Ê°ÝÃD¤w¸g¤Þ°_Ãöª`¡A¬ü°ê¹«~©MÃĪ«ºÞ²z§½¤wµo¥¬¤F°w¹ï¨x¬r©Êªº¶Â²°Äµ§i¡C ¥@¬É»â¥ýªº¨x¬r©Ê¬ã¨s¤¤¤ß§Qª«®ú¤j¾Çªº¬ì¾Ç®a¶i¦æ¤F¤@¶µ¬ã¨s¡A¥Hµû¦ô¦b¨âºØ²{¦¨ªº¨xÅé¥~¼Ò«¬¤¤¤@²Õ¤»ºØDHODH§í»s¾¯ªº¨x¬r©Ê¼ç¤O¡C¦b¤@ºØ¼Ò«¬¤¤¡AASLAN003¾¨ºÞ¬O³Ì¦³®ÄªºDHODH§í»s¾¯¤§¤@¡A¦ý³QÃÒ©ú¬O¬r©Ê³Ì§Cªº¤Æ¦Xª«¡A¦Ó¯S¥ß¬tÓi©M¨Ó¬t¦Ì¯S¦P¼Ë¬O¬r©Ê³Ì°ªªº¤Æ¦Xª«¡C¼Æ¾Ú¶i¤@¨Bªí©ú¡AASLAN003ªº¬¡©Ê¦b¾÷²z¤W¤£¦P©ó»P¨Ó¬t¦Ì¯S©M¯S¬t¦Ì¯S¬ÛÃöªº¨x¬r©Ê¡A¨Ã»P¨´¤µ¦bÁ{§É¸ÕÅ礤¹ïASLAN003ªº@¨ü©Ê¨}¦nªºÆ[¹îµ²ªG¤@P¡C³o¨Ç¼Æ¾Ú¥[¦b¤@°_ªí©ú¡A¸Ó¬ã¨s¤¤Æ[¹î¨ìªº¬r©Ê¥i¯à»P¸Ó¤Æ¦Xª«¹ïDHODHªº®Ä¤OµLÃö¡A¨ÃÃÒ¹êASLAN003¦³¼ç¤O¦¨¬°ªvÀø¦Û¨§K¬Ì©Ê¯e¯fªº¦PÃþ³Ì¨ÎÃĪ«¡C ¦bÁ{§É«e¬ã¨s¤¤¡A¤wÃÒ©úASLAN003¦b¦hºØ¦Û¨§K¬Ì©Ê¯e¯f°Êª«¼Ò«¬¤¤¦³®Ä¡CASLAN¥¿¦b³Ì²×½T©w¦Û¨§K¬Ì©Ê¯e¯fASLAN003ªºÁ{§É¶}µop¹º¡A¸Ó¤½¥q¹wp±N¦b2021¦~ªì¤À¨É§ó¦h²Ó¸`¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/27 ¤U¤È 11:04:43²Ä 609 ½g¦^À³
|
FDAªº¨î±¹¬I/´CÅé³ø¾É...¡AAPAP¥«³õ³Q«I»k¾P°âÃB¤@¸ô´î¡C ¼Ï¯Ã¸ÕÅç¥Øªº: 1.¹êÃÒSafeTynadol®(SNP-810)ªº¦w¥þ©Ê¥Ó½ÐFDA¬ð¯}©ÊªvÀø¡A¥Ó½Ðקï¥é³æ¤º®e(µL¨x¬r©Ê¡A¥]¸ËµL»Ý¥[µùĵ»y¡A¥i ´£°ª¤AñQÓi×ô¾¯¶q¡A¤£¨ü325mg¼W¶iÀø®Ä....¥þ±¨ú¥N¨ã¨x¬r©ÊªºAPAP¥«³õ 2.´£°ªSNP-810ªºAPAP¾¯¶q(500mg~1000mg§ó¦³®Ä)·m¦^³QNSAIDªü´µ¤ÇÆF,COX-2§í¨î¾¯OpioidsÃþ«I»kªº¥«³õ --------------------------------------------------------------------------------------------- ALF«æ©Ê¨x¥\¯à°IºÜ: 1¤äAPAPÃĪ«(46%) VS 1,036¤äÃĪ«(11%) ·í¥«³õ¥X²{¦w¥þµL¨x¬rª©¥»ªºAPAP¡AFDA·|¦p¦ó¸Ñ¨M[¨´¤µ¬°¤î³Ì¦MÀIªºÃĪ«]³y¦¨ªº¨x¬r©Ê°ÝÃD??? |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/27 ¤U¤È 10:42:02²Ä 608 ½g¦^À³
|
ªñ¦~Ãö¨Æ°È¦h¡A¬Q¤é»P¤µ¤Ñ¡AÓ¤H¥¼µo¤@§L¤@¨ò¡A! ¹j¤é¨RªÌ®ø®§±q¨º¨Ó? |
|
|
·|û¡G¾¾¹À©OÎN¹À«¡10150521 µoªí®É¶¡:2021/1/27 ¤U¤È 10:13:44²Ä 607 ½g¦^À³
|
¤¸¤j·s¦Ë¸g°ê¡A¬Q¤Ñ¦¬½L«e¡A¶R¶i68±i¡A§¡»ù88.33¡A¤µ¤Ñ½æ¥X66±i¡A§¡»ù104.63¡C ®Ú¾ÚIMS Health ²Îp¸ê®ÆÅã¥Ü¥þ¬üAcetaminophen ÃÄ«~¥«³õ¾P°âÃB¦Û 2015 ªº 35.6 »õ¡A ³v¦~¤U°¦Ü 2018 ªº 22.2 »õ¡C¨ä¤¤¡A³B¤èÃĦû 14.8»õ (ÃÄ«~¾P°â¶q¦û 67%)¡A«D³B¤èÃÄ OTC ¦û 7.4»õ (ÃÄ«~¾P°â¶q¦û 33%) ¡C OTC ¤§¤¤¡A McNeil ¤½¥q ³Ì¦h¡A¬° 3.0 »õ¡A GSK ¦³ 6700 ¸U¡C McNeil 3.0 »õ ¤¤¡A OTC ³æ¤è¦û 2.2 »õ¡A¨ä¤¤¥H Tylenol extrastrength 500 mg ³Ì¦h¡A¦û 1.1»õ¡C |
|
|
·|û¡Gmeetav10144056 µoªí®É¶¡:2021/1/27 ¤U¤È 08:17:28²Ä 606 ½g¦^À³
|
¬Q¤Ñ¤â¸}§Öªº¤µ¤Ñ¤]«Ü§Ö¡A¼F®`³á¡I |
|
|
·|û¡Gªü§»10146981 µoªí®É¶¡:2021/1/27 ¤U¤È 05:54:39²Ä 605 ½g¦^À³
|
¤µ¤Ñªºªí²{ªêÀY³D§À¡A®M¤F¤@°ï°l»ùªº¡A¨S·Q¨ì«Ü¦h¤H°µ¨º»òµu🤔¡A§Ú¤]¤W¬Ý300¥H¤Wªº¡C😁 |
|
|
·|û¡G¦h¦h10137435 µoªí®É¶¡:2021/1/27 ¤U¤È 03:35:19²Ä 604 ½g¦^À³
|
¬Q¤é«°T: ¥Ø«e¤w³q¹L¬ü°êFDA¼f¬d¨Ã¨ú±o¬ü°ê¥«³õ ¾P°â¸ê®æ¡C¹ê»Ú¤W¥«¾P°â®É¶¡µø»P¾P°â¤½¥qªº¨óij¦Ó©w ¬d¤F¤@¤UOTC ¦b¬ü°ê¥«³õ2018¦~¦û¾ãÅ饫³õ¬ù7.4»õ¬ü¤¸ ¦pªG·m¥e¤@¥b¥«¥e²v ¨ú¤À¼í10%,±ÄªYÄ£ªÑ¥»5E,³æOTC²£«~°^ÄmEPS20 ¥¼¨Ó·s¾¯«¬³q¹L»{ÃÒ,³B¤èÃĤ]·m¦û¤@¥b¥«³õ°^ÄmEPS¬ù40 ¦pªG¤À¼í¥i¥H½Í¨ì§ó°ª,¥B¥«¦û²v§ó°ª ¦³¾÷·|¨C¦~³Ð³yEPS 60°_¸õ ¥B¥þ¥@¬Éº³Ð ÁÙ¦³¼Ú¬wµ¥¦a¥«³õ ´N§â¥L·í¦¨«O°·¹«~ªÑ§a(¨þ¨þ!!) ¥»¯q¤ñ ¤£¥u¤Q¿§a~ ȱoªø´Á«ù¦³!!! |
|
|
·|û¡G¦h¦h10137435 µoªí®É¶¡:2021/1/27 ¤U¤È 02:33:35²Ä 603 ½g¦^À³
|
dk¤j,¤µ¤é¨«¶Õ·Pı¤W¥«ªº¬O·s¤f¨ý¥©§J¤O¿}, ¤£¬OÃÄ?!¯uªºµLªk§l¤Þ§ë¸ê¤H¥Ø¥ú~??? ¥i¯àn¶}µoªø¥Í¤£¦ÑÃÄ,©Î¬Oªø´¼¼zªºÃĤ~¦³¤H®ð!! |
|
|
·|û¡Gdk10140377 µoªí®É¶¡:2021/1/27 ¤U¤È 02:17:17²Ä 602 ½g¦^À³
|
¬Q¤Ñ¦³¤H¥ý¶R¨«¡A¤µ¤Ñ¤S¦º¤@°ï¦b¤s³»¡A ¬Ý±ÂÅvª÷§a¡A«½S´N¤j¼Q ¦³¹Ú³Ì¬ü¡A§Æ±æ¬ÛÀH¡C±ÂÅvª÷«¥¤ß¸Ì¤]¨S©³! ----------- ¥»¤H¤µ¤ÑÁÙ°l°ª....108¼Ó ¤µ¤é¨«¶Õ·Pı¤]¤£¬O«Ü±j,¥h¦~°ªÀÉ®M¨cªºÞ»î¤Ó¦h¤F ¥Í§ÞªÑ¤£¬O¥D¬y?!¥B§Ö¹L¦~¤F!,¨S¬Ý¨ì¯u¥¿ªºÅv§Qª÷¼Æ¦r ¥u¦nµ¥¤U¥hÅo~ ----------------------- |
|
|
·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2021/1/27 ¤U¤È 01:32:16²Ä 601 ½g¦^À³
|
5Áû¤jªGÁÙ¨S¦³¦Y¨ì¡A¥u¬O¤â§ì¨ì¤@Áû¡A³Û¤@Án¡G¡£§ì¨ì¤@Áû¤F¡I¡¤´Nªø¨ì100¤¸¤F¡F5Áû¥þ§ì¨ì¡E¦Y¨ì¡AÀ³¸Ó¦³300¢w1000¤¸¡A¤j®a¥[ªo¡I |
|
|
·|û¡G¦h¦h10137435 µoªí®É¶¡:2021/1/27 ¤U¤È 01:09:31²Ä 600 ½g¦^À³
|
¤µ¤é¨«¶Õ·Pı¤]¤£¬O«Ü±j,¥h¦~°ªÀÉ®M¨cªºÞ»î¤Ó¦h¤F ¥Í§ÞªÑ¤£¬O¥D¬y?!¥B§Ö¹L¦~¤F!,¨S¬Ý¨ì¯u¥¿ªºÅv§Qª÷¼Æ¦r ¥u¦nµ¥¤U¥hÅo~ |
|
|
·|û¡Gop123410143906 µoªí®É¶¡:2021/1/27 ¤W¤È 09:43:11²Ä 599 ½g¦^À³
|
®¥³ß§ë¸êªYÄ£¡A¤j®a¹L¦n¦~¡A¦n¹L¦~¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/27 ¤W¤È 06:38:51²Ä 598 ½g¦^À³
|
±ÂÅv¦¨¥\«á¡A¼Ï¯ÃÁ{§É¹êÅç®É¶¡·|«Üµu«Üµu! ¦]¬°¬O¦¬®×60¦ì[°·±d]¨ü¸ÕªÌ¡A§¹¦¨48¤H¡C(¥H¥¿±`¤H¶i¦æµL¨x¬r¸ÕÅç§Y¥i)---¤Ï˹³¬O¤@´ÁÁ{§É¡A¹w´Á6Ó¤ë~1¦~§¹¦¨¨S¬Æ¤j°ÝÃD! ¤]´N¬O¦¬¤Fñ¬ùª÷«á¡Aºò±µµÛ´N¥i¬Ý¨ì(¼Ï¯ÃÁ{§É)¨½µ{ª÷»P¾P°â¤À¼í..... ---------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/22 ¤W¤È 09:36:33²Ä 401 ½g¦^À³ ·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/15 ¤W¤È 08:43:49²Ä 396 ½g¦^À³ SNP-810ªº¼Ï¯Ã¸ÕÅç[µø±ÂÅv±¡§Î]??? ¹wp¦b¥xÆW(©Î°ê»Ú¦P®É)¦¬®×60¦ì°·±d¨ü¸ÕªÌ¡A§¹¦¨48¤H¡C(¥H¥¿±`¤H¶i¦æµL¨x¬r©Ê¸ÕÅç§Y¥i)¡A³o¬O¥»ÃĶ}µo¦¨¥\ªº·¥¤jÀuÂI¡C ¦A¨Óµ¥FDA®Öã¼Ï¯ÃÁ{§É¸ÕÅç? À³¸Ó´N¬O1ÓÂà±ÊÂI¡C(¯ÂÓ¤HÁr´ú!) ............................................................................................. ¬J¤wñq¦X§@¨óij¡AÀ³¸Ó¥xÆW»P°ê»Ú¦P®É¦¬®×¾÷²v«Ü°ª¡Aµ¥FDA®Öã¼Ï¯ÃÁ{§É¡A¦¬®×60¦ì°·±d¨ü¸ÕªÌ¡A§¹¦¨48¤HªºÁ{§É¹êÅç®É¶¡·|«Üµu«Üµu! |
|
|
·|û¡G¤p¤å¤l10144877 µoªí®É¶¡:2021/1/27 ¤W¤È 03:14:33²Ä 597 ½g¦^À³
|
¬ü°êFDA«D³B¤èÃÄ¡]OTC¡^§å㪺¹Lµ{¤jºõ §@ªÌ¡GDavid Hsu¡]®}§µ³®¡^ 11/13/2016 ©Ò¦³«D³B¤èÃIJ£«~ªºn¨D ¨âӥӽг~®| - OTC(«D³B¤èÃÄ) ¥ÑNDC·sÃĥӽС]NDA ³B¤èÃĥӽС^ - OTCÃĪ«±M½× (OTC Monograph) ©Ò¦³«D³B¤èÃÄ«~¦³¤°»òn¨D? - ¦w¥þ©Ê©M¦³®Ä©Ê¼Ð·Ç - ¨}¦n¥Í²£³W½d¡]ÀËÅç¡^ - ®Ú¾Ú21 CFR 201.66¼ÐÅÒ ¦w¥þ©Ê©M¦³®Ä©Ê OTC²£«~¼Ð·Ç - »P³B¤èÃĬۦPªº¼Ð·Ç - ®ø¶OªÌ¥²¶·¯à°÷¦Û§Ú¶EÂ_ - ¦Û§U - ¦Û§ÚºÞ²z - ¨ä¤¤¥i¥H³q¹Lµû¦ô³q¹L OTC¼ÐÅÒ - ¡§ÃĪ«¨Æ¹ê¡¨ - ¼Ð·Ç¤Æ¼ÐÅҮ榡 - ¦p¦P¡§Àç¾i¦¨¤À¼Æ¾Ú¡¨©M¡§¸É¥R¨Æ¹ê¼Æ¾Ú¡¨ - 21 CFR 201.66 - n¨DºI¦Ü2005¦~5¤ë OTC¼ÐÅÒ»P¼s§i - FDAºÞ¨îOTCÃĪ«¼ÐÅÒ - FD¡®Cªk¡G¡§¼ÐÅÒ¼ÐÅÒ¡¨¬O«ü©Ò¦³¼ÐÅÒ¡A©M¨ä¥L®Ñ±¡A¦L¨ê©Î¹Ï§Î¨Æ¶µ¡C 1.¥ô¦ó«D³B¤èÃÄ«~¥]¸Ë¤W©Î¥ô¦ó¨ä®e¾¹ 2.ªþ±aªº»¡©ú®Ñ - FTC½Õ¸`«D³B¤èÃļs§i - ¨S¦³¤½¤¹¥¿Ån¨D¡G¯q³B»Pĵ§i/¸T§Ò (FDA¸T¤î传¼½风险©M§Q¯qªº´Û骗©ÊÆΧi) ¥ÎNDA¤èªk¥Ó½ÐOTC - Rx¨ìOTCÂಾ - ¥þÂಾ¡]NDA补¥R¡^ - ³¡¤ÀÂಾ¡]·sNDA¡^ - ª½±µ¨ìOTC - ÉONDA¦³°¾®t¡]330.11¡^ - ¥é¨îÃÄ¡]ANDA¡^ µû½×OTC NDAs¬°«D³B¤èÃÄ - MAPP 6020.5R¡§¨}¦nªºµû»ù¹ê½î¡GOND - ¼f¬dIND©MNDAsªººÞ²z«D³B¤èÃIJ£«~ - ¨ãÅé¥DÃD¼f¬d¥q¡]SSMRD¡^¥i¥H¼f¬dÁ{§É¸ÕÅç - ¹|ODE-IV / Div¡C «D³B¤èÁ{§Éµû»ùºîz®ø¶OªÌ¦æ¬°¬ã¨s©M¤W¥««á¦w¥þ¼Æ¾Ú NDA»POTC±MµÛ¬yµ{¤ñ¸û NDA¹Lµ{ OTC±MµÛ¬yµ{ ¤W¥««e¼f§å ¨S¦³¤W¥««e¼f§å «O±K¤å¥ó ¤½¦@¹Lµ{ ÃÄ«~ ¯S²§©Ê¬¡©Ê¦¨¤À ²£«~ ¦¨¤À¯S²§©ÊOTCÃĪ«Ãþ§O ¥i¯à»Ýn¥Î¤á¶O µL¥Î¤á¶O Àç¾P±Æ¥L©Êªº¼ç¤O ¨S¦³Àç¾P±Æ¥L©Ê ±j¨îFDA¼f¬d®É¶¡ªí ¨S¦³±j¨î®É¶¡ªí ¥i¯à»ÝnÁ{§É¬ã¨s ¥i¯à»ÝnÁ{§É¬ã¨s ¼ÐÅÒ²z¸Ñ ¼ÐÅÒ²z¸Ñ©M¹ê»Ú¨Ï¥Î ¤£»Ýn¹ê»Ú¨Ï¥Î¬ã¨s ¤°»ò¬OOTCÃĪ«±MµÛ¡H - ¡§¹ÃЮѡ¨Àç¾P«D³B¤èÃÄ - GRASE±ø¥óªº¦Cªí©M»¡©ú - GRASE = ¤@¯ë»{¬°¦w¥þ¦³®Ä - ³Ì«áªº±MµÛµoªí©ó - Áp¨¹ªk³W¡G21 CFR part 331, 331-358 OTCÃĪ«±MµÛ¬O¥]¬A¤°»ò¡H - GRASE¬¡©Ê¦¨¤À - ¾¯¶q±j«× - ¾¯«¬ - ¼ÐÅÒn¨D - ¾AÀ³¯g - ĵ§i©M¨Ï¥Î»¡©ú - ³Ì²×°t¤è´ú¸Õ ¦p¦ó«Ø¥ß¤@ÓOTC±MµÛ¡H - ³]¥ß¤F17ӿԸ߼f¬d¤p²Õ - - ¨¾»Ä¼f¬d¤p²Õ¡A§Üµß¼f¬d¤p²Õ¡A¤î¦½¼f¬d¤p²Õ¡A¤ú¬ì¼f¬d¤p²Õ¡A«y¹Â/·P«_¼f¬d¤p²Õµ¥ - ¨C¼f¬d¤p²Õ¦³9Ó¦¨û - Âå¥Í¡AÃľ¯®v¡A¬r²z¾Ç®a¡A¦æ·~¥Nªí¡A®ø¶OªÌ¥Nªí - ¼f¬d¤F¤u·~¡AÂåÀø«O°·±M·~¤H¤h©M®ø¶OªÌ´£¥æªº14,000¨÷¼Æ¾Ú - Á|¦æ¤½¶}·|ij OTCÃĪ«¼f®Ö - Ãþ§OI¡GGRASE - Ãþ§OII¡G¤£GRASE - ²Ä¤TÃþ¡G¤£¯à½T©w¬O§_¦w¥þ¦³®Ä |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/26 ¤U¤È 08:13:26²Ä 596 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/23 ¤W¤È 09:09:55²Ä 413 ½g¦^À³ ±ÂÅvª÷«¥¤ß¸Ì¤]¨S©³!±ÂÅvª÷«¥¤ß¸Ì¤]¨S©³!±ÂÅvª÷«¥¤ß¸Ì¤]¨S©³! ------------------------------------------------------------------------------------------ °ª¤£¥ÎÁ§ڡA§C¤]§O«è§Ú¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/26 ¤U¤È 07:58:42²Ä 595 ½g¦^À³
|
www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm ¿ï:NDC code ¿é¤J:81389-001-01 ---------------------------------------------------------------------------------- ¤½§i¤¤§Ú¦b¥Gªº¬O:..¤w»P [°ê»Ú¥Dn¤îµhÃĤj¼tñq¦X¬ù]¡A[°£¦³Ã±¬ùª÷]¥t¦³ [¨½µ{¸Oª÷]--³Ì·s¶i®i¡A±N [ÀH®É¤½§i]¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/26 ¤U¤È 07:50:48²Ä 594 ½g¦^À³
|
www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm Proprietary Name NDC Package Code Strength Dosage Form Route Appl. No. Labeler Name Product NDC Nonproprietary Name Substance Name Product Type Name Start Marketing Date End Marketing Date SafeTynadol 81389-001-01 500 mg/1 TABLET, COATED ORAL part343 Sinew Pharma Inc. 81389-001 ACETAMINOPHEN ACETAMINOPHEN HUMAN OTC DRUG 01/21/2021 N/A |
|
|
·|û¡G¯È¤W´I¶Q10134993 µoªí®É¶¡:2021/1/26 ¤U¤È 07:12:52²Ä 593 ½g¦^À³
|
½Ð°ÝR¤j ½Ñ¦p¦¹Ãþ¨Æ¥ó Fda¦b³qª¾¤½¥q«e ·|¦bºô¯¸¤½§G¶Ü¡H ©Î¬O¥¼¨Ó´X¤Ñ¥i¦b¨ºÓºô§}Ápµ²¬d¨ì¶Ü¡H ¤p§Ì^¤å·¥®tµL¤ñ ³£¤£ª¾¸Ó¤W¦ó³B·j´M |
|
|
·|û¡G¦h¦h10137435 µoªí®É¶¡:2021/1/26 ¤U¤È 05:00:10²Ä 592 ½g¦^À³
|
§ë¸ê¥Í§Þ·sÃĪѪñ¤Q¦~²×©ó¦³ÃĦb¬ü°ê¤W¥« ÁöµM¬OOTC monograph,¦ý¬O¤]º¡¶}¤ß·P°Êªº ¥¼¨Ó½Í§P±ÂÅv»P·s¾¯«¬·sÃĪº¥Ó½ÐÀ³¸Ó§ó¦³§Q ½Ä§a,±a»â¤@¤U¥xÆW¥Í§Þ²£·~~ |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/26 ¤U¤È 04:30:56²Ä 591 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/7/10 ¤U¤È 01:20:11²Ä 102 ½g¦^À³ ..©Ò¥HSNP-810À˪þ»P¹ï·ÓÃÄ«~(ì¼tÃÄ´¶®³¯k)ÃÄ«~¥ÍÅé¬Ûµ¥©Ê¼Æ¾Ú§Y¥i¥Ó½Ð¾Ç¦WÃÄÃÄÃÒ¡A¤£¥Î§@P3¡C ............................................................................................... ·|û¡GROGER588910148151 µoªí®É¶¡:2020/7/3 ¤W¤È 09:28:01²Ä 45 ½g¦^À³ ´±«À£ªYÄ£¡A¥Dn¬O¤½¥qÁÙ¦³SNP8¨t¦C¡A¶i¥i§ð°h¥i¦u! «¥¬O»{¬°SNP8¨t¦C(¤AñQÓi×ô¦A¥[¤W¯S©w¤½»{¦w¥þ¤§¦¨¤À)î³ÃÄÃÒªº¡C ------------------------------------------------------------------------------------------- ¬ü°êÃÄÃÒ¥u¬O¤ùÀY¦±¡A¤j¼@ÁÙ¨S¶}ºt¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/26 ¤U¤È 04:23:34²Ä 590 ½g¦^À³
|
¥Ø«e¥»¤½¥qSNP-810·sÃĤw»P°ê»Ú¥Dn¤îµhÃĤj¼tñq¦X¬ù¡A°£¦³Ã±¬ùª÷¥t¦³¨½µ{¸Oª÷¡C²{¥¿¿n·¥¶i¦æ½T»{¸ÕÅç¡]confirmation study)¤¤¡A¦³³Ì·s¶i®i¡A±NÀH®É¤½§i¡C ------------------------------------------------------------------------------------------- ³o´X¤é¨ë¿E¡A¤G¦¸¦³¨Æ¥~¥X¿ì¨Æ¡A ¤@¦^¨Ó¤£¬O¤j¶^´N¤jº¦¡A¤]W¤f±C¤ß»¡¿³Âd¤£¾A¥Î§Þ³N½u«¬¾Þ§@ ¡C [°ê»Ú¥Dn¤îµhÃĤj¼tñq¦X¬ù] [°ê»Ú¥Dn¤îµhÃĤj¼tñq¦X¬ù] [°ê»Ú¥Dn¤îµhÃĤj¼tñq¦X¬ù]--¤£¬OJ&J´N¬OGSK! ©ú¤Ñ¬ÝµÛ¿ì!!! |
|
|
·|û¡Gº¦ªù¤H10146623 µoªí®É¶¡:2021/1/26 ¤U¤È 03:48:25²Ä 589 ½g¦^À³
|
ªGµM¦³¦n®ø®§¡AÃø©Ç§À½L¡K ¥»¸ê®Æ¥Ñ¡@(¿³Âd¤½¥q) 6634 ªYÄ£ ¡@¤½¥q´£¨Ñ §Ç¸¹ 1 µo¨¥¤é´Á 110/01/26 µo¨¥®É¶¡ 15:26:34 µo¨¥¤H ¦¶³Í¥Á µo¨¥¤H¾ºÙ ¸³¨ÆªøÝÁ`¸g²z µo¨¥¤H¹q¸Ü 02-27885365 ¥D¦® ¤½§i¥»¤½¥qµL¨x¬r©Ê¤AñQÓi×ô¤îµh·sÃÄSNP-810(¦w®õ®³¯k) ¤wÀò¬ü°êFDA OTC monograph(«D³B¤èÃĪ«±M½×)National Drug Code(°ê®aÃÄ«~ÅçÃÒ¸¹)¡A¨ú±o¬ü°ê¥«³õ¾P°âÅv ²Å¦X±ø´Ú ¡@²Ä 44 ´Ú ¨Æ¹êµo¥Í¤é 110/01/26 »¡©ú 1.¨Æ¹êµo¥Í¤é:110/01/26 2.¤½¥q¦WºÙ:ªYÄ£¥ÍÂåªÑ¥÷¦³¤½¥q 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q¡C 4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î¡C 5.µo¥Í½t¥Ñ: ¥»¤½¥q±µÀò¬ü°êFDA³qª¾¡A¥»¤½¥qµL¨x¬r¤AñQÓi×ô¤îµh·sÃÄSNP-810(¦w®õ®³¯k) ¤w§¹¦¨FDA OTC monographµù¥U¤Î¼f¬dµ{§Ç¨Ã¨ú±o°ê®aÃÄ«~ÅçÃÒ¸¹¡G81389-001-01 (National Drug Code: 81389-001-01)¡C 6.¦]À³±¹¬I:¤£¾A¥Î¡C 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ: 1.OTC Monograph¬°¬ü°êFDA©Ò¦CÁ|¤§«D³B¤èÃĪ«¡A¤Z¦C©óOTC monograph¤§ÃĪ« ¬¡©Ê¦¨¥÷¡B¾¯«¬¡B¨Ï¥Î¾¯¶q¬Ò³Q»{©w¦w¥þ¦³®Ä¡C¥»¤½¥qSNP-810¦]µ¦²¤¦Ò¶q¡A ¥ý¦æ¥Ó½Ð¬ü°êOTC monograph³\¥i¡A¥Ø«e¤w³q¹L¬ü°êFDA¼f¬d¨Ã¨ú±o¬ü°ê¥«³õ ¾P°â¸ê®æ¡C¹ê»Ú¤W¥«¾P°â®É¶¡µø»P¾P°â¤½¥qªº¨óij¦Ó©w¡C 2.®Ú¾ÚIMS Health²Îp¸ê®ÆÅã¥Ü¡A¥þ¬üAcetaminophen(¤AñQÓi×ô)ÃÄ«~¥«³õ¾P°âÃB ¦b2018¦~¹F22»õ¬ü¤¸¡C°£¥»¤½¥qSNP-810¥~¡A¥Ø«e¥«³õ¤W©|µL¨ä¥¦Ãþ¦üµL¨x¬r©Ê acetaminophen²£«~Ävª§¡C¥Ø«e¥»¤½¥qSNP-810·sÃĤw»P°ê»Ú¥Dn¤îµhÃĤj¼tñq ¦X¬ù¡A°£¦³Ã±¬ùª÷¥t¦³¨½µ{¸Oª÷¡C²{¥¿¿n·¥¶i¦æ½T»{¸ÕÅç¡]confirmation study)¤¤ ¡A¦³³Ì·s¶i®i¡A±NÀH®É¤½§i¡C 3.·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¤@©w¯à¦¨¥\¡A¦¹µ¥¥i¯à¨Ï§ë¸ê±Á{·ÀI¡A §ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C ¥H¤W¸ê®Æ§¡¥Ñ¦U¤½¥q¨Ìµo¨¥·í®É©ÒÄÝ¥«³õ§O¤§³W©w¥Ó³ø«á¡A¥Ñ¥»¨t²Î¹ï¥~¤½§G¡A¸ê®Æ¦p¦³µê°°¤£¹ê¡A§¡¥Ñ¸Ó¤½¥qt³d¡C |
|
|
·|û¡G¦h¦h10137435 µoªí®É¶¡:2021/1/26 ¤U¤È 03:11:34²Ä 588 ½g¦^À³
|
¶X¤H¤£³Æ³ºµM§À½L°½©Ô,쥻³o¨â¤Ñ¶^¯}¦¨¥»»ù,¬ðµM¤S¤j½Âà ¦n´Á«Ý¥i¥H¦³¦n®ø®§¥X¨Ó,±a»â¥þÅé¥Í§ÞªÑ½Ä§a~ |
|
|
·|û¡Gªü§»10146981 µoªí®É¶¡:2021/1/26 ¤U¤È 02:51:04²Ä 587 ½g¦^À³
|
¦³³ß°T¶Ü¡H«ç»ò§À½L¬ðµM😂 |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/26 ¤U¤È 01:41:11²Ä 586 ½g¦^À³
|
¡y¬ã¨s¹Î¶¤¶}µo¥XµL¨x¬r©Ê¤§Acetaminophen¡zªº©Ò¦³¦¨¤À(¥]¬A½á§Î¾¯µ¥)¬O§_»P¥»°ê¤w¤W¥«¤§ Acetaminophen §¹¥þ¬Û¦P¡A¦³µL¦w¥þ¤åÄm¡C¡v¦^ÂСG¦¹ [Acetaminophen ªº¥D¦¨¤À§¹¥þ¬Û¦P]¡AAPI ³£¬O 500 mg/tablet¡A½á§Î¾¯²¤¦³¤£¦P¡A¼W¥[ÁB¨ý¾¯¦p:Sucralose¡BMannitol ¨Ã´£¨Ñ¤HÅéBioequivalence µ²ªG¨ÓÃÒ©ú¦¹ÃĪ«¦w¥þµL¸·¡C SNP-810=APAP+ÁB¨ý¾¯¦p:Sucralose¡BMannitol (±M§Q¤]¼g³o2¤ä²Õ¦X®ÄªG³Ì¨Î) .......................................................................................... pµe¥D«ù¤H¡G³¯¥¿Â× pµe¦WºÙ¡G·s±j®Ä¤£¦¨Å}¤îµh²Õ¦XÃÄ Sebacoyl Dinalbuphine Ester ¤ÎµL¨x¬r¤AñQÓi×ô¥Î©óÂù °¼½¥Ãö¸`¸m´«³N«á¤§¤¤«×¦ÜÄY«¯kµhªvÀø ¥»°| IRB ½s¸¹¡G2020-11-005A °Q½×¨Æ¶µ¡G (1) ªk³W¡G ²¤¡C 18 (2) Û²z¡G ²¤¡C (3) ¬ì¾Ç¡G ³o¬O¼t°ÓÃÙ§UªºÀH¾÷¡BÂùª¼ªº²Ä I/II ´ÁÁ{§É¸ÕÅç¡A³æ¤@¤¤¤ß¡A°w¹ïÂù°¼½¥Ãö¸`««Ø³N«á¯f¤H¡A±N©ó³N«á¤T¤Ñµ¹¤©¤@ºØ·sªº²Õ¦X¡B¸ÕÅç¥ÎÃÄ¡]SDE »P AAP¡^¡A¨Ãµû¦ô¨ä¤îµh®ÄªG¤ÎÃĪ«°Ê¤O¾Ç ¡A ¥H ÃÒ ©ú SDE ¤Î AAP ¨ã ¦³ ¨ó ¦P ®Ä À³ ¡C AAP ¬Oacetaminophen ¡]tylenol¡^¡CSDE¡]Sebacoyl Dinalbuphine Ester¡ANaldebain¡A¯Ç¯k¸Ñ¡^¬O«DºÞ¨îÃþªºªü¤ùÃþÃĪ«¥B¤£·|¦¨Å}¡A¦ýSDE ¦b¥xÆW¤W¥«ªº¥u¦³¦Ù¦×ª`®gªº°w¾¯¡A¥»¸ÕÅ窺 SDE ¬°¤fªA½¦Ån¡C¹wp©Û¶Ò 36 ¦ì 20 ·³¥H¤Wªº¨ü¸ÕªÌ¡A¨Ì©Ê§O»P¦~ÄÖ¼h¤À°t¡A¦AÀH¾÷¤À°t¬° 3 ²Õ¡A¨C²Õ 12 ¤H¡G²Ä 1 ²Õ¤fªA¦w¼¢¾¯ A+ ¯Ç¯k¸Ñ 20 mg ¡B²Ä 2 ²Õ AAP 1000 mg+¦w¼¢¾¯ B¡B²Ä 3 ²ÕAAP 1000 mg+¯Ç¯k¸Ñ 20 mg¡A3 ²Õ³£¬O¨âÁû½¦Ån©M¨âÁû¿õ¾¯¡A¤@¤Ñ¨â¦¸¡A¦@¤T¤Ñ¡A¥B¨C´X¤p®É¥H¡uµøı¼ÒÀÀ¶qªí¡vµû¦ô¨ä¯kµhµ{«×¡A¨Ã©â¦å 3 ¦¸¡A¨C¦¸¬ù 60cc,¥H´ú¥Í¤Æ¡B¨x¥\¯à©MÃĪ«¿@«×¡C¥²n®É¡A¨ü¸ÕªÌ¥i¥H±µ¨ü¯kµh±Ï´©ÃĪ«¡C (4) ¨ü¸ÕªÌ«OÅ@¡G ¥»®×µL©ö¨ü¶Ë®`±Ú¸s¡C ¤w¨Ì©eûªì¼f·N¨£¡G¡u½Ð³]¥ß¸ê®Æ¦w¥þºÊ´úpµe(DSMP)¡v¦^ÂÐ ¡G¦P·N¼W³] DSMP¡A¨Ãªþ¤W DSMP¡C¡]ÂåÀø©eû¡B«DÂåÀø©eû¡^ ¤w¨Ì©eûªì¼f·N¨£¡G¡u«öÃĨƪk²Ä¤C±ø³W©w¡y¤fªA«¬¯Ç¯k¸Ñ¡z»P ¡y¬ã¨s¹Î¶¤¶}µo¥XµL¨x¬r©Ê¤§ Acetaminophen¡z¬O·sÃÄ¡A¤£¦P·N¤£³] DSMP¡FÀ³³] DSMB¡C°e½ÃºÖ³¡¼f¬d³q¹L«á¤~¯à°õ¦æ¡C¡v¦^ÂСG¦P·N¼W³] DSMP¡A¨Ãªþ¤W DSMP¡A¥²n®É¼W³] DSMB¡A¥B·|°e½ÃºÖ³¡¼f¬d¡C¡]ÂåÀø©eû¡B«DÂåÀø©eû¡^ ¤w¨Ì©eûªì¼f·N¨£¡G¡u¡y¤fªA«¬¯Ç¯k¸Ñ¡zªº©Ò¦³¦¨¤À(¥]¬A½á§Î¾¯µ¥)¬O§_»P¥»°ê¤w¤W¥«¤§¦Ù¦×ª`®g«¬¯Ç¯k¸Ñ§¹¥þ¬Û¦P¡A¦³µL¦w¥þ¤åÄm¡C¡v¦^ÂСG¤fªA¾¯«¬¯Ç¯k¸Ñ»P¤W¥«ÃÄ«~¤§¥D¦¨¤À§¹¥þ¬Û¦P¡A½á§Î¾¯ÃB¥~²K¥[ Tween20 ¤Î PEG400¡A¦¹¨âºØ½á§Î¾¯¨ÃµL¥ô¦óÃIJz§@¥Î¡A¼W¥[½á§Î¾¯¬O¬°¤F±N¨Ó SDE+AAP ²£«~»s³y»Ýn¡A¥B¨Ï¥Î¾¯¶q¤]¦b WHO ®Ö¥i½d³ò¤§¤º¡ATween20 4.4 mg/kg »PPEG400 4.5 mg/kg¡A®Ú¾Ú World Health Organ Tech Rep Ser «ü¥X¨C¤é¥i±µ¨ü¨Ï¥Î¶q Tween20 25 mg/kg1 ©M PEG400 10 mg/kg2.¡C¡]ÂåÀø©eû¡B«DÂåÀø©eû¡^ ¤w¨Ì©eûªì¼f·N¨£¡G¡u¡y¬ã¨s¹Î¶¤¶}µo¥XµL¨x¬r©Ê¤§Acetaminophen¡zªº©Ò¦³¦¨¤À(¥]¬A½á§Î¾¯µ¥)¬O§_»P¥»°ê¤w¤W¥«¤§ Acetaminophen §¹¥þ¬Û¦P¡A¦³µL¦w¥þ¤åÄm¡C¡v¦^ÂСG¦¹Acetaminophen ªº¥D¦¨¤À§¹¥þ¬Û¦P¡AAPI ³£¬O 500 mg/tablet¡A½á§Î¾¯²¤¦³¤£¦P¡A¼W¥[ÁB¨ý¾¯¦p:Sucralose¡BMannitol ¨Ã´£¨Ñ¤HÅéBioequivalence µ²ªG¨ÓÃÒ©ú¦¹ÃĪ«¦w¥þµL¸·¡C¡]ÂåÀø©eû¡B«DÂåÀø©eû¡^ |
|
|
·|û¡G¦h¦h10137435 µoªí®É¶¡:2021/1/26 ¤U¤È 01:19:10²Ä 585 ½g¦^À³
|
R¤j,¥h¦~©³½u¤W¦¬Å¥¤¤¤Ñ¥Í§Þªk»¡,©ó¦^µª§ë¸ê¤H°ÝÃD®É¦ü¥G¦³´£¨ìªYÄ£¬O±Ä¥Î¤¤¤Ñªº¸z¥ÍºA»Ã¯À¤@°_¸ÕÅ窺?! ¥i¯à¤£¬O³æ¿W²K¥[¤@¨Ç¥N¿}¯à°÷¸Ñ¨M¨x¬r©Ê? |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/26 ¤W¤È 11:15:05²Ä 584 ½g¦^À³
|
¯à»¡ªº¸Ó»¡ªº¤w¤@¦r¤£¯d¡A³o¸Ì«¥¤£¦Aµo¨¥¡AÁôÁô¬ù¬ùı±o´I¨¹¤¸´I§@¤â¦³³}¨Ó³o¸Ì! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/26 ¤W¤È 11:02:09²Ä 583 ½g¦^À³
|
¬ü°êLNK InternationalÃļtªº¨àµ£°t¤è´N¬O:APAP+¥ÌÅS¾J+¤T´â½©¿}+¦A¥[¤@°ïªF¦è ¦ý²K¥[¥Øªº¤£¬O¸Ñ¨M¨x¬r©Ê¡A¦Ó¬On[±»¹¢W¨ý] [¼W¥[²¢¨ý]¡AÅý¨àµ£Ä@·N¦Y¤U¥h¡A¬JµMSNP-810Àò¬ü°ê±M§Q¡A«h¤GªÌ¤£¬»Ä²! ACTIVE INGREDIENT/ACTIVE MOIETY ACETAMINOPHEN 160 mg INACTIVE INGREDIENTS CITRIC ACID MONOHYDRATE / CROSPOVIDONE / D&C RED NO. 27 ALUMINUM LAKE /D&C RED NO. 30/ ETHYLCELLULOSE / FD&C BLUE NO. 1--ALUMINUM LAKE / MAGNESIUM STEARATE / ¥ÌÅS¾J[MANNITOL] /STEARIC ACID /¤T´â½©¿}[SUCRALOSE] /DEXTROSE MONOHYDRATE /HIGH DENSITY POLYETHYLENE ------------------------------------------------------------------------------------------ ·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/26 ¤W¤È 06:40:37²Ä 576 ½g¦^À³ »·¦b¤ÑÃäªñ¦b²´«eªÖ©wÅýJ&J»PGSKªºÃĪ«¶}µo¤Hû§ãµÃ¹Ä®§¤£¤w! ¦]¬°APAP¦³·¥W¨ý¡A¦]¦¹µ¹¨àµ£ªA¥Îªº°t¤è·|²K¥[¥ÌÅS¾J+¤T´â½©¿}(¼W¥[²¢¨ý±»¹¢W¨ý)+¦A¥[¤@°ï¦³ªº¨Sªº=¨àµ£APAP°t¤è¡A[ì¨Ó]¯à¸Ñ¨M§x´o60¦h¦~ªº¨x¬rªº [¦³®Ä¦¨¤À]°t¤è´NÁôÂæb¨àµ£°t¤è¸Ì±¡AµL¨x¬rSNP-810n¨ú¥N²{¦³ªº¼s¤j¥«³õÀ³µLÄa©À¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/26 ¤W¤È 10:13:15²Ä 582 ½g¦^À³
|
¥ÌÅS¾J /³ÁªÞ¿}¾J /¤s±ù¿}¾J / ¤ìÁÞ¾J³o¨Ç³£¬O¿}¾J¡C ¥Ò¾J/¤A¾J(°sºë)¦P¬O¾JÃþ(¥Ò¾J³Ü¤F¦ºÂ¼Â¼¡A°s³Ü¦h¥ý¦¨¤F°s°¤~·|Åܦº°) ¥Ò¾J¤¤¬rªºÁ{§É¯gª¬ ¨CÓ¤H¹ï¥Ò¾Jªº·P¨ü©Ê®t²§«Ü¤j¡A¤@¯ë¦Ó¨¥¡A100²@¤É¦å²G¤ºY§t¥Ò¾J20²@§J¡A«h¬ù³Ü¤F¥Ò¾J12²@¤É¡CY°²°s¤º¥Ò¾J§t¶q¬°¦Ê¤À¤§¥|¡A´«ºâ¤§¡A«h³Ü°²°s¬ù300²@¤É´N·|²£¥Í¤¤¬r²{¶H¡C¥Ò¾JªºP¦º¶q¬ù¬°¤¤¬r¾¯¶qªº¤¿¡]¥Ò¾J¦b¦å²G¿@«×¤j©ó89²@§J¡þ100²@¤É¡^¡A¦Ó¥Ò¾JªºP¦º¶q¬ù¬°¤A¾JP¦º¶q¡]500²@§J¡þ100²@¤É¡^ªº¤¤À¤§¤@¡F¦ý³Ì¤jªº®t²§¬O¡A¤¤À¤§¤@ªº¤A¾JP¦º¶q¥u²£¥Í°s¾K¡A«Ü§Ö´N¥i«ì´_¡A¦Ó¤¤À¤§¤@ªº¥Ò¾JP¦º¶q«o¤Þ°_ÄY«ªº¤¤¬r²{¶H¡A¾ÉP50¢Hªº¤¤¬rªÌ³¡¤À©Î§¹¥þ¥¢©ú¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/26 ¤W¤È 09:50:23²Ä 581 ½g¦^À³
|
´I¨¹¤¸´I¦A¥Î¤O¿å¤@ÂI §Úµ¥µÛ§A¦^¨Ó |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/26 ¤W¤È 08:13:06²Ä 580 ½g¦^À³
|
ü¤S ¹ê¦b¬O²³æ¨ìÅý§ÚÃhºÃµL¨x¬r©Ê·|¤£·|¬O¶BÄF??? 109.11.2 wd.vghtpe.gov.tw/irb/files/IRB1-131%E6%9C%83%E8%AD%B0%E7%B4%80%E9%8C%84(%E5%85%AC%E5%91%8A%E7%89%88).pdf «Øij¨Æ¶µ/¤£³q¹Lì¦]¡G «Ø½Ð»¡©ú¡u¬ã¨s¹Î¶¤¶}µo¥XµL¨x¬r©Ê¤§ Acetaminophen¡v¤§¡uµL¨x¬r©Ê¡v¦ó¥H¦¨¥ß¡C ---------------------------------------------------------------------------------------- 109.12.7 ·s±j®Ä¤£¦¨Å}¤îµh²Õ¦XÃÄ Sebacoyl Dinalbuphine Ester ¤ÎµL¨x¬r¤AñQÓi×ô¥Î©óÂù°¼½¥Ãö¸`¸m´«³N«á¤§¤¤«×¦ÜÄY«¯kµhªvÀø [×¥¿«á³q¹L ]¡C ¤wµo¨ç |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/26 ¤W¤È 08:01:06²Ä 579 ½g¦^À³
|
SNP-810µL¨x¬r·s±M§Q°t¤è VS ¤jÃļt¦³¨x¬r©ÊAPAP°t¤è °t¤è²Õ¦¨¤À´X¥G¨SÅÜ¡AÃöÁä¤j©è¬O²V¦X¤ñ¨Ò½Õ¾ã(¥Í²£½u¤£¶·½Õ¾ãÅÜ°Ê¡A»ù®æÀ³¸Ó¤£·|¤j´T«×½Õº¦)¡A SNP-810¨ú¥N¥þ²y¤îµh¦¨¥÷ÃÄ¡u¤AñQÓi×ô¡v¡A±N¬O©ö¦p¤Ï´x! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/26 ¤W¤È 07:24:17²Ä 578 ½g¦^À³
|
¦³À¸¤F!!! ±ÂÅvSNP-810¥unµy·L½Õ¾ã²Õ¦¨°t¤è´N¬OµL¨x¬rAPAP¡A²ª½Åý¤HµLªk¬Û«H³o»ò²³æ¡A´N¸Ñ¨M¤F§x´o¤jÃļt60¦h¦~ªº¨x¬r©Ê°ÝÃD!!! Tylenol¦¨¤Hª©APAP (¤T´â½©¿}¡A¤ì¿}¾J) ----------------------------------------------------------------------------------------- www.tylenol.com/products/tylenol-extra-strength-dissolve-packs#ingredients ¬¡©Ê¦¨¤À ¹ï¤A酰®ò°ò×ô 500²@§J «D¬¡©Ê¦¨¤À ÂfÂc»Ä¡A¤A°òÅÖºû¯À¡A»®Æ¡Aµw¯×»ÄÁâ¡A³ÁªÞ½kºë¡AºÒ»Ä²B¶u¡A¤T´â½©¿}¡A¤ì¿}¾J |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/26 ¤W¤È 07:06:34²Ä 577 ½g¦^À³
|
¸¹¥~! ¸¹¥~! »·¦b¤ÑÃäªñ¦b²´«e¡AJ&J/GSKÀ£®Ú¨S·Q¨ì¦Û®a°t¤è¤¤¥Î¨Ó¸Ñ¨MW¨ýªº¿}¾J¡A¤]¯à¸Ñ¨M¨x¬r©Ê!!!!! ¿}¾J:¥ÌÅS¾J /³ÁªÞ¿}¾J /¤s±ù¿}¾J / ¤ìÁÞ¾J (¦PÃþ) ¤T´â½©¿} ------------------------------------------------------------------------------------------- Tylenol¨àµ£APAP(¦U¦¡¤ôªG¨ýAPAP) www.tylenol.com/products/childrens-tylenol-oral-suspension Äå®ç µL¤ôÂfÂc»Ä¡AFD¡®C¬õ¦â½s¸¹¡C40¡A»®Æ¡A¥Ìªo¡A°ªªG¿}¥É¦Ì¿}¼ß¡A·L´¹ÅÖºû¯À©Mßn¥Ò°òÅÖºû¯À¶u¡A¯Â²b¤ô¡Af¥Ò»Ä¶u¡A¤s±ù¿}¾J·»²G¡A¤T´â½©¿}¡A¶À콦 ©Î µL¤ôÂfÂc»Ä¡A¹ïßm°òf¥Ò»Ä¤Bà¡AFD¡®C¬õ¦â½s¸¹¡C40¡A½Õ¨ý®Æ¡A¥Ìªo¡A°ªªG¿}¥É¦Ì¿}¼ß¡A·L´¹ÅÖºû¯À©Mßn¥Ò°òÅÖºû¯À¶u¡A¤þ¤G¾J¡A¯Â²b¤ô¡Af¥Ò»Ä¶u¡A¤s±ù¿}¾J·»²G¡A¤T´â½©¿}¡A¶À콦 |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/26 ¤W¤È 06:40:37²Ä 576 ½g¦^À³
|
»·¦b¤ÑÃäªñ¦b²´«eªÖ©wÅýJ&J»PGSKªºÃĪ«¶}µo¤Hû§ãµÃ¹Ä®§¤£¤w! µL¨x¬rSNP-810¦¨¤À¥u¬O [·¥¥©§®]ªº¨Ï¥Î[ì¨Ó][¦³®Ä¦¨¤À]:APAP+¥ÌÅS¾J+¤T´â½©¿}¡C ¥ÌÅS¾J(²¢«×¬ù¬O½©¿}ªº70%)+¤T´â½©¿}(²¢«×¬O½©¿}ªº600¿¡A¨S¦³¼ö¶q)---À³¸Ó¾á¼~¤p«Ä¤l·í¿}¦Y!? ¦]¬°APAP¦³·¥W¨ý¡A¦]¦¹µ¹¨àµ£ªA¥Îªº°t¤è·|²K¥[¥ÌÅS¾J+¤T´â½©¿}(¼W¥[²¢¨ý±»¹¢W¨ý)+¦A¥[¤@°ï¦³ªº¨Sªº=¨àµ£APAP°t¤è¡A[ì¨Ó]¯à¸Ñ¨M§x´o60¦h¦~ªº¨x¬rªº [¦³®Ä¦¨¤À]°t¤è´NÁôÂæb¨àµ£°t¤è¸Ì±¡AµL¨x¬rSNP-810n¨ú¥N²{¦³ªº¼s¤j¥«³õÀ³µLÄa©À¡C --------------------------------------------------------------------------------------------- ½Ð°ÝSNP-810¦³¦ó¿W¨ì¤§³B¡H ªYÄ£SNP-810ªº¬ð¯}¡A¬O¸Ñ¨M¤F60¦h¦~¥H¨Ó¦b¥þ²y¥«³õ¤W¦z¥ß¤£·n¡B³Ì¼sªx¨Ï¥Î¤§¤îµhÃÄ ³y¦¨ªA¥ÎªÌ¡uÄY«¨x·l¶Ë¡v¡A¬Æ¦ÜP¦ºªºÃøÃD...¦ÓªYÄ£¤½¥q¤@Á|¬ð¯}¡A¦¨¥\µo©ú¤FSafeTynadol¦w®õ®³¯kµL¨x¬r©Ê¤îµh·sÃÄ¡A¬J¨Ï¥Î [ì¨Ó] [¦³®Ä¦¨¤À]¡A¤S¤£¦A¦³¥ô¦ó¨x¬r©Ê¡C --------------------------------------------------------------------------------------------- SNP-810±ÂÅvª÷¥i¯à³W¼Ò? ---¤AñQÓi×ô¬O¥@¬É¤W·¥«nªº¤îµhÃĤ§¤@¡A¦ý¬O¦³¨x¬r©ÊP¦ºªº¯ÊÂI¡C§Ú̬O¥H [·¥¥©§®ªº¤è¦¡] ¨Ó¸Ñ¨M60¦~¤jÃļt¤@ª½µLªk¸Ñ¨Mªº°ÝÃD¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/25 ¤U¤È 10:40:47²Ä 575 ½g¦^À³
|
--[µL¨x¬r¤AñQÓi×ô]¥Î©óÂù°¼½¥Ãö¸`¸m´«³N«á¤§¤¤«×¦ÜÄY«¯kµhªvÀø---§ï¥ÎJ&J Tylenol? ²ö«D¥h¦~¤½§iñ¦X§@¨óijªº¬OJ&J??? ¥t¥~¡ASNP-810¼Ú¬w±M§Q¤°»ò®ÉÔ®³±o¨ì??? |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/25 ¤U¤È 10:28:31²Ä 574 ½g¦^À³
|
»O¥_ºa¥ÁÁ`Âå°|¤HÅé¸ÕÅç©eû·|(¤@)²Ä 131 ¦¸·|ij¬ö¿ý ¤½§iª© ¶}·|®É¶¡¡G109 ¦~ 11 ¤ë 2 ¤é¤U¤È 2 ®É¥¿ pµe¥D«ù¤H¡G³¯¥¿Â× pµe¦WºÙ¡G·s±j®Ä¤£¦¨Å}¤îµh²Õ¦XÃÄ Sebacoyl Dinalbuphine Ester ¤Î [µL¨x¬r¤AñQÓi×ô]¥Î©óÂù °¼½¥Ãö¸`¸m´«³N«á¤§¤¤«×¦ÜÄY«¯kµhªvÀø ------------------------------------------------------------------------------------ ¶¶¤Ñªø®Ä¯Ç¯k¸Ñ+SNP-810=·s´ÚSNP-830(SNP-830/840§t¾~¤ùÃþÃĪ«¼È°±¶}µo-¦]¬°[¤îµhÃĤ§¤ý]¾~¤ù¤Þµo¬ü°êÃĪ«¥ÆÀݾµ¹Ú ´¶«×»sÃÄ´£¥X3700»õ¤Ñ»ù©M¸Ñª÷¯}²£) SNP-810=APAP(API /AAP) +¥ÌÅS¾J+¤T´â½©¿}(µL»~) ³o¦¸§ï¥ÎJ&JªºTylenol???? |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/25 ¤W¤È 08:48:35²Ä 573 ½g¦^À³
|
µ¥¤£¤Î¤À¼íª÷/ñ¬ùª÷/ùµ{ª÷¤½¥¬¡An¤£¥h¹q¤½¥q°Ý°Ý? ³o2Ó¶W¯Å¤j«GÂI¡A¬O¤£¬O¤@¤@«G¿O¡A«¥¨S¦³ªÖ©wµª®×¡A¥u¦³¤@¥y«ø¥Ø¥H«Ý! 1.°ê»Ú«e10¤jÃļt? (¹ï¤ñ¥xÆW¤§«eªº¨º´X®a±ÂÅvÃĪ«¡AÁÙ¦³¤H½èºÃ¾P°â³q¸ô¶Ü?) 2.±ÂÅvª÷ÃB³Ð·s¬ö¿ý? |
|
|
·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2021/1/24 ¤U¤È 03:57:41²Ä 572 ½g¦^À³
|
·sÃÄ°£±ÂÅvª÷Ãe¤j¥~¡AÃĪ«¤W¥««á¬O§_ÁÙ¦³¤À¼íª÷¥i¥H®³¡H½Ð±ÐÁA¸Ñªº¤j¤j¡AÁÂÁ¡C |
|
|
·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2021/1/23 ¤U¤È 12:09:09²Ä 571 ½g¦^À³
|
¨Ìr¤j¸ê°Tg¥i¯à±o¼Ð¡A±ÂÅvª÷¶V°ª¶V¦n¡F6«Y¦C¦n¹³¤ñ8¨t¦C§ó±j¡I |
|
|
·|û¡GRock00910149258 µoªí®É¶¡:2021/1/23 ¤W¤È 10:24:00²Ä 570 ½g¦^À³
|
Roger¤j ³oÓñ¬ùª÷»Pùµ{ª÷·|¤£·|¬O¦b12/25«á¤~¤J±b¦C¬°¤@¤ë±b «Ý¤G¤ë¥÷¤½§G¤@¤ëÀ禬´N·|¨£¯u³¹¡H |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/23 ¤W¤È 07:50:40²Ä 569 ½g¦^À³
|
J&J¤]¬O¦P²z¡ASNP-810±o¥¢¤§¶¡,blockbusters (+2¤ä) VS (-1¤ä)¡A¤@¨Ó¤@©¹§Î¦P3¤ä«½SÃĪ«¡A«ç¯à¤£¿n·¥·mSNP-810? [±ÂÅvª÷...¤]±o¨ì°ê»Ú¤j¼tªº»{¥i¡C] +[°ê»ÚÃļt¨Ì¾Ú¥»¦X§@¨óij±N¤ä¥I¥»¤½¥q¤@©wª÷ÃB¤§Ã±¬ùª÷¤Î¨½µ{¸Oª÷] °£¤Fµ¥ÁÙ¬Oµ¥§a!!! --------------------------------------------------------------------------------------------- SNP-810±ÂÅvª÷¥i¯à³W¼Ò? ¤AñQÓi×ô¬O¥@¬É¤W·¥«nªº¤îµhÃĤ§¤@¡A¦ý¬O¦³¨x¬r©ÊP¦ºªº¯ÊÂI¡C§Ú̬O¥H·¥¥©§®ªº¤è¦¡¨Ó¸Ñ¨M60¦~¤jÃļt¤@ª½µLªk¸Ñ¨Mªº°ÝÃD¡C¥HÀ°§U¯f¤H´£¨Ñ§ó¦w¥þªºÃÄ«~¡A±ÂÅvª÷±N¬O¦b¤Ï¬M¦¹°^Ämªº»ùÈ¡A¤]±o¨ì°ê»Ú¤j¼tªº»{¥i¡C ---------------------------------------------------------------------------------------------- 109/12/21ªYÄ£»P°ê»ÚÃļtñqSNP-810¬ãµo¦X§@¨óij109/12/21 ..°ê»ÚÃļt¨Ì¾Ú¥»¦X§@¨óij±N¤ä¥I¥»¤½¥q¤@©wª÷ÃB¤§Ã±¬ùª÷¤Î¨½µ{¸Oª÷.. |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/23 ¤W¤È 07:33:32²Ä 568 ½g¦^À³
|
2021.1.12 Glaxo Aims to Double Blockbusters in Bid to Revive Portfolio GlaxoSmithKline Plc set an ambitious goal of more than doubling the number of blockbusters in its portfolio by 2026 as the British pharma giant moves to revive its product lineup. ----------------------------------------------------------------------------------------------- SNP-810±o¥¢¤§¶¡,blockbusters (+2¤ä) VS (-1¤ä)¡A¤@¨Ó¤@©¹§Î¦P3¤ä«½SÃĪ«¡AGSK²j¯à¤£¿n·¥·mSNP-810? |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/23 ¤W¤È 07:21:47²Ä 567 ½g¦^À³
|
®Ú¾ÚIMS Health²Îp¡A¥þ¬ü¤AñQÓi×ôÃÄ«~2016¦~¹F40»õ¬ü¤¸¡C ®Ú¾ÚIMS Health²Îp¡A¥þ¬ü¤AñQÓi×ôÃÄ«~2018¦~¹F22»õ¬ü¤¸¡C -------------------------------------------------------------------------------------------- ALF«æ©Ê¨x¥\¯à°IºÜ: 1¤äAPAPÃĪ«(46%) VS 1,036¤äÃĪ«(11%) FDAn¦p¦ó¸Ñ¨M³oºØÅå¤HªºÄa®í¤ñ¨Ò??? (¤Ö¤F2¤ä«½SÃĪ«) ---------------------------------------------------------------------------------------- ·m¨ìµL¨x¬rSNP-810¡A¤£¥uÀ°FDA¸Ñ¨M§x´o40¦h¦~ªºÀYµh°ÝÃD¡AÁ٦ܤּW¥[2¤ä¥H¤Wªº«½SÃĪ«¾P°â! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/23 ¤W¤È 06:40:39²Ä 566 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/10 ¤U¤È 08:52:14²Ä 484 ½g¦^À³ ..¤@Áû¦A´¶³q¤£¹Lªº´¶®³¯k¤îµhÃÄ¡A §¹¥þ§l¤Þ¤£¤F§ë¸ê¤H¦a²´²y!!!¦b«¥²´¸Ì«o¬O«½SÃĪ«>10»õ¬ü¤¸!!! ............................................................................................... 2021.1.12 Glaxo Aims to Double Blockbusters in Bid to Revive Portfolio GlaxoSmithKline Plc set an ambitious goal of more than doubling the number of blockbusters in its portfolio by 2026 as the British pharma giant moves to revive its product lineup. ----------------------------------------------------------------------------------------- »¡ªºÁ`¬O¤ñ°µªº®e©ö¤£¬O¶Ü¡H SNP-810´N¬O1¤ä10»õ¬ü¤¸«½SÃĪ«¬Æ¦Ü¬O50»õ¬ü¤¸ªº¶W¯Å«½SÃĪ«¡A ³ÌÁV¿|ªº¨Æ¡A¤@¥¹¨S·m¨ìSNP-810¡A§ó±NÄY«½ÄÀ»¦Û®aºX¤Uªº¤îµhÃÄ«½SÃĪ«¾P°â¶q¡A¬O±z·|Åý¥¦·È¹L? |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/23 ¤W¤È 06:21:43²Ä 565 ½g¦^À³
|
¨º¤@¦~GSK±Æ¦W²Ä8¡A«e¤Q¦W´£4¦¸¡AGSK³Ì¿n·¥¶i¨ú!? (J&J±Æ¦W²Ä4) -------------------------------------------------------------------------------------------- ·|û¡G«ä¦Ò¤¤10147262 µoªí®É¶¡:2020/7/23 ¤U¤È 09:36:18²Ä 195 ½g¦^À³ ¤µ¤ÑµL²á¥h104¬ÝªYÄ£¼x¤H µ²ªG¬Ý¨ì¤W±¼gªº¤½¥q¤j¨Æ°On 2019/02 »P¸ó°ê«e¤Q¦W»sÃĤ½¥qñ¸p¦³Äv·~¸T¤î¤§«O±K¨ó©w¡A°Ó°QSNP-810¦X§@¨Æ©y¡C 2019/04 »P¸ó°ê«e¤¦W¤§»sÃĤ½¥q¡A¬ãµo¹Î¶¤¦@¤E¦ì¤£¦P³æ¦ì°ÆÁ`µô¤Î¨Mµ¦¤H¤h¡A¦b¬ü°êÁ`³¡³sÄò¤K¤p®É¡A¸Ô²Ó°Q½×½T¥ßµL¨x¬r©Ê¤îµh·sÃÄSNP-810¤§¬ì¾Ç·N¸q¡B«nÁ{§ÉÀ³¥Î¡B¥þ²y±M§Q§G§½¤Î¦X§@±ÂÅv¨Æ©y¡C 2019/04 »P¸ó°ê«e¤Q¦W»sÃĤ½¥q¬ãµo¹Î¶¤¡A¦b¬ü°êÁ`³¡¡A¬¢½Íªø¹F¥|¤p®É¦³Ãö¤îµhÃÄSNP-810¦X§@¨Æ©y¡C 2019/07 »P¸ó°ê«e¤Q¦W»sÃĬü°ê¤½¥q¹Î¶¤Á|¦æ²Ä¤G¦¸¹q¸Ü·|ij¡A²`¤J°Q½×¥þ²yº¨ÒµL¨x¬r¤îµhSNP-810¤§¬ì§Þ¡B¬ãµo¶i«×¤Î¦X§@¨Æ©y¡C 2019/12 »P¸ó°ê«e¤Q¦W»sÃĤ½¥q¬ü°ê¡B¼Ú¬w¡B·ç¤h¤§°Ó·~µo®i¡B¬ãµo³¡¤Î±M§Q«ß®v¡AÄ~«e¤T¦¸§¹¦¨¬ì§Þ¤Î¬ãµo¶i«×«á¡A²Ä¥|¦¸Á|¦æ¦¸¹q¸Ü·|ij¬¢½ÍSNP-810¦X§@¡B±ÂÅv¡B°Ó·~µo®i¨Æ©y¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/23 ¤W¤È 06:04:28²Ä 564 ½g¦^À³
|
2021.1.12 Glaxo Aims to Double Blockbusters in Bid to Revive Portfolio GlaxoSmithKline Plc set an ambitious goal of more than doubling the number of blockbusters in its portfolio by 2026 as the British pharma giant moves to revive its product lineup. ----------------------------------------------------------------------------------------- »¡ªºÁ`¬O¤ñ°µªº®e©ö¤£¬O¶Ü¡H ¤j©ó10»õ¬ü¤¸ªºblockbusters³è¤â¥i±o? ©Ò¥Hn¹F¥Ø¼ÐGSK±o«ç»ò°µ? |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/23 ¤W¤È 12:07:26²Ä 563 ½g¦^À³
|
·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2021/1/22 ¤U¤È 12:02:33²Ä 558 ½g¦^À³ §Ú²q¬Ojj±o¨ì¡A¥L·G°â¦Û¤v»ùȤ£°ªªºÃÄ¡A¥þ¤O«÷810¡A¬ù8¢w12»õ¬ü¤¸¡C ............................................................................................... «D¤]!«D¤]! GSK¦³¤@Ó¶¯¤ß¸U¤V³¥¤ß«k«kªº¥Ø¼Ð! ¤W¶g2021.01.12 JP Morgan Healthcare¤j·|¡A»¡¨ì2026¦~±NºX¤U«½SÃĪ«(>10»õ¬ü¤¸)ªº¼Æ¶q½¤@¿! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/22 ¤U¤È 01:13:09²Ä 562 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/22 ¤U¤È 12:22:16²Ä 560 ½g¦^À³ SNP-810§â½d³òÂX¤j20¿¸Ñ¨MÂå®v¥ÎÃħx´o---ªí¥Ü¤W¥««áÃļtªº¥]¸Ë®e¶q¥i¥H©ñ¤j½æ§ó¦hÃĪ«! -------------------------------------------------------------------------------------- ^°ê§â¡uÃĤY«·s¥]¸Ë¡v¦Û±þ²v¤j´T°§C43%¡I¥xÆW¤]À³¸Ó¸ò¶i¡I www.teepr.com/611925/angelpan/%E8%8B%B1%E5%9C%8B%E6%AD%A2%E7%97%9B%E8%97%A5%E5%8C%85%E8%A3%9D%E6%94%B9%E5%B0%8F%E8%87%AA%E6%AE%BA%E7%8E%87%E9%99%8D%E4%BD%8E43/ §â¥]¸Ë¶q§ï¤p¥[¨îÁʶR¼Æ¶q----³o¹ïÃļt¾P°âµLºÃ¬O«Ü¤j½ÄÀ» ¾P°âÃB·íµM·È·Æ±è¤U¨Ó |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/22 ¤U¤È 12:53:52²Ä 561 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/20 ¤W¤È 07:43:52²Ä 534 ½g¦^À³ ... GSK¦³1¤ä¦bNASHÁ{§É¥¢±ÑªºDGAT1§í¨î¾¯¡A½æµ¹¨ä¥LÃļtªvÀø[ÄY«¿È½H]Á{§É¹êÅç¡C --------------------------------------------------------------------------------------------- ·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2021/1/22 ¤U¤È 12:02:33²Ä 558 ½g¦^À³ §Ú²q¬Ojj±o¨ì¡A¥L·G°â¦Û¤v»ùȤ£°ªªºÃÄ¡A¥þ¤O«÷810¡A¬ù8¢w12»õ¬ü¤¸¡C -------------------------------------------------------------------------------------------- §Ú»{¬°TÂ_¬Þ¯}(¥¤â)¡A¤p¼t¶R¨Ó·f°t¨ä¥LÃĪ«.... |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/22 ¤U¤È 12:22:16²Ä 560 ½g¦^À³
|
SNP-810§â½d³òÂX¤j20¿¸Ñ¨MÂå®v¥ÎÃħx´o---ªí¥Ü¤W¥««áÃļtªº¥]¸Ë®e¶q¥i¥H©ñ¤j½æ§ó¦hÃĪ«! ¦w¥þ°t¤è:¥ÌÅS¾J(²¢«×¬ù¬O½©¿}ªº70%)+¤T´â½©¿}(²¢«×¬O½©¿}ªº600¿¡A¨S¦³¼ö¶q)---À³¸Ó¾á¼~¤p«Ä¤l·í¿}¦Y!? |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/22 ¤U¤È 12:13:53²Ä 559 ½g¦^À³
|
³s¦bÂå°|¥ÑÂå®v¬IÃĪºª¬ªp¤U¡AÁÙ·|µo¥ÍÄY«ªºP©R©Ê«æ©Ê¨x°IºÜ! °ÝÃDÄpµ²´N¦bAPAPªºªvÀø¾¯¶q»P¦w¥þ¾¯¶qªº¾¯¶q½d³ò¤Ó¯¶¡C SNP-810§â½d³òÂX¤j20¿¸Ñ¨MÂå®v¥ÎÃħx´o! -------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/21 ¤U¤È 10:29:45²Ä 551 ½g¦^À³ ´¶®³¯kªº¦w¥þ¾¯¶q¯u¦pÃļt»¡ªº1¤Ñ4g??? ¦pªG [¨x¥\¯à¤£¦n] [¶¼°s][¨C¤éªA¥Î] [¯S®í¯e¯f] ªÌ¡A³Ì¦n§â¾¯¶q¦A´î§C¤ñ¸û¦w¥þ! onlinelibrary.wiley.com/doi/abs/10.1111/bcpt.13389 ³o¦ì30·³ªº¨k¤l¦b¥|¤Ñ¤ºÁ`¦@µ¹¤©¤F14.5 g¼³¼ö®§µh¡Cµ²ªG¦]¬°ÄY«ªºP©R©Ê«æ©Ê¨x°IºÜ¡A¤J°|«á11¤Ñ¦º¤`¡C ª`·N:¬O [Âå¥Í¬IÃÄ]¡A¦Ó¥B¾¯¶q14.5g/4¤Ñ=3.625g/¤Ñ < [©Ò¿×ªº¦w¥þ¾¯¶q4g/¤Ñ] ¡C -------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2020/7/27 ¤U¤È 10:51:23²Ä 217 ½g¦^À³ www.sinewpharma.com/upload/userfiles/file/About%20us/About+Us.pdf SD¤j¹«¤¤¡Aµ¹¤©¹ï¤AñQ®ò°ò×ô¬Û·í©ó¨C¤Ñ¤HÃþ¨Ï¥Î¾¯¶q¬°77gªºSNP-810¡Aµ¹ÃÄ«á¡A¤j¹«¨x¥\¯à¤´µM«O«ù¥¿±`¡C 77g VS 4g(500mg*8Áû--¤AñQ®ò°ò×ôªº¦w¥þ¾¯¶q¬°4g/¤Ñ) |
|
|
·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2021/1/22 ¤U¤È 12:02:33²Ä 558 ½g¦^À³
|
§Ú²q¬Ojj±o¨ì¡A¥L·G°â¦Û¤v»ùȤ£°ªªºÃÄ¡A¥þ¤O«÷810¡A¬ù8¢w12»õ¬ü¤¸¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/22 ¤W¤È 11:14:08²Ä 557 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/15 ¤W¤È 09:01:39²Ä 507 ½g¦^À³ 1.2020¦~3¤ë27¤é«e---J&J»PFDA[¥P©é¥P]ªº©Û¦¡! ¥X¤âªý¤îFDA¹ïTylenol³o´Ê·n¿ú¾ð(2014¦~¾P°â40»õ)¨î©w§óÄY®æªº [¦w¥þ]ªk³W¦b³o: ------------------------------------------------------------------------------------------ ·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/28 ¤U¤È 02:18:27²Ä 431 ½g¦^À³ SNP-810(APAP 325mg+SNP-820)¥þ±¨ú¥N¨ã¨x¬r©ÊªºAPAP¥«³õ SNP-810(APAP 500mg~1000mg©Î§ó°ª+SNP-820)·m¦^³QNSAIDªü´µ¤ÇÆF,COX-2§í¨î¾¯OpioidsÃþ«I»kªº¥«³õ --------------------------------------------------------------------------------------------- ¦]¬°FDAªº¨î±¹¬I¡A¾P°âÃB¤@¸ô±q2014¦~ªº40»õ¬ü¤¸´î¤Ö¬°20¦h»õ¬ü¤¸¡ASNP-810§U§ð·m¦^¥«³õ>50»õ¬ü¤¸¤£¬O¤Ñ¤è©]ÃÓ¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/22 ¤W¤È 10:53:38²Ä 556 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/10 ¤U¤È 08:52:14²Ä 484 ½g¦^À³ ..¤@Áû¦A´¶³q¤£¹Lªº´¶®³¯k¤îµhÃÄ¡A §¹¥þ§l¤Þ¤£¤F§ë¸ê¤H¦a²´²y!!!¦b«¥²´¸Ì«o¬O«½SÃĪ«>10»õ¬ü¤¸!!! ............................................................................................ ·|û¡G¦h¦h10137435 µoªí®É¶¡:2021/1/22 ¤W¤È 10:29:50²Ä 554 ½g¦^À³ §Æ±æ´N¬OªYÄ£¨Ó±a»â,ª½±µ¨ÓÓ¤Q»õ¬üª÷±ÂÅv,¤GE¬üª÷ñ¬ùª÷(·Q¹³¤@¤U¤~¯à¿Eµo«ù¦³ªº¨M¤ß) .............................................................................................. ¤Q»õ¬üª÷±ÂÅv¬O¦h¦h¤j·Q¹³! «¥ªº«½SÃĪ«¬O«ü¾P°âÃB [10»õ~50»õ]¬ü¤¸ªºÃĪ« ¡A>50»õ¬ü¤¸ºÙ¬°¶W¯Å«½SÃĪ«¡C ¤£¹L¤@¥¹FDA±j¨î¤U¬[¦³¨x¬r©ÊªºAPAP¡ASNP-810¦¨¬°1Áû¶W¯Å«½SÃĪ«¬O¦³¾÷·|¡C |
|
|
·|û¡Gdk10140377 µoªí®É¶¡:2021/1/22 ¤W¤È 10:48:54²Ä 555 ½g¦^À³
|
¨S¿ù¡A¤Ö¶q§C»ù§@¤F¤@¤U(·sÃĤ£¦n§@) §@ªø§@µu¬Ý¦Û¤w¡A³o»ò¤jªº¤H¤F¡A¦Û¤wt³d¦Û¤w¨M©w ¤@¨ý¬Ý¦n¤@¨ý¬Ý®t ¦Û¦æt³d Ó°Q½×°Ï¦h¬O§@¦hªº¤H ¤Oª÷/¬u³Ñ/³ø¤F¼Æ¦~¡A±qÁÈ´X¿¨ì¦^¦¨¥»¡A¤S¨ì¤W¥« ¤£¬O¯«¬Ý¦n´N©ñ --------------------------------------------------- §OµS¿Ý¡A»°ºò¸òµÛ¤j¤á¸}¨B»{½ß±þ¥X¦A§C»ù¶R¦^ÁÈ»ù®t! |
|
|
·|û¡G¦h¦h10137435 µoªí®É¶¡:2021/1/22 ¤W¤È 10:29:50²Ä 554 ½g¦^À³
|
«¢«¢!! R¤j,¥Í§ÞªÑ·QnÁȤjªº³£¥²¶·§Ô¨ü¤W¤W¤U¤U,½T¹êµ¥«Ý¬O¨¯Wªº,¤S¦^¨ì¤p§Ìªº¦¨¥»°Ï¶¡ ¯uªº¦³°÷XX,¦ý¬O¥¼¨Ó¨É¨ü²¢¬ü¦¨ªG,¤Ï¥¿¶¢¿ú´Nµ¥¤U¥h¤F Q1¥i¯àªº§Q¦h ¤]´N¬O¬Ý¬Ý810¬O§_¯à¦¬®×§¹¦¨,©M630¶}©l°e¥óFDA¥Ó½Ð¤@´Á ¦Ü©ó12/21¦X§@¨Æ¶µ±À¦ô¤]n´X©u§a,¤£¤Ó¥i¯à¤@¨âÓ¤ë¬Ý¨ìµ²ªG ¦ý¬O¥un¦³¦X§@ªí¥Ü§Æ±æ«D±`¤jÅo,·PÁÂR¤j¤@ª½¤£Â_ªº¤À¨É¬ÛÃö±¡¸ê ¥Í§ÞªÑ²{¦b¤í¯Ê¯S¤j§Q¦h,§Æ±æ´N¬OªYÄ£¨Ó±a»â,ª½±µ¨ÓÓ¤Q»õ¬üª÷±ÂÅv,¤GE¬üª÷ñ¬ùª÷(·Q¹³¤@¤U¤~¯à¿Eµo«ù¦³ªº¨M¤ß) ªÑ»ù¾Ä«i¦V¤W,¥[ªo¤F~ |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/22 ¤W¤È 10:15:15²Ä 553 ½g¦^À³
|
§OµS¿Ý¡A»°ºò¸òµÛ¤j¤á¸}¨B»{½ß±þ¥X¦A§C»ù¶R¦^ÁÈ»ù®t! |
|
|
·|û¡Gdk10140377 µoªí®É¶¡:2021/1/22 ¤W¤È 09:49:58²Ä 552 ½g¦^À³
|
³o´X¤Ñ³£¬O¤j¤á¦b»{½ß«b¥X¡A¦pªG¨S¦³§Q¦n®ø®§¡A¤£¶^´N°½¯º¤F ü¡A¤Snªø´Á§ë¸ê¤F |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/21 ¤U¤È 10:29:45²Ä 551 ½g¦^À³
|
·|û¡G¤p¤å¤l10144877 µoªí®É¶¡:2021/1/16 ¤W¤È 06:45:02²Ä 516 ½g¦^À³ ..¥u¬ß¯à¸Ñ¯fµh¤§W¡C¡C¡C§Æ±æª©¤W¤W²î½Ñ§g¯à¤ß·Q¨Æ¦¨¡C¡C¡C ............................................................................................ ´¶®³¯kªº¦w¥þ¾¯¶q¯u¦pÃļt»¡ªº1¤Ñ4g??? ¦pªG [¨x¥\¯à¤£¦n] [¶¼°s][¨C¤éªA¥Î] [¯S®í¯e¯f] ªÌ¡A³Ì¦n§â¾¯¶q¦A´î§C¤ñ¸û¦w¥þ! onlinelibrary.wiley.com/doi/abs/10.1111/bcpt.13389 ³o¦ì30·³ªº¨k¤l¦b¥|¤Ñ¤ºÁ`¦@µ¹¤©¤F14.5 g¼³¼ö®§µh¡Cµ²ªG¦]¬°ÄY«ªºP©R©Ê«æ©Ê¨x°IºÜ¡A¤J°|«á11¤Ñ¦º¤`¡C ª`·N:¬O [Âå¥Í¬IÃÄ]¡A¦Ó¥B¾¯¶q14.5g/4¤Ñ=3.625g/¤Ñ < [©Ò¿×ªº¦w¥þ¾¯¶q4g/¤Ñ] ¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/21 ¤U¤È 09:11:11²Ä 550 ½g¦^À³
|
¥h¦~12/22¨º®Úªø¬õ´Î´N¬O¤G®aªº³Ç§@¡A¦û·í¤é¦¨¥æ±i¼Æ50%¡C ------------------------------------------------- §Úµ¥µÛ§A¦^¨Ó §Úµ¥µÛ§A¦^¨Ó §Ú·QµÛ§A¦^¨Ó §Ú·QµÛ§A¦^¨Ó µ¥§A¦^¨ÓÅý§Ú¶}Ãh µ¥§A¦^¨ÓÅý§ÚÃöÃh |
|
|
·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2021/1/21 ¤U¤È 07:03:31²Ä 549 ½g¦^À³
|
¤µ¬Qªº½L©Ç©Çªº¡A¶q¤jÀ³»ù´¡A¦n¹³¦Û½æ¦Û¶R¡AÀ£§C»ù¿ú¡A¯u¥¿n¥X³fªº¥u¯à½æ§C¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/21 ¤U¤È 04:40:49²Ä 548 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/21 ¤U¤È 12:21:31²Ä 546 ½g¦^À³ ·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/20 ¤U¤È 06:13:06²Ä 544 ½g¦^À³ ¤µ¤Ñ354±i¡A 960T´I¨¹(³y¶Õ???) ¶R¶i114,043ªÑ / ½æ¥X108,790ªÑ ---------------------------------------------------------------------------------------- ´I¨¹¤µ¤Ñ¤j·§¤S³y¤s¤£¦¨ÅÜ«õ¤s·¾? ----------------------------------------------------------------------------------------- ¤µ¤Ñ477±i(³o2¤Ñ½æÀ£¨Ó¦Û³Í°ò???) ´I¨¹ ¶R¶i140,700ªÑ / ½æ¥X134,440ªÑ (+6±i) ¤¸´I ¶R¶i91,890ªÑ / ½æ¥X87,700ªÑ (+4±i) |
|
|
·|û¡Gdk10140377 µoªí®É¶¡:2021/1/21 ¤U¤È 01:21:04²Ä 547 ½g¦^À³
|
¤@±N¥\¦¨¸U°©¬\ ----------------------------- ¥üÂ×??´I¨¹?? ´«¿ùªÑ¡A¥X°ê³»ÅÜ·sÃÄ |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/21 ¤U¤È 12:21:31²Ä 546 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/20 ¤U¤È 06:13:06²Ä 544 ½g¦^À³ ¤µ¤Ñ354±i¡A 960T´I¨¹(³y¶Õ???) ¶R¶i114,043ªÑ / ½æ¥X108,790ªÑ ---------------------------------------------------------------------------------------- ´I¨¹¤µ¤Ñ¤j·§¤S³y¤s¤£¦¨ÅÜ«õ¤s·¾? |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/20 ¤U¤È 06:48:45²Ä 545 ½g¦^À³
|
«x??? APAP¤¤¬r·|¤Þ°_Å¥¤O·l¥¢¡C 2021.1.4 NATURE¤å³¹ www.nature.com/articles/s41419-020-03328-6 ¤§«e¨S¬Ý¹L³oÃþ¬ã¨s³ø§i! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/20 ¤U¤È 06:13:06²Ä 544 ½g¦^À³
|
¤µ¤Ñ354±i¡A 960T´I¨¹(³y¶Õ???) ¶R¶i114,043ªÑ / ½æ¥X108,790ªÑ |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/20 ¤U¤È 02:57:57²Ä 543 ½g¦^À³
|
ªB¤Í¨Ó³X¡A¥h¦Ê³f¤½¥q¦Y¤È¶º¦^¨Ó¡A1¬ÝªGµM1°ï¤H¬Ý§Þ³N½u§@¿³ÂdªÑ²¼! |
|
|
·|û¡Gop123410143906 µoªí®É¶¡:2021/1/20 ¤W¤È 09:53:24²Ä 542 ½g¦^À³
|
R¤j:§Æ±æ¤½¥q¯à¦b¹A¾ä¦~«e°e¤j®a¤@Ó¤j¬õ¥]¡C¥[ªo¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/20 ¤W¤È 09:34:16²Ä 541 ½g¦^À³
|
¤@¥¹¤½¥¬¥¿¦¡±ÂÅvñ¬ù¡A¥]±z¶R¤£¦^¨Ó! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/20 ¤W¤È 09:26:44²Ä 540 ½g¦^À³
|
¿³ÂdªÑ²¼¬Ý§Þ³N½u«¬¾Þ§@? 1®Úªø¬õ§áÂà¥þ³¡§¡½u! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/20 ¤W¤È 09:09:10²Ä 539 ½g¦^À³
|
1. 108.04 ©e°U¥xÄ£¤Æ¾Ç(ªÑ)¤½¥qÃÄ«~¦X¦¨¥X³f ©e°UÃÄ«~¦X¦¨¬ÛÃö¨Æ©y----±q®É¶¡¤W¬Ý¦n¹³¬OSNP-810??? 2019/02 »P¸ó°ê«e¤Q¦W»sÃĤ½¥qñ¸p¦³Äv·~¸T¤î¤§«O±K¨ó©w¡A°Ó°QSNP-810¦X§@¨Æ©y¡C 2019/04 »P¸ó°ê«e¤¦W¤§»sÃĤ½¥q¡A¬ãµo¹Î¶¤¦@¤E¦ì¤£¦P³æ¦ì°ÆÁ`µô¤Î¨Mµ¦¤H¤h¡A¦b¬ü°êÁ`³¡³sÄò¤K¤p®É¡A¸Ô²Ó°Q½×½T¥ßµL¨x¬r©Ê¤îµh·sÃÄSNP-810¤§¬ì¾Ç·N¸q¡B«nÁ{§ÉÀ³¥Î¡B¥þ²y±M§Q§G§½¤Î¦X§@±ÂÅv¨Æ©y¡C... --------------------------------------------------------------------------------------- 2. 109.12¦X¥þÃÄ·~»´ä¦³¤½¥q ÃÄ«~¦X¦¨¥X³f ©e°UÃÄ«~¦X¦¨¬ÛÃö¨Æ©y---±q®É¶¡¤W¬Ý¦n¹³¬OSNP-610??? 2020.12¤ë¤½§i SNP-610¨ú±o¬ü°ê±M§Q: ¬°°t¦X°ê»Ú¤jÃļt¤§¦X§@¡B§ÞÂà¡B±ÂÅv¤§»Ýn¡A¤w§¹¦¨²Ä¤G´ÁÁ{§É¸ÕÅ礧°ª [²{¥¿¿n·¥ ]±À°Ê°ê»ÚÃļt¦X§@©Î±ÂÅvµ¥¨Æ©y¡C .............................................................................................. ©Ò¥H¤¤¤Æ»sÃijQ«c°£¤F? |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/20 ¤W¤È 08:49:32²Ä 538 ½g¦^À³
|
¦~³ø:SNP-810¤]¬O©e°U cGMP ¤¤¤Æ»sÃĤ½¥q¶i¦æSafeTynadol®ÃÄ«~¸Õ»s |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/20 ¤W¤È 08:42:02²Ä 537 ½g¦^À³
|
¦~³ø: SNP-610 ³Ì¨Î³B¤è¡A©e°U cGMP ¤¤¤Æ»sÃĤ½¥q¶i¦æÃÄ«~¸Õ»s¡C ¤U±©e°UÃÄ«~¦X¦¨ÃÄ«~¦X¦¨¥X³f???? ----------------------------------------------------------------------------------------------- ·|û¡G¾¾¹À©OÎN¹À«¡10150521 µoªí®É¶¡:2021/1/19 ¤U¤È 10:44:38²Ä 524 ½g¦^À³ ¦~³ø¦³§ó·s¤WӤ리¤J¬O»P ¦X¥þÃÄ·~»´ä¦³¤½¥q 109/12~ÃÄ«~¦X¦¨¥X³f ©e°UÃÄ«~¦X¦¨¬ÛÃö¨Æ©y |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/20 ¤W¤È 08:29:23²Ä 536 ½g¦^À³
|
109.12.30³Ì·s¸ê®Æ: SNP-6 ¨t¦C²£«~§¡¥i¹F¦¨¦¹¤T¶µ¾÷Âध¦³®Ä©Ê(¥´2ÂI´N¬O²¤³ÓÄvª§ªÌ¤@Äw)¡A¥H¸Ñ¨M¦¹«¤j¦Ó¥¼¸Ñ¨Mªº°ÝÃD¡C ............................................................................................ ¾ãÅé¦Ó¨¥¡A¥»¤½¥q¬ãµo·sÃĤ§µ¦²¤¬°¦b¹F¦¨Á{§ÉÅçÃÒ¦³®Ä©Î¤G´ÁÁ{§É¸ÕÅ秹¦¨¤§«á¡A±N±ÂÅv°ê»ÚÃļt¶i¦æ«áÄò¬ãµo¡A¬¢½Í¹ï¶H°£¼Ú¬üÃļt¥~¡A¥ç¥]§t¤¤°ê¤j³°¤Î·s¿³°ê®a¤§»â¾ÉÃļt¡Cdoc.twse.com.tw/pdf/202012_6634_B1c_20210120_065444.pdf ¥Ø«e¥þ²y¬ãµo¤¤¯×ªÕ¨x·sÃÄ´¶¹M¦@ÃѬ°¡G¦¨¥\¯×ªÕ¨xª¢ÃÄ¥²¶· ¨ã ³Æ ¦³¦hÓ¾÷Âà¦P®É¦³®Ä ¡A §Y (1). ° §C Triglyceride (2). ´î ¤Ö Inflammation (3).´î¤Ö Fibrosis ¤~¯àºÙ¬°¯×ªÕ¨x¤§¦³®ÄªvÀø¡A¦Ó¥»¤½ ¥q©Ò¬ãµo¥X SNP-6 ¨t¦C²£«~§¡¥i¹F¦¨¦¹¤T¶µ¾÷Âध¦³®Ä©Ê¡A¥H¸Ñ¨M ¦¹«¤j¦Ó¥¼¸Ñ¨Mªº°ÝÃD¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/20 ¤W¤È 07:55:31²Ä 535 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/27 ¤W¤È 10:16:06²Ä 425 ½g¦^À³ ..¦pªG¯u¬O³oºØ«O°·¹«~°t¤è? ªA¥Î¹L¶q°Æ§@¥ÎÀ³¸Ó´N¬OÅé«öt¤É! .............................................................................................. §ó¥¿: [CYP2E1 ]ÃĪ«¾÷¨î¡A¥[¤W¥ÌÅS¾J(¤@¤½§J²£¥Í¤G¤j¥d¼ö量¡A²¢«×¬ù¬O½©¿}ªº70%)»P¤T´â½©¿}(²¢«×¬O½©¿}ªº600¿¡A¨S¦³¼ö¶q)¡A©Ò¥H¤Ï¦Ó¯à´î«!!! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/20 ¤W¤È 07:43:52²Ä 534 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/20 ¤W¤È 06:15:59²Ä 530 ½g¦^À³ ¤@¥¹SNP-810/SNP-610±ÂÅv¦¨¥\¡A¨º»ò SNP-630¦¨¥\¾÷²v±N¤W¤É¨ì«D±`°ª!!! ---------------------------------------------------------------------------------------- SNP-610/SNP-630:[ CYP2E1 + DGAT1] §í¨î¾¯¡A¥´2ÓÂI¡AªvÀøNASH¡C GSK¦³1¤ä¦bNASHÁ{§É¥¢±ÑªºDGAT1§í¨î¾¯¡A½æµ¹¨ä¥LÃļtªvÀø[ÄY«¿È½H]Á{§É¹êÅç¡C SNP-810:[CYP2E1]§í¨î¾¯¡AªýÂ_APAP¬r©Ê¥NÁª«NAPQI¥Í¦¨¡C ichgcp.net/clinical-trials-registry/NCT03451487 |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/20 ¤W¤È 07:06:12²Ä 533 ½g¦^À³
|
·|û¡Gdk10140377 µoªí®É¶¡:2021/1/19 ¤U¤È 03:25:56²Ä 523 ½g¦^À³ ..°ê³»¤]¬O¦³°w¹ï¯×ªÕ¨x³o¤@³¡¥÷¡C -------------------------------------------------------------------------------------- ªü¯÷®üÀq¯g³Ð·sÃĪ«¤j¼ú¦n§l¤Þ¤H! °÷¸Þ²§ªº....3¨¥2»y»¡¤£²M¡A«¥¦¥X²M¨SÁȨS½ß¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/20 ¤W¤È 06:24:50²Ä 532 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/8 ¤U¤È 02:53:10²Ä 471 ½g¦^À³ 1~11¤ëÀ禬0 12¤ëÀç·~¦¬¤J46.2¸U--«Y¾P°â¹«~¤¤¶¡Åé©ÒP¡C .......................................................................................... ·|û¡G¾¾¹À©OÎN¹À«¡10150521 µoªí®É¶¡:2021/1/19 ¤U¤È 10:44:38²Ä 524 ½g¦^À³ doc.twse.com.tw/pdf/202012_6634_B1c_20210119_223207.pdf ¦~³ø¦³§ó·s¤WӤ리¤J¬O»P ¦X¥þÃÄ·~»´ä¦³¤½¥q 109/12~ÃÄ«~¦X¦¨¥X³f ©e°UÃÄ«~¦X¦¨¬ÛÃö¨Æ©y ------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/20 ¤W¤È 05:26:34²Ä 525 ½g¦^À³ 2018-09-21 [¾Ú¤F¸Ñ¡A¤¤°ê±Æ¦W«e¤T¤jÃļt¤w¸g©MªYÄ£¶i¤@¨B¬¢½Í¡C]??? -------------------------------------------------------------------------------------------- ·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/20 ¤W¤È 06:15:59²Ä 530 ½g¦^À³ ...©Ò¥H:SNP-610 =¥ÌÅS¾J¡A¤T´â½©¿}¡AC6-¥ÌÅS¾J¨ä¤¤¤§¤@ ??? ---------------------------------------------------------------------------------------- ¨º»ò¾P°âªº¹«~¤¤¶¡ÅéÀ³¸Ó¬OC6-¥ÌÅS¾J(SNP-610)??? µ¹ÃÄ©ú±d±o??? ¤@¤f®ð¥´§¹¦Y¦À\³Ü¥d¸¥h! |
|
|
·|û¡G¤p¤å¤l10144877 µoªí®É¶¡:2021/1/20 ¤W¤È 06:20:53²Ä 531 ½g¦^À³
|
·PÁ¾¾¹À©OÎN¹À«¡¤j´£¨Ñ¦p¦¹Ä_¶Q¸ê®Æ¡Aì¨Ó¤W¤ëÀ禬¬O¸òÃÄ©ú±d¼w¤l¤½¥q¦³Ãö¡A¨º¯uªº¤@»y¬ð¯}ª¼ÂI¤F¡A¤µ¦~¯uªº¬OªYÄ£¶}ªáªº¤¸¦~¡A¦³¾÷·|6¨t¦C»P8¨t¦C¤@Á|Àò±o±ÂÅv¡A§Ú©Ò®ï¬ßªº¸ÑÃĤ]Â÷§Ú¶V¨Ó¶Vªñ¤F¡AªYÄ£¥[ªo¡C¡C¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/20 ¤W¤È 06:15:59²Ä 530 ½g¦^À³
|
¤@¥¹SNP-810/SNP-610±ÂÅv¦¨¥\¡A¨º»ò SNP-630¦¨¥\¾÷²v±N¤W¤É¨ì«D±`°ª!!! 1.¤½¥qºô¶: ªYÄ£ªº¥Dn§Þ³N¥¥x¬O¨Ï¥Î [¦w¥þªº½Æ¦Xª« ] ¨Ó½Õ±±¨xŦ»Ã¯À¤Î°ò¦]¡A¦¹ºØ§Þ³N¥iÀ³¥Î©ó¥i¯à¾ÉP¨x¬r©Ê(SNP-8) ¤§ÃĪ«¥H¤Î¨xŦ¯e¯f(¦p¯×ªÕ¨x SNP-6)¤§ªvÀø¡C 2. patents.google.com/patent/CN107614475A/zh ¥]¬A«eÃÄ¡]¤Æ¦Xª«F¡^¤Î¨ä¥NÁª«¡A§Y¥ÌÅS¾J¡A¤T´â½©¿}»P¨ã¦³«OÅ@°òªºC6-¥ÌÅS¾J¡]¦¡C¡^¤w¸gÃÒ¹ê§@¬°P450 2E1 §í»s¾¯¬O¦³®Äªº [0385] 总¤§¡A试验¤Æ¦Xª«(¥]¬A¥ÌÅS¾J©M¤T´â½©¿}µ¥¡^¥i¥Hú£¤Ö¨x脏¤¤ªº¯×ªÕ§t¶q¡Bú£¤Ö ¨x脏损 伤©M§ïµ½¨x脏ªº§Ü®ñ¤Æ¬¡©Ê¡C这¨Ç¤Æ¦Xª«¤w经³q过动ª«实验³Q证实¬O¦w¥þªº¡A¦}¥B 发现¦³¥i¯à发®i为«O°·¹«~©Î药 ª«¡A¥Î¥Hú£¤Ö¨x脏¯×ªÕ©M§ïµ½¬Û关¯e¯f¡K 3. SNP-630 ·|¤À¸Ñ¬° 3 Ó¬¡©Ê¥NÁª«(SNP-610¬O¨ä¤¤¤§¤@)¡A¨ä§@¥Î©ó NASH ¾÷Âà»P¥ÀÃĬۦü¡A±©¨ä(SNP-610)ÃÄ ²z¬¡©Ê§¡§C©ó SNP-630¡C 4.SNP-610»PSNP-630¦³¦óÃö«Y¡H SNP-630¬°·s¦¨¤À·sÃÄ¡A SNP-610¬°¨ä¦³®Ä¥NÁª«¤§¤@¬O·sÀø®Ä·sÃÄ¡CªvÀø«D°sºë©Ê¯×ªÕ¨xª¢¡A§ÚÌ¥ýµo®i§Ö³t¥H SNP-630¤§¥NÁª«SNP-610§Ö³t¶i¤JÁ{§É¤@´Á¡B¤G´Á¡C¨ä¶¥¬q©Ê¥Øªº¤Î»ùȦb©ó§Ö³tÃÒ¹êSNP-630¤ÎSNP-610¤§¤HÅéÀø ®Ä(Proof of Concept)¡C ¥Ø«eSNP-610¶}©ñ¦¡Á{§É¤G´Á¬ã¨s¤]¤wÀò±oÅãµÛ¤HÅéÀø®ÄÃÒ¾Ú¡A¦¹µ²ªG¤]ÅýSNP-630ªº¦¨¥\ªº¾÷·|±o¨ì«O»Ù¡C ----------------------------------------------------------------------------------------------- ¥H¤W¾É¥X ¦]¬°: [¦w¥þªº½Æ¦Xª« ]-SNP-6»PSNP-8 ±q¥ÌÅS¾J©M¤T´â½©¿}¦Ó¨Ó¡C ©Ò¥H: SNP-610 =¥ÌÅS¾J¡A¤T´â½©¿}¡AC6-¥ÌÅS¾J¨ä¤¤¤§¤@ ??? SNP-630=«eÃÄ¡]¤Æ¦Xª«F¡^??? SNP-820=¥ÌÅS¾J+¤T´â½©¿} SNP-810= APAP+SNP-820 = APAP+¥ÌÅS¾J+¤T´â½©¿} |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/20 ¤W¤È 06:02:53²Ä 529 ½g¦^À³
|
¬°¤°»òªYÄ£»¡SNP-610»PSNP-630ªº²£«~Àu¶Õ´£¨ì: ¥i¦P®É¥Î©ó[°sºë©Ê]¯×ªÕ¨xª¢ASH©M [«D°sºë©Ê]¯×ªÕ¨xª¢NASH?(¥Nªí¥«³õ§ó¤j) ¦Ó¨ä¥LÄvª§ªÌ¶}µoªºÃĪ«¥u¯à¥Î©ó[«D°sºë©Ê]¯×ªÕ¨xª¢NASH? 1½g2017¦~¤å³¹³o»ò¼g: aasldpubs.onlinelibrary.wiley.com/doi/pdf/10.1002/hep4.1115 ¥»¬ã¨sªí©úCYP2E1 ¦b¦UºØ¹êÅç©Ê¨xÅÖºû¤Æ¼Ò«¬¤¤µo´§¤£¦Pªº§@¥Î¡A³Ì©úÅ㪺¬O[°sºë©Ê] ¨x¯f¡C ......................................... [°sºë©Ê] ¨x¯f---ªvÀø²Ä1¨B´N¬O±wªÌ§Ù°s!!! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/20 ¤W¤È 05:52:07²Ä 528 ½g¦^À³
|
SNP-610¬OCYP2E1 + DGAT1§í¨î¾¯¡A¥´2ÓÂI!!! CYP2E1(P450)»P¨xÅÖºû¤Æ¬ÛÃö??? 1.2017¦~ www.oncotarget.com/article/22937/text/ ¡K.³o¨Ç¼Æ¾Úªí©úCYP2E1¬¡©Ê¥i¯à¬O¨xÅÖºû¤Æªº¦³«e³~ªº¥Íª«¼Ð»xª«¡A¾¨ºÞ¦b [ÅÖºû¤Æ]¤¤¼W¥[CYP2E1¬¡©Êªº¼ç¦b¾÷¨î «Ý½T©w¡C 2. 2012¦~ ---Critical role of cytochrome P450 2E1 (CYP2E1) in the development of high fat- induced non-alcoholic steatohepatitis pubmed.ncbi.nlm.nih.gov/22668639/ ¨x²Õ´¾Çªí©ú¡A¾¨ºÞ¦bÁý¹HFDªº [WT ] ©M [Cyp2e1µL®Ä] ªº¤p¹«¤¤¯×ªÕÅܩʼW¥[¡A¦ý¶ÈÁý¤JHFDªºWT¤p¹«·|µo®i ¥XNASH¡C ¦P²Õ¤H°¨ :2017¦~µoªí¦bNATURE www.nature.com/articles/srep39764 Cytochrome P450-2E1 promotes fast food-mediated hepatic fibrosis ³o¨Çµ²ªGªí©ú¡ACYP2E1¦b³t¹¤¶¾Éªº¨xÅÖºû¤Æ¤¤«Ü«n¡A²ÓM¦â¯ÀP450-2E1«P¶i§ÖÀ\¤¶¾Éªº¨x [ÅÖºû¤Æ] |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/20 ¤W¤È 05:45:33²Ä 527 ½g¦^À³
|
DGAT1§í»s¾¯AZD7687ªº¾÷¨îÃÒ©ú¡Gº¦¸¤HÃþ³æ¾¯¶q¬ã¨sªºµ²ªG(ªü´µ§Q±d¦b¤@´ÁÁ{§É«á²×¤î) insights.ovid.com/diabetes-obesity-metabolism/domet/2013/02/000/proof-mechanism-dgat1-inhibitor-azd7687-results/5/00127973 p <0.0001 vs.¦w¼¢¾¯¡^¡Cµ²½×¡GAZD7687¹ïÀ\«áTAG°¾²¾ªº°I´î§@¥Î¬°¸z¹DDGAT1§í¨î´£¨Ñ¤F¾÷²zÃÒ©ú¡C¦ý¬O¡A¾¯¶q©M¶¼¹¬ÛÃöªº [G¸z¹D°Æ§@¥Î] ¥i¯à·|¼vÅTDGAT1§í»s¾¯ªº¶i¤@¨Bµo®i¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/20 ¤W¤È 05:37:39²Ä 526 ½g¦^À³
|
SNP-610(CYP2E1 + DGAT1, ¥´2ÓÂI)¦b¤@´Á»P¤G´ÁÁ{§É¹êÅçÀ³¸Ó¬O¸ó¹LG¸z°Æ§@¥ÎªùÂe»Ùê¡A¦¨¥\¸ô¤W¦AÁÚªñ¤@¨B! (GSK / ¿ÕµØ/ªü´µ§Q±d/½÷·çªºDGAT1ÃĪ«¤À§O±¾¦bP1»PP2) -------------------------------------------------------------------------------------------- 1.2017.9¤ë file:///C:/Users/USER/Downloads/19787-Article%20Text-36724-1-10-20181214.pdf A Novel Acyl-CoA: Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitor, GSK2973980A, Inhibits Postprandial Triglycerides and Reduces Body Weight in a Rodent Diet-induced Obesity Model DGAT1¬OÃöÁä酶 ¶Ê¤Æ¥Ìªo¤T»Äà¡]TG¡^¦X¦¨ªº³Ì²×¨BÆJ¡A¨Ã¯A¤Î¯×ªÕ§l¦¬©M ©Ê®æ¡C¦ý¬O¡A¥Ñ©ó¥H¤Uì¦]¡Aªýê¤F´XºØDGAT1§í»s¾¯ªº¶}µo¡G ¦bÁ{§É¸ÕÅ礤Æ[¹î¨ìªºG¸z¹D¡]GI¡^@¨ü©Ê¤£¥i±µ¨ü¡C 2.·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/1 ¤W¤È 10:59:49²Ä 450 ½g¦^À³ 2020.12¤ë³Ì·s³Ì©P¥þ¸ê®Æ! static1.squarespace.com/static/5b5f666c9772ae3d286108fa/t/5fd8166c59305f0926a31c85/1607997042425/BB_WhitePaper+NASH_email+12_10B.pdf ²Ä6±i¹Ïªí: SNP-610¾÷¨î:CYP2E1 inhibitor ; [DGAT1 ] inhibitor 3.2020¦~9¤ë18¤é谢«Bþ÷³Õ¤h | NASH·s药¬ã发¦~«×综z¡X¡X¦^顾®À§é¡A¤ÀªR难点©M®i±æ¥¼来 www.drugtimes.cn/2020/09/18/d24daf450b/ ¡K.DGAT¬OTG¦X¦¨¤¤ªº关键酶¡ADGAT§í¨î剂¤]´¿¬O热门ªº°¯×¹v点¡C¦Z来发现[DGAT1]§í¨î剂¼v响肠¹Dªº¯×ªÕ处²z¡A带来严«ªºG肠¹D°Æ¤Ï应¡A许¦h¤½¥q©ñ弃¤F这¤@¹v点ªº开发¡C¡C¦Ò虑¨ìDGAT2¥Dn¦b¨x脏¤¤ªí达¡A¨x¹v¦V©ÊªºDGAT2§í¨î剂¥Î¤_NASH¤´¦b积Ìå开发¤§¤¤¡C «e±´£¨ì¨ü®Àªº¤@¨Ç热门¹v点¡A¤ñ¦pFXR¡BPPAR¡BACC¡BASK1µ¥¡A¦³关¤½¥q¤´¦b积Ìå开发¡Aµ¦²¤¥Dn¬O调¾ã临§É设计©M药ª«联¥Îµ¥¡C对¤_NASH这ý©ªºÎ`杂¯e¯f¡A [[[联¥Î¤]许¬O¥¿Ú̪º选择¡AÉó¨î¤¬补ªº组¦X¤×¨äȱo´Á«Ý¡C]]] 4. www.sciencedirect.com/science/article/pii/S2352345X19300463 ¦b¤HÃþ¨ü¸ÕªÌ¤¤¨Ï¥ÎDGAT1§í»s¾¯Æ[¹î¨ì60ºØ©úÅã¥B¾¯¶q¨üªºGI°Æ§@¥Î¡A¾ÉP¤Æ¦Xª«°±¥Î¡C(®ÄªG¤j¦ý¬O°Æ§@¥ÎÄY «) |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/20 ¤W¤È 05:26:34²Ä 525 ½g¦^À³
|
2018-09-21 [¾Ú¤F¸Ñ¡A¤¤°ê±Æ¦W«e¤T¤jÃļt¤w¸g©MªYÄ£¶i¤@¨B¬¢½Í¡C]??? www.gbimonthly.com/2018/09/32593/ ..ªYÄ£Á`¸g²z¦¶³Í¥ÁÂå®vªí¥Ü¡ASNP-6¨ã¦³¦h«§@¥Î¾÷Âà¡A¤£¶È°§C¨xŦ¤T»Ä¥Ìªo¯×°ï¿n¡A¦P®É¯à§í¨î¨xŦomega®ñ¤Æ¬ÛÃö酶°§Cµoª¢®ñ¤Æª«½è¡A¨Ã°§C¨xµoª¢ÅÖºû¤ÆªºÁͤƦ]¤lCCL2¡C³o¬O³Ì¤£¦P©ó¥Ø«e°ê»Ú¶¡Á{§É¶i¦æ¤¤ÃĪ«¡A¥]¬AVK2809¡BInterceptµ¥¡A³o¨ÇÃĪ«©Î¯à°§C¨x¯×ªÕ§t¶q¡A¦ý¤´Ãø¸Ñ¨Mµoª¢¤ÎÅÖºû¤Æ°ÝÃD¡C ............................................................................................... doc.twse.com.tw/pdf/202012_6634_B1c_20210119_223207.pdf---µLªk³s¤W¥´¶}@ ¦X¥þÃÄ·~»´ä¦³¤½¥q(ÃÄ©ú±d¼w·sÃĶ}µo¦³¤½¥q¤l¤½¥q) |
|
|
·|û¡G¾¾¹À©OÎN¹À«¡10150521 µoªí®É¶¡:2021/1/19 ¤U¤È 10:44:38²Ä 524 ½g¦^À³
|
doc.twse.com.tw/pdf/202012_6634_B1c_20210119_223207.pdf ¦~³ø¦³§ó·s ¤WӤ리¤J¬O»P ¦X¥þÃÄ·~»´ä¦³¤½¥q 109/12~ÃÄ«~¦X¦¨¥X³f ©e°UÃÄ«~¦X¦¨¬ÛÃö¨Æ©y |
|
|
·|û¡Gdk10140377 µoªí®É¶¡:2021/1/19 ¤U¤È 03:25:56²Ä 523 ½g¦^À³
|
ÃÄÃÒ«D¸UÆF¤¦¡A¥é³æ¬OºòãT©G Keryx¤§«eªºªk»¡¤@ª½±j½Õ·sÃÄZerenexªº¥«³õ¶D¨D¬OÂå¥Í»P¬~µÇ¤¤¤ß±N¦]¦¨¥»¦]¯À¦Ó¤j¶qª½±µ±Ä¥ÎZenenex¡C Zenerex³Ì¤jªº½æÂI´N¬O¥i¥H¼W¥[¬~µÇ¯f±w¨¤Wªº¦å²GÅK¶q¥HµÎ½w³h¦å¡A¦ý¬OFDA³W©wªº¥é³æ¤W«oÅý³oÓ [ÀuÂI]¦¨¬°[¯ÊÂI] ------------------------------ R¤j±M·~ Ä_0¤é¥»¥«³õ¤£¿ù¡A²{¦b³Ñ¤Uª£¤j³°³o¶ô¤F¡A¥»¨·~¿n¤]¦]쥻±ÂÅv½Í¤£¦n¦Ó°_¤£¨Ó¡C §Æ±æ·sÄô¤£n³Q½â½æ¤F¡A¥»¤H¬O¬Ý¦n³o¬O«½SªºÃÄ¡C°ê³»¤]¬O¦³°w¹ï¯×ªÕ¨x³o¤@³¡¥÷¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/18 ¤U¤È 01:02:05²Ä 522 ½g¦^À³
|
¥ð®§®É¶¡¥´³õÄ_ÄÖ²y±j¨°·°©!(°ÝÃD¤£¦b²y¹D¡A¬O²y¯Ê1¨¤¤£¶ê) ÃÄÃÒ«D¸UÆF¤¦¡A¥é³æ¬OºòãT©G(¥þ¤åºô§}¦b³Ì¤U±) Keryx¤§«eªºªk»¡¤@ª½±j½Õ·sÃÄZerenexªº¥«³õ¶D¨D¬OÂå¥Í»P¬~µÇ¤¤¤ß±N¦]¦¨¥»¦]¯À¦Ó¤j¶qª½±µ±Ä¥ÎZenenex¡C Zenerex³Ì¤jªº½æÂI´N¬O¥i¥H¼W¥[¬~µÇ¯f±w¨¤Wªº¦å²GÅK¶q¥HµÎ½w³h¦å¡A¦ý¬OFDA³W©wªº¥é³æ¤W«oÅý³oÓ [ÀuÂI]¦¨¬°[¯ÊÂI]..... ............................................................................................. ·|û¡GROGER588910144700 µoªí®É¶¡:2018/9/8 ¤U¤È 09:28:39²Ä 4972 ½g¦^À³ ÃÄÃÒ«D¸UÆF¤¦¡A¥é³æ¬OºòãT©G owenlin.pixnet.net/blog/post/43938052-%E8%97%A5%E8%AD%89%E9%9D%9E%E8%90%AC%E9%9D%88%E4%B8%B9%EF%BC%8C%E4%BB%BF%E5%96%AE%E6%98%AF%E7%B7%8A%E7%AE%8D%E5%92%92--%E5%AF%B6%E9%BD%A1%E5%AF%8C%E9%8C%A6%E5%8F%96%E5%BE%97 ¦ý¬OFDA³W©wªº¥é³æ¤W«oÅý³oÓÀuÂI¦¨¬°¯ÊÂI..... |
|
|
·|û¡Gdk10140377 µoªí®É¶¡:2021/1/18 ¤W¤È 11:12:41²Ä 521 ½g¦^À³
|
¦U¦ì¤j¤j »¡©ú¦X¤@¤Î¤¤¤Ñ¡A¥Dn¬O¦^À³¤§«e¤j¤j¦³´£¨ìªºª¬ªp¡A¨Ã¤£¬O¤¤¤Ñ¶°¹Î´N¤@©w¦n©ÎÃa¡A§ë¸ê¦³·ÀI¡A¦h¤è°Ñ¦Ò¡C §ë¸ê®É¶¡ªøµu¤]¬O¦Ò¶q¡A§Æ±æ¤j®aÁÈ¿ú «Ü¦h¥Í§Þ³£¬O¿±·¡A³Ì¦§ë¸êªºÄ_0´N¬O¥Nªí§@(¦Ü¤Ö¨ì²{¦b¨S¬Ý¨ì¤§«eªº¹w¦ô)¡A§ä¨ì¤jÃļt±ÂÅv¦X§@¹ï¥¼¨Óªº³q¸ô¤]«Ü«n |
|
|
·|û¡G¤p¤å¤l10144877 µoªí®É¶¡:2021/1/16 ¤U¤È 02:35:23²Ä 520 ½g¦^À³
|
dk¤j¡G ªYÄ£¤£¬O¤¤¤Ñ¤l¤½¥q¡A¬O³z¹LÆp¥Û¥Í§ÞÂà§ë¸êªº¤½¥q¡C¡C¡C³o¥y¸Ü¬O§_Åý§A¦w¤ß³\¦h©O¡H |
|
|
·|û¡Gdk10140377 µoªí®É¶¡:2021/1/16 ¤U¤È 02:06:07²Ä 519 ½g¦^À³
|
¤§«e§ë¸ê¬u²±³Q¤¤¤Ñ¤@ª½¦X¨Ö¡A´«¦¨¦X¤@¤]¼Æ¦~®É¶¡¡A¨ä¤¤¤ß»Ä¤£¬°¤Hª¾¡K¤¤¤Ñ©ú©ú´N¬Oª¾¹D¬u²±¦b½Í±ÂÅv¡A«K©y¤F¦X¤@¡AªÑ²¼¾Þ°µ¤ÓÃø¬Ý¤F |
|
|
·|û¡G¤p¤å¤l10144877 µoªí®É¶¡:2021/1/16 ¤U¤È 12:52:04²Ä 518 ½g¦^À³
|
°òª÷·| Search Ãö©ó§ÚÌ ³Ì·s®ø®§ ¨x¯f¸ê°T ¨x¯fª¾ÃÑ ¦n¤ß¨x·|¥Z «O¨x½Ã±Ð¤â¥U ½Ã±Ð¼vµ ¨x¯f¬¡°Ê ®½´Ú±M°Ï ¦n¤ß¨x¬G¨Æ ¸q¤u¶é¦a Ápµ¸§ÚÌ ¼vµÀW¹D ¯»µ·¹Î 简Ê^ª© ½Ã±Ð¼vµ ¨x¯f¸ê°T ²rÃz©Ê¨xª¢¨ä¹ê¸ò¡uÃz¨x¡v¨SÃö«Y 2019-07-05ªð¦^¤W¤@¼h «Ü¦h¤H·Q·íµMº¸¥H¬°²rÃz©Ê¨xª¢¤@©w¬O¡u¿n³Ò¦¨¯e¡v¡A©Î¬O³Ìªñ¤u§@¤Ó²Ö¡uÃz¨x¡v¡A¨ä¹ê²rÃz©Ê¨xª¢ªºµo¥Í¡A¦b°ê¤º¥~¡A«Ü¤Ö¬O¿n³Ò¦¨¯e¡A©Î¬O³Ìªñ¤u§@¤Ó²ÖÃz¨xªº¡C¯f¬r©Ê¨xª¢¡B°¾¤è¸ÉÃÄ¡B¤£·í¨Ï¥ÎÃĪ«µ¥¡A¤~¬O¯u¥¿ªº¡u¥û¤â¡v¡C ¦n¤ß¨xªù¶E¤¤¤ß¨xÁx¸zG¬ì¥D¥ô³¢«Ø¿³¡A´¿¦b±µ¨ü¡m¦n¤ß¨x¡n·|¥Z¿Ô¸ß®Éªí¥Ü¡A©Ò¿×²rÃz©Ê¨xª¢«üªº¬O¨xŦ¥\¯à¬ðµM¤§¶¡ªºÄY«³à¥¢¡C¨xŦ¨ã¦³³\¦h¥\¯à¡A¥]¬AÀç¾i¯Àªº¥NÁ¡B¦X¦¨¤Î¸Ñ¬r¥\¯à¡A¦X¦¨¾®¦å¦]¤l¤Î»s³y¥Õ³J¥Õ¡A¥H¤Î§K¬Ì§@¥Î¡C·í¤H¦]¬°¬Y¨Çì¦]¬ðµMµo¥Í¨x²ÓM¤j¶qÃa¦º¡AP¨Ï¨xªº¥\¯à¤j¶q³à¥¢¡A§Y¬°²rÃz©Ê¨xª¢¡C ¦Ó¤@¯ë¤H±`»¡ªº«æ©Ê¨x°IºÜ¡B«æ©Ê²rÃz¨x°IºÜ¡A¨ä¹ê»¡ªº³£¬O²rÃz©Ê¨xª¢¡C²rÃz©Ê¨xª¢ªºµo¥Í²vÁöµM§C¡A¦ý¬Oµo§@°_¨Ó«o¬O¨Ó¶Õ¬¤¬¤¡A¦º¤`²v°ª¹F8¦¨¡Aȱo¤j®a¯d·N¡C «Ü¦h¤H¥H¬°²rÃz©Ê¨xª¢¤@©w¬O¡u¿n³Ò¦¨¯e¡v¡A©Î¬O³Ìªñ¤u§@¤Ó²Ö¡uÃz¨x¡v¡C¨ä¹ê²rÃz©Ê¨xª¢ªºµo¥Í¡A¦b°ê¤º¥~³£¤£¬O¿n³Ò¦¨¯e¡A©Î¬O³Ìªñ¤u§@¤Ó²Ö¡C¿n³ÒÁöµM¥i¯à¦³·l¨xŦ¡A¦ý¬O·lÃaªº¨xŦµoª¢«ü¼Æ¤£·|¤Ó°ª¡A¦Ó¨Æ¹ê¤W¤]¨S¦³¡uÃz¨x¡v³o¥ó¨Æ¡A¬ðµM¦a¥[¯Z¼õ©]¡B¹L³Ò¡A¼vÅTªº¦h¥b¬O¤ß¦åºÞªº°ÝÃD¡A¨Ã¤£·|¦]¦¹¦Ó¨xÃz±¼©Î¬O²rÃz©Ê¨xª¢¡C ¬O¤°»òì¦]¤Þ°_²rÃz©Ê¨xª¢©O¡H¦b°ê¥~¡Aµo¥Í²rÃz©Ê¨xª¢³Ì±`¨£ªºì¦]¬OÃĪ«¹L¶q©Ò¤Þ°_¡A¦ÓÃĪ«¥Dn¬O¡uacetaminophen¡]¤AñQÓi×ô¡^¡v¡A³o¬O¤@ºØ±`¥ÎÂíµh¸Ñ¼öÃĪ«¡A¦b¥xÆW«UºÙ´¶®³¯k¡A¥Ñ©ó¥¦¤£·|§í¨î©Î¼vÅT¾®¦å§@¥Î¡A¤]¤£·|¤Þ°_¸zG¼ìºÅ¡A¦b¥b¤p®É¨ì¨â¤p®É¤º¥i¦b¦å¤¤¹F¨ì³Ì°ª¿@«×¨³³t¤îµh¡A©Ò¥H±`³Q¨Ï¥Î¡C¦ý¬O·í³oÓÃÄ«~³Q¹L¶q¨Ï¥Î¡A·í¨ä¬r©Ê¥NÁª«µLªk³Q±Æ¥X®É¡A·|³y¦¨¤j¶q¨x²ÓMÃa¦º¡C ¡C¡C¡C¡C¡C³o´N¬OÃļtªºì¸o¡A©Ò¥H¤~¥²¶·¥I¥X¤j§â¶r²¼¥hÅ«¸o¡A¦ý¬°¦ó¤£¥h§ä¤@³Ò¥Ã¶hªº¤èªk©O¡C¡C¡C |
|
|
·|û¡G¤p¤å¤l10144877 µoªí®É¶¡:2021/1/16 ¤U¤È 12:31:46²Ä 517 ½g¦^À³
|
>>¤W¤@¶ ´¶®³¯k¤¤¬r «æ¶EÂå¾Ç¬ì ¡@¡@´¶®³¯kªº¦¨¤À¬O¤AñQ®ò×ô(Acetaminophen)¡A¬O¤@¯ë®a®x¤¤±`¥Îªº¤îµh¡B°h¿NÃÄ¡A±`¨£ªº²£«~¥]Panadol¡BScanol¡Btynolol¡B·Å§Jµhµ¥¡C ¡@¡@ ¤j³¡¤À(80-90%)ªº¤AñQ®ò×ô³£¬O¸g¥ÑµÇŦ±Æ°£¡A¤p³¡¤À«h¸g¥Ñ¨xŦ¥NÁ¡C¦ý¬O¤AñQ®ò×ôªº¬r©Ê¡A«o¬O¨Ó¦Û¨ä¸g¥Ñ¨xŦ¥NÁ²£¥Íªº¬r©Êª«½èNAPQI(N-acetyl-p-benzoquinonimine)©Ò¾ÉP¡C ¡@¡@¦¨¤HªA¥ÎAcetaminophen(APAP)¶W¹L7.5§J¡A©Î¤p«ÄªA¥Î¶W¹L¨C¤½¤ç150²@§J¡A´N¦³¤¤¬rªº¥i¯à¡C«æ©Ê¤¤¬rªº¯gª¬¥i¤À¬°¥|Ó¶¥¬q¡A¦´Á±`µL©úÅ㪺¯gª¬¡AÂåÀø¤HûY©¿²¤¤F¥¦ªºÄY«©Ê¡A§Y¥i¯à¿ù¥¢¤FªvÀøªº«´¾÷¡C «æ©Ê¤¤¬rªº¥|Ó¶¥¬q¡G ²Ä¤@´Á(0-24¤p®É)¡G¯f±w¥i¯à¨S¦³©úÅ㪺¯gª¬¡A©Î¶È¥X²{¹½¹¡Bäú¤ß¡B¹Ã¦R¡B«å¡B©Î¥X¦½µ¥¯gª¬¡C ²Ä¤G´Á(24-72¤p®É)¡G«ùÄò²Ä¤@´Áªº¯gª¬¡A¦ý¯gª¬³q±`·|´î»´¡F¦¹®É¨x¥\¯à¤Îprothrombin time¶}©l²£¥Í²§±`¡A¨Ã¥i¯à¥X²{¥k¤W¸¡¯kµhªº²{¶H¡C ²Ä¤T´Á(3-5¤Ñ)¡G²£¥Í¶À¯n¡B©úÅã¨x¥\¯à¤Î¾®¦å¥\¯àªº²§±`¡B¨x¸£¯fÅÜ¡B¨x©ü°g¡B§C¦å¿}¡B©ÎµÇ°IºÜµ¥²{¶H¡C ²Ä¥|´Á(5-14¤Ñ)¡G¯f±¡³vº¥´c¤Æ¬Æ¦Ü¦º¤`¡A©Î³vº¥«ì´_¥¿±`¡C ¡@¡@¦´Á¶EÂ_¥Dn¾a¯f¥v¡A¤fªAAcetaminophen«á4-24¤p®É¤§¶¡¥i´ú¦å¤¤Acetaminophenªº¿@«×¡A¹ï·ÓNomogram¡A§@¬°ªvÀø¤Î¹w«áªº«ü¼Ð¡C¦p¯f±wªA¥Îªø®ÄªºAPAP®É¡AÀ³¦bªA¥Î¥|¤p®É«á¥ý©â¤@¦¸¦å¡A©â§¹²Ä¤@¦¸¦å«á4-6¤p®É¦A©â¤@¦¸¦å¡A¦p¥ô¤@¦¸¦å¤¤ªºAPAPªº¿@«×°¾°ª¡A³£À³¤©¥H¥þµ{ªºN-Acetylcysteine(NAC)ªvÀø¡C ²{³õªºªvÀøì«h¡G éw¥Í©R¼x¶H¡C ±N¸ËÃĪº®e¾¹±a¦ÜÂå°|¡]¼ÐÅҤſò¸¨¡^¡C ¦pµL¸T§Ò¥i¤©¥H¶Ê¦R¡A¨Ãµ¹¤©¬¡©ÊºÒ¡C ¥H¥ª°¼½ö«º¶Õ¡A¾¨³t°eÂå¡C «æ¶EªvÀøì«h¡G éw¥Í©R¼x¶H ¤©¥H¬~G¡A§ë¤©¬¡©ÊºÒ¤ÎÂm¾¯¡C µ¹¤©¸Ñ¬r¾¯N-Acetylcysteine(NAC)¡G¦p¯à¦b¯f±wªA¥ÎAcetaminophen«á8¤p®É¤º¡A¨Ï¥ÎNACªvÀø¡A¯f±w´X¥G³£¥i§¹¥þ«ì´_¡C ¤ä«ù©ÊÀøªk:¥]¬A¨x¸£¯fÅÜ¡B¾®¦å¥\¯àªº²§±`¡B¤Î§C¦å¿}µ¥ªºªvÀø ÄY«¯f±w¡A¨ä°eÂå®É¶¡¦b8¤p®É¥H¤WªÌ¡A¥i¦Ò¼{¦å²G³zªRªvÀø¡C ¡C¡C¡C¡C¡C§Ú°O±oªYÄ£8¨t¦C¦³¤@¶µ¬O¸Ñ¬r¾¯¡A¥i¨£¨ä±±Ñ¨ì¤§³B¡C¡C¡C |
|
|
·|û¡G¤p¤å¤l10144877 µoªí®É¶¡:2021/1/16 ¤W¤È 06:45:02²Ä 516 ½g¦^À³
|
R¤j¡G §Ú¦Û»{¹ï·sÃijo¶ôµÛ¹ê¤£À´¡A¥ý«e»¡¹L¤Ö¶q¶R¶iì¦]¡A¶È¬Oªí¹F¹ïªYÄ£ªº2´Ú«½S·sÃÄSNP-610(¯×ªÕ¨x)¡ASNP-810(µL¨x¬r¤îµhÃÄ)ªº®ï¬ß¤§·N¡A³o¬O§Ú¨Å骺µh³B¡A¤£¦]¨D°]¡A¥u¬ß¯à¸Ñ¯fµh¤§W¡C¡C¡C§Æ±æª©¤W¤W²î½Ñ§g¯à¤ß·Q¨Æ¦¨¡C¡C¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/15 ¤U¤È 09:28:00²Ä 515 ½g¦^À³
|
¡u§A²Ö¤F¶Ü¡H¡v §Ú²Ö¤Fn¥ð®§¦n¤@°}¤l! ¤µ¤Ñ@¤H´M¨ýªºQ&A: ¦pªG¹ï¦X¤@¦³«H¤ß¡A¤£¥²¨C¤Ñ¤@ª½°Ý´XÂI´X¤À¡A¥un½T©w¤è¦V¹ï¤F¡A Âצ¬ªº¤j²î¤@©w·|¾a©¤ªº¡A®`©È®ü¤Wªº·®ö´N¤£n¤W²î¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/15 ¤U¤È 09:19:16²Ä 514 ½g¦^À³
|
FDAªº²×·¥¤jµ´©Û[withdrawal of all complex drugs]---¦X²z®É¶¡ÂI:¦w¥þµL¨x¬rSNP-810¤W¥«¡C ............................................................................................. ·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/27 ¤W¤È 09:53:25²Ä 424 ½g¦^À³ ¬ü°êÃĪ«±M®a»¡:®õ¿Õ¡]Tylenol,APAP)¬O¡§¨´¤µ¬°¤î³Ì¦MÀIªºÃĪ«! ¤@¥¹¥X²{§ó¦w¥þÃĪ«SNP-810¡AFDA¤£µL¥i¯à±N¥u§t[¤AñQÓi×ô]¦¨¤ÀªºÃĪ«±j¨î¤U¥«¡A ³oÓ¼s¤j¥«³õ·|Åܦ¨¦³¦h¤j??? .............................................................................................. ·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/15 ¤U¤È 08:38:23²Ä 512 ½g¦^À³ ¸U¤@FDA²×©ó¨Ï¥X¤jµ´©Û[withdrawal of all complex drugs]??? |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/15 ¤U¤È 08:53:10²Ä 513 ½g¦^À³
|
1¤äAPAPÃĪ«(46%) VS 1,036¤äÃĪ«(11%) FDAn¦p¦ó¸Ñ¨M³oºØÅå¤HªºÄa®í¤ñ¨Ò??? .............................................................................................. ·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/27 ¤W¤È 09:53:25²Ä 424 ½g¦^À³ ......¤d¨¥¸U»y¤£¦p¤@±i¹Ïªí²³æ©öÀ´! FDA¸ê®Æ²Ä7¶ www.fda.gov/media/87626/download ALF«æ©Ê¨x¥\¯à°IºÜ:¹ï¤A酰®ò°ò×ô(APAP)¤ñ¨Ò46% ¤W¥«ÃĪ«¤ñ¨Ò11% (¤W¥«ÃĪ«:¥Ñ1,036ºØFDA§å㪺ÃĪ«²Õ¦¨) |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/15 ¤U¤È 08:38:23²Ä 512 ½g¦^À³
|
¦M«æ¦s¤`¤§¬î¡A¨â®an·m¤@ӱϥͰé¡C 2020¦~3¤ë27¤é¤t´¶Ã±¸p¡m«D³B¤èÃĦw¥þ¡A³Ð·s©M§ï²ªk®×¡n¥´³qFDA¥ô·þ¤G¯ß¡A ¸U¤@FDA²×©ó¨Ï¥X¤jµ´©Û[withdrawal of all complex drugs]??? --------------------------------------------------------------------------------------------- 2017 ¼Ú¬wÂå¾Ç©MÃIJz¾Çµû½×--´¶®³¯kªº¨x¬r©Ê¤Î¬ÛÃö¦º¤` ...The most drastic proposal suggested by FDA is the [withdrawal of all complex drugs], both available over the counter (OTC) and by prescription ... www.europeanreview.org/wp/wp-content/uploads/95-101-Hepatotoxicity-of-paracetamol-and-related-fatalities.pdf |
|
|
·|û¡Gdk10140377 µoªí®É¶¡:2021/1/15 ¤U¤È 04:28:54²Ä 511 ½g¦^À³
|
¦pªGªYÄ£¬O¤U¤@Ó¦X¤@¡A¨º±ÂÅvª÷¤½§iªº°Ê§@¤]¤ÓºC¤F®@~~¥[ªo¦n¶Ü §@·s¼Öªº¥xgg¡C¬ü°êªº»@´Ú³£´X»õ¬ü¤¸°_¡A®³¨Óµ¹±ÂÅv¤£´N¦n¤F |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/15 ¤U¤È 12:07:18²Ä 510 ½g¦^À³
|
«ö¤j½L«ü¼Æ¦ì¶¥¡A¤é«á¦³ªø¿¼ç¤OªÌ¤w¬O»ñ¤òÅ﨤¡C ................................................................................................. 2021/01/04 ²Î¤@§ë¬ã³¡«ü¥X¡A¥xÆW¥Í§Þ2020¦~«ÂI¤½¥q¾ãÅéÀò§Q¡]¤£§tÑÔ¼w¡^³s¤T¦~³Ð°ª¡A¹w´Á2021±N³s¥|¦~³Ð°ª¡A¦ý¥Ø«e¤WÂd¡B¤W¥«¥Í§Þ«ü¼Æªº¦ì¸m¶È²¤°ª©ó2019¦~©³¡A¶È¬ù2014¦~°ª®p®Éªº¤»¦¨¡C www.chinatimes.com/newspapers/20210104000214-260204?chdtv |
|
|
·|û¡G¤p¤å¤l10144877 µoªí®É¶¡:2021/1/15 ¤W¤È 11:33:16²Ä 509 ½g¦^À³
|
www.storm.mg/article/1644860 ¡u¤îµhÃĤ§¤ý¡v¤Þµo¬ü°êÃĪ«¥ÆÀݾµ¹Ú ´¶«×»sÃÄ´£¥X3700»õ¤Ñ»ù©M¸Ñª÷ ¬ü°êªñ´Á¥þ¤O¥´À»¾~¤ùÃþÃĪ«¥ÆÀݲ{¶H¡A¥Í²£³B¤è¤îµhÃÄ¡u¶ø¬I±d©w¡vªº´¶«×»sÃıÁ{°ª¹F2000°_¶D³^®×¡C¬ü°ê´CÅé28¤é³zÅS¡A´¶«×»sÃÄ¥i¯à¹F¦¨©M¸Ñ¨óij¡AÁn½Ð¯}²£«á§â¤½¥q¥æ¥I¤½¯q«H°U¡C´x±±´¶«×¶°¹ÎªºÂħJ°Ç®a±Ú¤]¶·±q¨p¤H°]²£¤¤±Ç¥X¤@³¡¥÷¦¬¯q¡AÁ`p³Ì°ª±N®³¥X·s¥x¹ô3700»õ¤¸©M¸Ñ¡C Án½Ð¯}²£¥æ¥I«H°U ´¶«×»sÃÄ¡]Purdue Pharmaceuticals¡^¥Ø«e¥¿¦b«X¥è«X¦{§J¨½¤ÒÄõ®i¶}©M¸Ñ½Í§P¡A¦h®a´CÅé³ø¾É¡A´¶«×´£¥Xªº©M¸Ñª÷¦b100¦Ü120»õ¬ü¤¸¡]¬ù·s¥x¹ô3140»õ¦Ü3700»õ¤¸¡^¤§¶¡¡C´¶«×¤½¥q¶ÈÃҹ꥿¦b½Í©M¸Ñ¡A¦ýª÷ÃB¤è±¤£¤©¸mµû¡C ¼b¥Í¤]Àò§P181»õ¤¸ 8¤ë26¤é¡A¶ø§J©Ô²ü°¨¦{¤~«Å§P¡A»sÃĤj¼t¼b¥Í¡]Johnson & Johnson¡^¥²¶·¬°¡u¾~¤ù¦M¾÷¡vt°_³¡¤À³d¥ô¡A¼b¥Í³Q±±¨è·N²H¤Æ¾~¤ùÃþ¤îµhÃĪº¦¨Å}·ÀI¡A³Q§Pú¥æ5.7»õ¬ü¤¸¡]¬ù·s¥x¹ô181»õ¤¸¡^ªº»@´Ú¡A±N¥Î¨Ó¨ó§U¨ü®`ªÌÂ\²æ¬rÅ}¡C¦P¤@§å¶D³^®×¤¤¡A´¶«×»sÃĤ]¦b³Q§i¤§¦C¡A³Q»@´Ú2.7»õ¬ü¤¸¡C °£¤F¶ø§J©Ô²ü°¨¦{¡AÁÙ¦³40Ó¦{¤À³£¹ï´¶«×¡B¼b¥Íµ¥»sÃÄ¥¨ÀY´£¥X±±¶D¡C¥t¥~ÁÙ¦³¼Æ¤Q®a¤½¥q¤]¦]¾~¤ùÃþÃĪ«ÀݥΦӱÁ{¶D³^¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/15 ¤W¤È 09:19:43²Ä 508 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/6 ¤U¤È 01:58:35²Ä 467 ½g¦^À³ ¬G¨Æªº³Ì²×³¹---¤]¬O³Ì½÷·×ªº¤@³¹---¥¿¦b»W¶Õ«ÝµoÁßÆC·í¤¤¡C ®É¶¡·|§i¶D§A! ........................................................................................ ·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/8 ¤U¤È 02:53:10²Ä 471 ½g¦^À³ 1~11¤ëÀ禬0 12¤ëÀç·~¦¬¤J46.2¸U--«Y¾P°â¹«~¤¤¶¡Åé©ÒP¡C ..................................................................................... ¸U¨ÆÑ³Æ ªF·¤w²{ |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/15 ¤W¤È 09:01:39²Ä 507 ½g¦^À³
|
1.2020¦~3¤ë27¤é«e---J&J»PFDA[¥P©é¥P]ªº©Û¦¡! ¥X¤âªý¤îFDA¹ïTylenol³o´Ê·n¿ú¾ð(2014¦~¾P°â40»õ)¨î©w§óÄY®æªº [¦w¥þ]ªk³W¦b³o: www.propublica.org/article/new-court-docs-maker-of-tylenol-had-a-plan-to-block- tougher-regulation 2.2020¦~3¤ë27¤é«á----J&JªºÅK¥¬m³Q¤t´¶¯}Åo! 2020¦~3¤ë27¤é¤t´¶Ã±¸p¥Í®Äªº¡mCARESªk®×¡n¡A¼Ð»xµÛ¬ü°êFDA«D³B¤èÃÄ [ºÊºÞ] «¤j§ï²¥¿¦¡±Ò¹õ¡C [«D³B¤èÃÄ]---ÃĦw¥þ!Ãijзs!Ãħï²! Åý [¦w¥þ] µL¨x¬rSNP-810§ó·m¤â¥[È! ............................................................................................. ·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/4 ¤U¤È 04:18:55²Ä 460 ½g¦^À³ J&JªºTylenolªºª÷ÄÁ¸nÅK¥¬m¦b2020.3.27³Q¤t´¶¥´¯}Åo! 2020¦~3¤ë27¤é¤t´¶Ã±¸p¡m«D³B¤èÃĦw¥þ¡A³Ð·s©M§ï²ªk®×¡n¡CÅýµL¨x¬rSNP-810§ó·m¤â¥[È! ....................................................................................... ·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/2 ¤U¤È 08:37:57²Ä 459 ½g¦^À³ ycharts.com/analysis/story/protecting_jandjs_tylenol_cash_cow_from_regulators ¼ÐÃD: «OÅ@±j¥ÍªºTylenol·n¿ú¾ð§K¨üºÊºÞªÌ(FDA)ªº«I®` ........................................................................................... |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/13 ¤U¤È 10:08:35²Ä 506 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/11/14 ¤U¤È 01:42:46²Ä 377 ½g¦^À³ ¤û¹GÅo¡A¹j¤@Ó¤ë¤j³°·sÃıÂÅvª÷¬ö¿ý¤@¸õ3¿! 2020.9.5¦ã§B维ÉO¤Ñ¹Ò达¦¨ªñ30亿¬ü¤¸±Â权协议 ¨ê·s¤¤国¥Íª«药¥æ©ö纪录 ..................................................................................... ·|û¡GROGER588910148151 µoªí®É¶¡:2020/8/28 ¤U¤È 12:14:04²Ä 328 ½g¦^À³ §Úªº¦Ñ¤ÑÃZ°Ú!¥xÆW¦ó®É·|¥X²{>10»õ¬ü¤¸ªº±ÂÅvÃĪ«??? 2020.8.19 ¤j³°Ä¬¦{Innovent¥H10.3»õ¬ü¤¸±ÂÅv§¨ÓPD-1ÃĪ«! 2亿¬ü¤¸ªºº¥I´Ú---³oÓ¼F®`Åo! ............................................................................................. ¤j³°´CÅé¯u¤£¥Î¥\ ©ú©ú¬ö¿ý¬O30»õ¬ü¤¸¡A ®`«¥¸òµÛ±¼¤U§|! ¤£¹Lº¥I´Ú6.5»õ¬ü¤¸¤]¯uÀ~¤H! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/13 ¤U¤È 10:01:06²Ä 505 ½g¦^À³
|
2021/01/13 22»õ¬üª÷¯}¬ö¿ý¡I¤¤°ê¦ÊÀÙ¯«¦{PD-1§ÜÅé·sÃıÂÅv¿ÕµØ ¬Q(12)¤é¡A¤¤°ê§K¬Ì¸~½F·sÃĬãµo¤½¥q¦ÊÀÙ¯«¦{(BeiGene)«Å¥¬»P¿ÕµØ(Novartis)¹F¦¨°ª¹F22»õ¬ü¤¸ªº·sÃĦX§@±ÂÅv¨óij¡A±N±ÂÅv¿ÕµØ¨ä¦Û¥D¬ãµoªºPD-1³æ®è§ÜÅéÃĪ«¢wTislelizumab ¹w¥I´Ú°ª¹F6.5»õ¬ü¤¸¡A¦¨¬°¦Ü¤µ¹w¥I´Ú³Ì°ªªº¤¤°ê·sÃıÂÅv¦X§@¶µ¥Ø¡C ............................................................................................... ¹w¥I´Ú°ª¹F6.5»õ¬ü¤¸,³oÓ¼F®`Åo! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/13 ¤U¤È 07:36:52²Ä 504 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/9 ¤W¤È 11:34:51²Ä 474 ½g¦^À³ ¨S·Q¨ì»PSNP-840¦PÃþªºCL-108±ÂÅvª÷°ª¹F6.8»õ¬ü¤¸!!! .................................................. ......................................... ·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/15 ¤W¤È 08:43:49²Ä 396 ½g¦^À³ SNP-810ªº¼Ï¯Ã¸ÕÅç[µø±ÂÅv±¡§Î]??? ¹wp¦b¥xÆW(©Î°ê»Ú¦P®É)¦¬®×60¦ì°·±d¨ü¸ÕªÌ¡A§¹¦¨48¤H¡C(¥H¥¿±`¤H¶i¦æµL¨x¬r©Ê¸ÕÅç§Y¥i)¡A³o¬O¥»ÃĶ}µo¦¨¥\ªº·¥¤jÀuÂI¡C¦A¨Óµ¥FDA®Öã¼Ï¯ÃÁ{§É¸ÕÅç? À³¸Ó´N¬O1ÓÂà±ÊÂI¡C(¯ÂÓ¤HÁr´ú!) ............................................................................................. CL-108 (Á{§ÉP3) 6.8»õ¬ü¤¸(ñ¬ùª÷®³1»õ¬ü¤¸) VS SNP-810(¼Ï¯Ã¸ÕÅç) ±ÂÅvª÷???(ñ¬ùª÷®³???) ¼Ï¯Ã¸ÕÅç:¦¬®×60¦ì°·±d¨ü¸ÕªÌ¡A§¹¦¨48¤H¡C(¥H¥¿±`¤H¶i¦æµL¨x¬r©Ê¸ÕÅç§Y¥i)¡A³o¬O¥»ÃĶ}µo¦¨¥\ªº·¥¤jÀuÂI¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/13 ¤U¤È 06:36:58²Ä 503 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/23 ¤W¤È 09:09:55²Ä 413 ½g¦^À³ 1.ªYÄ£¦~³øºô¶»P»¡©ú·|¦³±ø¦CNASHÃĪ«(SNP-610)ªº±ÂÅv¦æ±¡¡A¦ý¨S¦³SNP-810ªº¡C 2.¥Í§Þ³ß³s¨Ó ¦Aªï¦Ê»õ±ÂÅv®×¹Ïªí¤¤ªºSNP-810±ÂÅv»ùÈ:[µû¦ô¤¤] money.udn.com/money/story/10161/4651212 .......................................................................................... ªYÄ£¦~³ø¨S¦³APAP(SNP-810)ªº°ê»Ú±ÂÅvª÷ÃB¡A´CÅé¤~·|±NSNP-810±ÂÅv»ùÈ¥Î[µû¦ô¤¤]³o3¦r¡C ¸³¨Æªø«D±`©M®ð¡A[»¡¤£¦n]¬O¤£¯à½T©w¡A§O®`°¸! |
|
|
·|û¡Gdk10140377 µoªí®É¶¡:2021/1/13 ¤U¤È 05:08:15²Ä 502 ½g¦^À³
|
R¤j ------------------------------------- Y¬O©M±z»¡ªº¤@¼Ë¡A³o°ª¼h¯uªº¤ÓLOW¡AMARKETING¤]¤Ó®t¤F¡C ¦pªG¬O¬ì§Þ·~¡A¦ý¤Ö³£·|¬d¤@¤U¹ï¤â©Î±M§Q³¡¤À ¤£¦pÁٽбz¥h·íÅU°Ý¦n¤F¡A¦~·s¦Ê¸U¡A¥un±ÂÅvª÷¦h½ÍÓ1%´NÀ~¦º¤F ------------------------------------------------------------ ª÷ÃB¦½Í§´....¤£¤½§iñ¬ùª÷¤Î¨½µ{¸Oª÷¾÷²v~0 ¥t¥~¡AªYÄ£°ª¼h»¡¤£¦n¤]¤£ª¾¹DJ&J½æ±¼JNJ-10450232!? |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/12 ¤U¤È 12:19:45²Ä 501 ½g¦^À³
|
ÁÙ¦³«¥²Ä6·P½ä©wGSK¤S±NxJ&Jªº¾÷²v°ª! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/12 ¤U¤È 12:09:27²Ä 500 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/9 ¤W¤È 11:34:51²Ä 474 ½g¦^À³ ¨S·Q¨ì»PSNP-840¦PÃþªºCL-108±ÂÅvª÷°ª¹F6.8»õ¬ü¤¸!!! SNP-840¡GSNP-810(Acetaminophen+¯S©w¤½»{¦w¥þ¦¨¤À)+ hydrocodone (²B¥ià¬) CL-108: Acetaminophen + promethazine +hydrocodone (²B¥ià¬) .................................................. ......................................... ·|û¡GROGER588910148151 µoªí®É¶¡:2020/9/2 ¤W¤È 11:04:43²Ä 334 ½g¦^À³ 2014.02.11 Mallinckrodt13»õ¬ü¤¸¦¬ÁÊCadence¥HÀò±oÂíµhÃÄOfirmev(º¤ä¹ï¤A酰®ò°ò×ôÀR¯ßª`®g¾¯) (³Ì²×¦¬ÁÊ»ù¬O14»õ¬ü¤¸) .................................................. ............................................ ±q³o2¥ó¹ï¤A酰®ò°ò×ôªº°ê»Ú±ÂÅv»P¦¬ÁʮרҡA SNP-810ªº±ÂÅvª÷¥i´Á«Ý³Ð·s°ª¦ý¤S©È¨ü¶Ë®`! Orz. |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/12 ¤U¤È 12:01:28²Ä 499 ½g¦^À³
|
¤é ´Á¡G2020¦~12¤ë21¤é ¥D ¦®¡GªYÄ£»P°ê»ÚÃļtñqSNP-810¬ãµo¦X§@¨óij .. °ê»ÚÃļt¨Ì¾Ú¥»¦X§@¨óij±N¤ä¥I¥»¤½¥q¤@©wª÷ÃB¤§Ã±¬ùª÷¤Î¨½µ{¸Oª÷¡C ©¡®É±N¥t¦æ¤½§i¡C .............................................................................................. ª÷ÃB¦½Í§´....¤£¤½§iñ¬ùª÷¤Î¨½µ{¸Oª÷¾÷²v~0 ¥t¥~¡AªYÄ£°ª¼h»¡¤£¦n¤]¤£ª¾¹DJ&J½æ±¼JNJ-10450232!? |
|
|
·|û¡G¤j¶Q10149981 µoªí®É¶¡:2021/1/12 ¤W¤È 11:40:58²Ä 498 ½g¦^À³
|
Roger¤j¤j: Y¦³©¯ªYÄ£¬O»PJNJñ¬ù¡A ·|¤£·|¦³¥i¯à¹³±z´£¨ì³o°¦ÃĪ« JNJ-10450232¤£¤½§i±ÂÅvª÷ÃBªº¥i¯à©Ê©O¡H ¥Ø«eªYÄ£µ¹¤H·Pı¬O³Q±ÂÅv¤è¹ï¦¹Ã±¬ù·¥«×ªº«O±K¨ì®a Y¬O¦p¦¹ªÑ²¼±N¤£µ¹¤O¤F¡K?? |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/12 ¤W¤È 10:31:31²Ä 497 ½g¦^À³
|
ªYÄ£(6634)µL¨x¬r©Ê¤îµh·sÃÄSNP-810¨ú±o¬ü°ê±M§Q¤½§i (4)...°£¥»¤½¥qSNP-810¥~¡A¥Ø«e¥«³õ¤W©|µL¨ä¥¦Ãþ¦üµL¨x¬r©Ê¤§Ävª§acetaminophen¤§¤îµh²£«~¡C ............................................................................................... ¤½¥q°T®§¦³»~¡C J&J»PGSK°£¥~¡A¦¦³µL¨x¬r©Ê¤§acetaminophenÄvª§ªÌ¡A¥u¬O¾÷¨î¤£¦P! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/12 ¤W¤È 10:09:20²Ä 496 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/8/27 ¤W¤È 10:21:21²Ä 323 ½g¦^À³ µL¨x¬r©ÊSNP-810ªºÄvª§ªÌ¤§(¤G)¡C 2006¦~8¤ë21¤éµL¨x¬r©Ê[¹ï¤A酰®ò°ò×ô]Ãþ¦üª«ªº¦X¦¨(pubmed.ncbi.nlm.nih.gov/16919959/ ) ³o¤ä¬ü°ê¶¤¸g¹Lº©ªø14¦~²×©ó¬ð¯}²~ÀV¡A³Ìªñ·s»D¦h¡A¶i«×¤]»â¥ý©³¤UÄvª§ªÌ¤§(¤@)¦n¨Ç¦~¡A¦ý¤´µM»·»·¸¨«áªYÄ£¡A³o¤G¤ä¬ü°ê¶¤³£¬O¶}µoµL¨x¬r©Ê[¹ï¤A酰®ò°ò×ô]Ãþ¦üª«¡A»PªYÄ£SNP-810§@¥Î¾÷¨îºIµM¤£¦P¡C Ó¤H³W¹º¬Oªø´Á«ù¦³ªYÄ£(±ÂÅv«á¤£¶È¤£·|½æ¥X¤ÏË·|¥[½X¡A°£«D¦X¬ùª÷ÃB»P«¥¦ô»ù®t¶Z«Ü¤j)¡A¦³Ävª§ªÌ«_¥XÀY¡A ©Ò¿×ª¾©¼ª¾¤v¡A¦Ê¾Ô¤£¬p¡A¦C¤Jªø´Á°lÂܦӤw¡A¤ð±e¼~¼{! ............................................................................................... ·|û¡GROGER588910148151 µoªí®É¶¡:2020/8/24 ¤W¤È 09:08:58²Ä 315 ½g¦^À³ ³o¬O¤w«_¥XÀYȱoÆ[¹îª`·NªºÄvª§ªÌ¤§(¤@)¡A¥Ø«e®t¶ZÁÙ«Ü»»»·¡C Researchers have developed a safer building block for the development of new medicines. www.futurity.org/1-aminonorbornane-aniline-side-effects- -------------------------------------------------------------------------------------------- ¥[¤WJ&JªºJNJ-10450232¡A³o3¤ä¬OAPAPµ²ºcÃþ¦üª«¡A»PªYÄ£SNP-810§@¥Î¾÷¨îºIµM¤£¦P¡C ¤j«v°Ý-J&J¬°¦ó½æ±¼JNJ-10450232??? |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/12 ¤W¤È 08:16:18²Ä 495 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/7/18 ¤U¤È 04:09:16²Ä 171 ½g¦^À³ J&Jªº¤îµhÃĦ¿¤s¦MÀIÅo! ¤H®aì¥ý¹êÅç¬OAdvil©MTylenol(J&J)ªº²Õ¦X´N¯à¹ï¯fµh°_¨ìÅãµÛªº½w¸Ñ§@¥Î¡A¨Ã¥B¤£¨}¤ÏÀ³·|§ó¤Ö! 2018¦~J&J·mÁʽ÷·ç¥¢§Q¡A³QGSK§áÂনAdvil©MPanadol(GSK)ªº²Õ¦X¡C2020¦~2¤ë¦¨¬°²Ä¤@ÓFDA§å㪺Advil+Panadol¡C .......................................................................................... ¤Ç¯÷³ù¤j¾Çªº¤ú¬ì©MÃIJz¾Ç±Ð±ÂPaul Moore³Õ¤hªí¥Ü¡G¡u¨ä¹ê¤j¦h¼Æªº±wªÌ¦b§Y¨Ï¨S¦³¨Ï¥Îªü¤ùÃþ¤îµh¾¯ªº±¡ªp¤U¤]¬O¥i¥H§Ô¨ü¯fµhªº¡A¤ñ¦p§Ú̵o²{ªºAdvil©MTylenol(J&J)ªº²Õ¦X´N¯à¹ï¯fµh°_¨ìÅãµÛªº½w¸Ñ§@¥Î¡A¨Ã¥B¤£¨}¤ÏÀ³·|§ó¤Ö ............................................................................................ ¤W1§½: ì¥ý°ê¥~¹êÅç¬OAdvil©MTylenol(J&J)ªº²Õ¦X¡Aµ²ªGJ&J³QGSK±Nx¡C ³o1§½: ªYÄ£SNP-810Á{§É¹êÅç¹ï·ÓÃĪ«¬OGSK ªº´¶®³¯k¡AJ&J¯à¤Ï±NxGSK??? A Study to Evaluate the Pharmacokinetics of Acetaminophen and Its Toxic Metabolites With 2 Formulations (Panadol and SafeTynadol) in Healthy Volunteers |
|
|
·|û¡Gop123410143906 µoªí®É¶¡:2021/1/12 ¤W¤È 07:48:20²Ä 494 ½g¦^À³
|
¤j¶Q¤j:®¥³ß±z§ÖnÅܦ¨¤j´I¤j¶Qªº¤H¡C Á`¤ñ¦³¨Ç¥Í§Þ¤½¥q¡A¤°»òn¦b²Ä¥|§Þµoªí?¤S¤°»ò¼W¸ê¤S---¨S¦³¤@¶µ§I²{¡A«¢«¢«¢¡I ¦³¸Û«Hªº¤½¥q´N©ñ¤ß¡Aµ¥¦n®ø®§¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/11 ¤U¤È 11:19:02²Ä 493 ½g¦^À³
|
69 Summary of the preclinical pharmacology of NTM-006 (formerly JNJ-10450232): a novel orally-active non-opioid analgesic ..... JNJ-10450232, a structural analog of acetaminophen (JNJ-10450232¡Aµ²ºcÃþ¦ü¹ï¤A酰®ò°ò×ôAPAP) ............................................................................................... JNJ-10450232ªºµ²ºcÃþ¦ü¹ï¤A酰®ò°ò×ô(APAP)¡A¨º»ò¥Ù¬Þ¹ï¨M´N¤£©_©Ç¡A©_©Çªº¬O¬°¦ón§âT½æµ¹§O®a??? |
|
|
·|û¡G¤j¶Q10149981 µoªí®É¶¡:2021/1/11 ¤W¤È 10:41:46²Ä 492 ½g¦^À³
|
ÁöµMªYÄ£¤£¿ù¡A ¦ý¿³Âd¥æ©ö¯uªº¦nÃø¶R½æ¡K ±ÀÂ˨é°Ó³£nÁȤ@¤â¡A¥u¯à¥Î¥L̳øªº³Ì¨ÎÀɤ~¦³¿ìªk¦¨¥æ¡A ¶R½æ»ù®t¯uªº«Ü¤j¡K µL©` |
|
|
·|û¡G¤j¶Q10149981 µoªí®É¶¡:2021/1/11 ¤W¤È 10:32:59²Ä 491 ½g¦^À³
|
§Ú¬O·íªìÁʶR¦¨¥»¤Ó°ª¡A¥u¦n¤@ª½©¹¤U¶R¡AÄ~ÄòÅu¤F¡K |
|
|
·|û¡G¤p¤å¤l10144877 µoªí®É¶¡:2021/1/11 ¤W¤È 09:49:28²Ä 490 ½g¦^À³
|
¤j¶Q¤j¡G ·Q¤£¨ì§A«ùªÑ¤]¸òJ¤j¨º»ò¦h³á¡C¡C¡C¦pªGªYÄ£ªÑ»ù¼Q¤F¡C¡C¡C§A¥i§ï¦W¥s¤j´I¤j¶Q¤F³á¡C¡C¡C |
|
|
·|û¡G¤j¶Q10149981 µoªí®É¶¡:2021/1/11 ¤W¤È 09:28:17²Ä 489 ½g¦^À³
|
ÁÂÁÂROGER¤£§[§iª¾¡A¤p§Ì«ùªÑ¤]¸òROGER¤j®t¤£¦h ªYÄ£ªº·sÃÄÃD§÷¯uªº«Ü§l¤Þ¤H¡A«s«s¡A¥i±¤ªÑ»ù«Ü¤£µ¹¤O¡A µ¥«Ýªº¹Lµ{¯uªº«Ü·Î¼õ¡K¦n¤£®e©ö©Ô¤W¥h¡A¤S¦bµuµu´X¤Ñ¨º¶^¤U¨Ó ¦pªG¦³¹³¦X¤@·íªìª£¤W¥h¨º¼Ë¡A¦³³sÄòÃD§÷Ãzµo¡A ¬Û«HªÑ»ù¤@©w·|Åý¤j®aº¡¸ü¦ÓÂk¡C ©ê¦³ªYÄ£¤w¸g¤£ª¾¤£Ä±¹L¤F¥b¦~¦h¤F¡K |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/11 ¤W¤È 08:00:39²Ä 488 ½g¦^À³
|
J&J®³¦Û®aªº¥Ù(JNJ-10450232)¬Þ(Tylenol)¹ï¨M¡A¦b³ÌÁ䪺®É¨è«e³Û°±¡AµM«á§â¥ÙJNJ-10450232½æ¥X??? ®É¶¡ÂI´N³o»ò¥©¦X¦b»PªYÄ£°Ó°QSNP-810¦X§@¨Æ©y«á?¦ÓNeumentum CEOª¾¹D³o¥ó¨Æ? «ÜÃøÅý¤H¤£Áp·Q¨ä¤¤¦³¿ß¿°¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/10 ¤U¤È 10:30:17²Ä 487 ½g¦^À³
|
2019.10.22 Neumentum¡¦s CEO Discusses Deal With J&J for Non-Opioid Acute Pain Treatment www.biospace.com/article/neumentum-s-ceo-discusses-deal-with-j-and-j-for-non-opioid-acute-pain-treatment-/ |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/10 ¤U¤È 10:23:14²Ä 486 ½g¦^À³
|
¦³ÂI·N«ä¦a¤@¥ó¨Æ¡Aµo¥Í®É¶¡±µªñ¦³µLÃöÁp©Ê¡A¥Ø«e«¥¥u¯à»¡¦³5¦¨¾÷²v? ¨Ó¤éY¬OJ&J·m¨ìSNP810¡A¨º»ò2¥ó¨Æ8¦¨¦³Ãö³s¡A¤]¬O¤j´Û¤pªºªí²{¡C 1.ªYÄ£ 2019/02 »P¸ó°ê«e¤Q¦W»sÃĤ½¥qñ¸p¦³Äv·~¸T¤î¤§«O±K¨ó©w¡A°Ó°QSNP-810¦X§@¨Æ©y¡C(«e10´N²[»\GSK/ J&J) 2019/04 »P¸ó°ê«e¤¦W¤§»sÃĤ½¥q¡A¬ãµo¹Î¶¤¦@¤E¦ì¤£¦P³æ¦ì°ÆÁ`µô¤Î¨Mµ¦¤H¤h¡A¦b¬ü°êÁ`³¡³sÄò¤K¤p®É¡A¸Ô²Ó°Q ½×½T¥ßµL¨x¬r©Ê¤îµh·sÃÄSNP-810¤§¬ì¾Ç·N¸q¡B«nÁ{§ÉÀ³¥Î¡B¥þ²y±M§Q§G§½¤Î¦X§@±ÂÅv¨Æ©y¡C(«e5ª½«üJ&J) 2. 2019.10.22---J&J±NºX¤UJNJ-10450232¤îµhÃĽ浹Neumentum¤½¥q(¥æ©ö±ø¥óª÷ÃB§¹¥þ«O±K¤£»¡) JNJ-10450232»P acetaminophen / TylenolÀY¹ïÀYÁ{§É¹êÅç clinicaltrials.gov/ct2/show/NCT02209181?term=JNJ-10450232&draw=2&rank=1 |
|
|
·|û¡G¤p¤å¤l10144877 µoªí®É¶¡:2021/1/10 ¤U¤È 09:39:13²Ä 485 ½g¦^À³
|
R¤j¡G ·|ª`·N¨ìªYÄ£¡A¨Ã¤Ö¶q«ù¦³¡A¨Ã¤£¬O·QÁȤj¿ú¡A¦Ó¬O§Æ±æµ¹¤©¹ê»Ú¤Wªº¤ä«ù¡A¦]¬°§Ú¥»¨¦³¯×ªÕ¨x¡A¤S¨C¤Ñ§]´¶®³¯k¡A©Ò¥H²{¹ê¤W§Ú¯uªº§Æ±æªYÄ£³o2´Ú«½SÃĪ«¯à¦¨¥\¡AªYÄ£¥[ªo¡C¡C¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/10 ¤U¤È 08:52:14²Ä 484 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/4/19 ¤W¤È 11:03:12²Ä 2466 ½g¦^À³ ·|û¡GROGER588910148151 µoªí®É¶¡:2019/11/13 ¤U¤È 02:35:40²Ä 1537 ½g¦^À³ «¥°ß¹ï¾P°âÃB¦³¼ç¤O¦¨¬°«½SÃĪ«ªº·sÃĦ³¿³½ì¡C[§Ú̹ï©óªñ´Á¤½¥¬ªº ASLAN004 ¼Æ¾Ú·P¨ì«D±`¿³¾Ä¡A§Ú̬۫H³o¶µÃĪ«¨ã³ÆÀu©ó²{¦³ÃĪ«ªº¯S©Ê¡A¨Ã¾Ö¦³¼ç¤O¦¨¬°²§¦ì©Ê¥Ö½§ª¢¤Î¨ä¥Lµoª¢©Ê¯e¯f¤§¦P¯Å³Ì¨ÎÀøªk]----¤µ¤Ñ§ë¸êªÌ¤w»{¬°¬O¦Ñ¤ý½æ¥Ê¤F!!! ¶K3Ó¤§«e»`¶°ªº²§¦ì©Ê¥Ö½§ª¢¸ê®Æ,ÁÙ¦³¿³½ìªÌ¥h¬ã§PASLAN004¯à¤£¯àÀu©óDupilumab!................ ........................................................................................... ¤@Áû¦A´¶³q¤£¹Lªº´¶®³¯k¤îµhÃÄ¡A §¹¥þ§l¤Þ¤£¤F§ë¸ê¤H¦a²´²y!!! ¦b«¥²´¸Ì«o¬O«½SÃĪ«>10»õ¬ü¤¸!!! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/10 ¤U¤È 08:44:52²Ä 483 ½g¦^À³
|
2017¦~«¥¤Þ¥Î¸ê®Æ¼g¬u²±FB825±ÂÅvª÷5»õ¬ü¤¸¤§¤W,©Û²³¤H¶á¤§¥H»ó¡A½Ö«H¤F??? ¤@Áû¦A´¶³q¤£¹Lªº´¶®³¯k¤îµhÃÄ¡A §¹¥þ§l¤Þ¤£¤F§ë¸ê¤H¦a²´²y!!! .......................................................................................... ·|û¡GROGER588910144700 µoªí®É¶¡:2017/6/23 ¤W¤È 10:50:10²Ä 534 ½g¦^À³ FB825ªº»ùÈÁô¬ùÂæb³o½g! ·s«½S药¦a带 www.yyjjb.com/html/2016-12/30/content_245982.htm ¤½¥q¬£»¡5»õ¬ü¤¸¤§¤W¦ó¨Ó§j¼N??? ................................................................................... ¿ð¨ìªº5.3»õ¬ü¤¸,²×©óÅý«¥¦R¤F¤@¤j¤f«è®ð!!! .................................................................................. 2017»¡±ÂÅvª÷5»õ¬ü¤¸¤§¤W,¦³½Ö¬Û«H¤F???¦b¤¤¸ÎªÅª©¤O¾Ô¸s¶¯¶K¨ì¤âµm¤S¦³½Ö«H¤F??? ..´Nºâ¨È·à±d¯un¦b¥x¤U¥«, ¥i¥H¥tÃþ«ä¦Ò¤@¤U³o«h´N·s»D:´¦¶}³¯®õ»Ê±N°ê¥¨¤U¥«¤º¹õ¡þ¤j¦ÑÁ󪺳¥ÆZª÷¿ú¹CÀ¸ stock.pchome.com.tw/magazine/report/po/businesstoday/4299/130262400027479004001.htm |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/10 ¤U¤È 08:12:20²Ä 482 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/10/22 ¤W¤È 08:48:51²Ä 9546 ½g¦^À³ «e°}¤l¥´¹q¸Üµ¹[¤pªL§Ó¬Â]°Ý¨Æ¡Aªü©f»¡¥DºÞ̦b¶}·|¡An§Ú¯d¤U¸ê®Æ....¡A 2¤p®É«á¡A¨S·Q¨ì¸³¨Æªø¿Ë¦Û¨Ó¹q¡CÃĵدu¤ßÃö¤Á¹L¤pªÑªFªº°ÝÃD? .............................................................................................. ·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/26 ¤W¤È 06:11:45²Ä 422 ½g¦^À³ ·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/23 ¤W¤È 09:09:55²Ä 413 ½g¦^À³ ±ÂÅvª÷«¥¤ß¸Ì¤]¨S©³!±ÂÅvª÷«¥¤ß¸Ì¤]¨S©³!±ÂÅvª÷«¥¤ß¸Ì¤]¨S©³! ............... 3.«¥´¿¥h¹q¤½¥q¸ß°Ý¨Ç¨Æ±¡.... ¥Ñ¤W¬ã§P¡AªYÄ£°ª¼h«Ü¥i¯à¤£ª¾¹D¦³2014¦~Mallinckrodt¥H13»õ¬ü¤¸¦¬ÁÊCadenceªº°ê»Ú¦æ±¡¥i°Ñ¦Ò¡C ........................................................................................... ¦³¤@»¡¤@¹ê¸Ü¹ê»¡¡A¨S¦³¦nÁô¿f¤§¨Æ! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/10 ¤U¤È 08:04:56²Ä 481 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/28 ¤U¤È 06:20:51²Ä 435 ½g¦^À³ ªÑªF¤H¼Æ±q3084(7/24)-1952(12/25)=´î¤Ö1132¤H ½Ð°Ý¶}ª©¥D±zÁÙ«ù¦³ªYÄ£¶Ü? .......................................................................................... ¤[¤£¨£¶}ª©¥Dhung120110149413¦^À³¡A¬Ý¨Ó¬O¦ì¦C¦b1132¤F¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/10 ¤U¤È 07:58:20²Ä 480 ½g¦^À³
|
·|û¡GROGER588910148151 ³o»ò©ú¥Õ»¡¦n¤Fwww.tdcc.com.tw/smWeb/QryStockAjax.do Y¸ê®Æ¬O¯u,«¥¦b«eXX¤º ...¬O½Ö¬~½Ö??? ............................................................................................... ·|û¡GROGER588910148151 µoªí®É¶¡:2020/7/3 ¤W¤È 09:28:01²Ä 45 ½g¦^À³ ´±«À£ªYÄ£¡A¥Dn¬O¤½¥qÁÙ¦³SNP8¨t¦C¡A¶i¥i§ð°h¥i¦u! «¥¬O»{¬°SNP8¨t¦C(¤AñQÓi×ô¦A¥[¤W¯S©w¤½»{¦w¥þ¤§¦¨¤À)î³ÃÄÃÒªº¡C ............................................................................................... XX¨º¬q¤é´Á¯S·N®³±¼¡A«e¨Ç¤é¤l¤U±þ¤S¼W¥[¤@¨Ç«ùªÑ¡A©Ò¥H±Æ¦æ¦A«e¶i¨Ç¡C ¨D¤H¤£¦p¨D¤v¡A¤j´I¤j¶Q±o¾a¦Û¤v!!! |
|
|
·|û¡G¤j¶Q10149981 µoªí®É¶¡:2021/1/10 ¤U¤È 06:51:01²Ä 479 ½g¦^À³
|
³o¸Ì¦³¤H¦³«ùªÑ¶W¹L50±i¶Ü¡H ½Ð°Ý¤è«Kª¾¹DROGER¤j¤j«ù¦³¦h¤Ö¶Ü¡H |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/10 ¤W¤È 08:25:11²Ä 478 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/28 ¤W¤È 06:34:59²Ä 429 ½g¦^À³ 4128¤¤¤Ñ109/12/31 15:00 ½u¤Wªk»¡·|:»¡©ú¥»¤½¥q¸gÀçÁZ®Ä¡BÀç¹B²{ªp¤Î¥¼¨Ó®i±æµ¥¡C³sµ²ºô§}reurl.cc/OqZ7O9 ---------------------------------------------------------------------------------------- ¤£¹H«O±Kì«h¤U¯à³zº|¨º¨Ç®ø®§??? .......................................................................................... ¦ª¾¹D¤£¥i¯à»¡¤°»ò¡C ¥u¦³¤@¥y:ªYÄ£¤£¬O¤¤¤Ñ¤l¤½¥q¡A¬O³z¹LÆp¥Û¥Í§ÞÂà§ë¸êªº¤½¥q¡C ¨Ì¤½¥qªkÃö«Y¥ø·~³¹¤§©w¸q:ª½±µ©Î¶¡±µ«ù¦³¥L¤½¥q¤wµo¦æ¦³ªí¨MÅv¤§ªÑ¥÷Á`¼Æ©Î¸ê¥»Á`ÃB [¶W¹L¥b¼Æ] ¤§¤½¥q¡A¬°¥À¤½¥q¡F³Q«ù¦³ªÌ¡A¬°¤l¤½¥q¡C |
|
|
·|û¡G¤p¤å¤l10144877 µoªí®É¶¡:2021/1/10 ¤W¤È 05:34:47²Ä 477 ½g¦^À³
|
·s«aªÍª¢¬Ì±¡ÀI®m¡Aªñ¤é¥@¬É½Ã¥Í²Õ´¡]WHO¡^ĵ§i¡A¥Á²³Y¬O¦³·s«aªÍª¢ªº¯gª¬¥X²{¡A´N¤£À³¸Ó¦Û¦æªA¥Î§Üµoª¢ÃĪ«¥¬¬¥ªâ¡C ®Ú¾Ú¥~´C³ø¾É¡A¥@¬É½Ã¥Í²Õ´µo¨¥¤HChristian Lindmeier¦b17¤é¦V°OªÌ³zÅS¡AÁöµM¥Ø«e¨S¦³¥ô¦óÃÒ¾ÚÅã¥Ü¡A®øª¢ÃĪ«©M¦º¤`²vªº¼W¥[¦³Ãö¡A¦ý¥L¤]¸É¥R»¡©ú¡A±M®a³Ìªñ¤w¸g¶}©lµÛ¤â½Õ¬d¤¤¡C Christian Lindmeier«Øij¡A¦b¨S¦³Âå®vªº«Øij¤U¡A¥Á²³¦Û¦æªAÃÄ®ÉÀ³¸Ó¿ï¾Üacetaminophen¡]¤SºÙ¤AñQÓi×ô¡B´¶®³¯k¡^¤îµhÃÄ¡A¦ÓÁקKªA¥Î¥¬¬¥ªâ¡C ¨Æ¹ê¤W¡A¥¬¬¥ªâ¬O¥xÆW¤H±`¥ÎªºÃĪ«¡A¦bÃħ½¸Ì«Ü®e©ö¥i¥H¶R¨ì¡A¥xÆW®È«È¨ì¤é¥»®É±`¶Rªº¤îµhÃĤ]§t¦¹¤@¦¨¤À¡C ªk°ê½Ã¥Í³¡ªøOlivier Véran¤W©P¤»¤~¦b±À¯S¤Wĵ§i¡A®øª¢ÃĪ«¹³¬O¥¬¬¥ªâµ¥µ¥¡A¦³¥i¯à·|¨Ï·s«aªÍª¢¯gª¬¥[¼@¡A¤£«Øij¦b¨S¦³Âå®vªº«ü¥Ü¤UªA¥Î¡AY¦³µo¿N¯gª¬¡A«Øij¥ý¦bÂå®v«ü¥Ü¤UªA¥Î´¶®³¯k¡A¦ý¤]§OªA¥Î¹L¶q§_«h·|¶Ë®`¨ì¨xŦ¡C «ÂI¬O³Ì«á¨º¥y¡AªA¥Î¹L«×·|¶Ë¨x¡A¦ýªYÄ£810¬OµL¨x¬r¡A820¬O¸Ñ¬r¾¯¡C¡C¡CÃø©Ç³Ì¥i¯àÀu¥ýÀò±o±ÂÅv¡C¡C¡C |
|
|
·|û¡G¤p¤å¤l10144877 µoªí®É¶¡:2021/1/9 ¤U¤È 02:43:17²Ä 476 ½g¦^À³
|
°ê»ÚÃļt¨Ì¾Ú¥»¦X§@¨óij±N¤ä¥IªYÄ£¤@©wª÷ÃBªºÃ±¬ùª÷¤Î¨½µ{¸Oª÷¡A¥Ø«e°ò©ó¹ï¤èn¨Dªº«O±K¬ù©w¡A¤£´¦ÅS¦X¬ù±ø¤å¤Î¬ãµo¾÷±K¤§¤º®e¡A¥]¬A¡GÀø®Ä°t¤è¡C¡C¡C ¨ä¹ê³o¦¸À禬¤½§i¡A¨Ã¥¼¦³Ã±¬ùª÷¤J±b¡A¦ý«o¦³§Ú©ÒÅå³YÀø®Ä°t¤è©Ò¥²»Ýì®ÆÀ禬¤J±b¡AY³o¤]¬O¦X¬ù¤º®e¡A¶H¼x¥H«áªYÄ£¤w¯à¦Û¦æ³Ð³yÀ禬¤F¡A¤£¥Î¾añ¬ùª÷¡A±ÂÅvª÷©Î¨½µ{¸Oª÷³o¨Ç¤@¦¸©Ê¦¬¤J¤F¡A³oÀ³¸Ó¬O³o¦¸À禬¤½¥¬ªº«GÂI¡A¦ý¦]ñ¬ùª÷¨Ã¥¼¤J±b¡A§«ô¤@¸{·¦å«B¬O§K¤£¤F³á¡A¦]¬°¤£²Å¦X¬Y¨Ç¤Hªº´Á«Ý°Ú¡C¡C¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/9 ¤U¤È 02:14:56²Ä 475 ½g¦^À³
|
³B¤è¾~¤ùÃÄCL-108´î¤Öäú¤ß©M¹Ã¦Rªº§ïµ½±ÂÅvª÷È6.8»õ¬ü¤¸!!! www.biospace.com/article/daiichi-sankyo-terminates-650-million-deal-with-this-u-s-pharma-/ --------------------------------------------------------------------------------------------- OTC«D³B¤è(325mg)+ ³B¤è(>325mg)ªºSNP-810¥H·¥¥©§®ªº¤è¦¡¨Ó¸Ñ¨M60¦~¤jÃļt¤@ª½µLªk¸Ñ¨Mªº°ÝÃD¡C ¥HÀ°§U¯f¤H´£¨Ñ§ó¦w¥þªºÃÄ«~¡A±ÂÅvª÷±N¬O¦b¤Ï¬M¦¹°^Ämªº»ùÈ¡A¤]±o¨ì°ê»Ú¤j¼tªº»{¥i¡C [¤]±o¨ì°ê»Ú¤j¼tªº»{¥i]---«Ì®§«ø¥Ø¥H«Ý¡A±Æ¦æ²Ä4»P²Ä8ªºÃļt¤â°©¦³¦h²Ê???(¤£ª¾¬°¤£ª¾¡A¬Oª¾¤]¡C) |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/9 ¤W¤È 11:34:51²Ä 474 ½g¦^À³
|
¨S·Q¨ì»PSNP-840¦PÃþªºCL-108±ÂÅvª÷°ª¹F6.8»õ¬ü¤¸!!! SNP-840¡GSNP-810(Acetaminophen+¯S©w¤½»{¦w¥þ¦¨¤À)+ hydrocodone (²B¥ià¬) CL-108: Acetaminophen + promethazine +hydrocodone (²B¥ià¬) 2014¦~CL-108±ÂÅvª÷ 6.8»õ¬ü¤¸ www.fiercebiotech.com/biotech/daiichi-axes-650m-pain-pact-7-months-after-fda-setback |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/9 ¤W¤È 11:24:27²Ä 473 ½g¦^À³
|
¦Û¸Ñ: µL¨x¬rSNP-810=APAP+SNP-820 SNP-820=¥ÌÅS¾J+¤T´â½©¿}(SNP-810±M§Q¼g³o2¤ä²Õ¦X®ÄªG³Ì¦n) ¦pªG½T»{¨º46¸U¾P°âªº¬O[¥ÌÅS¾J+¤T´â½©¿}]¡A¨º»ò¤£½T©wªº¬O·|²Õ¦X¦¨GSK(Panadol+SNP-820)? ÁÙ¬OJ&J(Tylenol +SNP-820)? ----------------------------------------------------------------------------------------- ¥ÌÅS¾J¦³¤u·~¯Å /¹«~¯Å /ÂåÃįųW®æ ¤T´â½©¿}¦n¹³´N¥u¦³¹«~¯Å³W®æ |
|
|
·|û¡G¤p¤å¤l10144877 µoªí®É¶¡:2021/1/9 ¤W¤È 10:46:34²Ä 472 ½g¦^À³
|
R¤j¡G ¹ïªYÄ£¬ã¨sº¡º¡ªº§A¡AÀY¤@¦¸¨£§AÅS¥XºÃ´bªºªí±¡¡C¡C¡C¹«~¤¤¶¡Åé¡A¨ì©³¬OÔ£ªFªF¡A¦³½Ö¯à¸Ñ´b¶Ü¡C¡C¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/8 ¤U¤È 02:53:10²Ä 471 ½g¦^À³
|
1~11¤ëÀ禬0 12¤ëÀç·~¦¬¤J46.2¸U--«Y¾P°â¹«~¤¤¶¡Åé©ÒP¡C ..................................................................................... [¹«~¤¤¶¡Åé]---¬O«üSNP-810ªº¦w¥þ¦¨¤À:[¥ÌÅS¾J+¤T´â½©¿}]??? |
|
|
·|û¡Gdk10140377 µoªí®É¶¡:2021/1/6 ¤U¤È 10:02:42²Ä 470 ½g¦^À³
|
Ó¤Hªº·Pı¡A¯d¦b¿³Âd¦n |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/6 ¤U¤È 05:08:38²Ä 469 ½g¦^À³
|
½Ð°Ý¶Q¤½¥q¦³¥Ó½Ð¤W¥«Âdªº®Éµ{ªí¶Ü? §Ú̦³³W¹º2021¦~©³´£¥X¤WÂd¥Ó½Ð¡A±©¸gÀÙÁ`Å骬ªp¡B°ê»Ú¬Ì±¡¡B±ÂÅv¶i«×µ¥½Ñ¦h¦]¯À·|¼vÅT¤WÂdªº°e¥ó®É¶¡¡C ............................................................................................... ±ÂÅv¶i«×·|¼vÅT¤WÂdªº°e¥ó®É¶¡¡C ·|´£«e©Î©µ«áÁÙ¬O«öìq®Éµ{??? |
|
|
·|û¡Gdk10140377 µoªí®É¶¡:2021/1/6 ¤U¤È 03:10:49²Ä 468 ½g¦^À³
|
ÁÂÁÂR¤j¡A¦pªG¬OFOLLOW¤¤¤Ñ¶°¹Î¡A³ÌªñÀ³¸Ó´Nn¦³®ø®§¥X¨Ó¡C¤½§i±ÂÅvª÷¡C¬Ý¬Ý¬O¤£¬O¤U¤@Ó¦X¤@!! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/6 ¤U¤È 01:58:35²Ä 467 ½g¦^À³
|
¬G¨Æªº³Ì²×³¹---¤]¬O³Ì½÷·×ªº¤@³¹---¥¿¦b»W¶Õ«ÝµoÁßÆC·í¤¤¡C ®É¶¡·|§i¶D§A! 1»õ¬ü¤¸ªºªÑ»ù? 3»õ¬ü¤¸ªºªÑ»ù? 5»õ¬ü¤¸ªºªÑ»ù? >5»õ¬ü¤¸ªºªÑ»ù? |
|
|
·|û¡Gdk10140377 µoªí®É¶¡:2021/1/6 ¤U¤È 01:03:14²Ä 466 ½g¦^À³
|
¦pªG¦³±ÂÅvª÷¡A·|¤½§iªº§a¡A¤£¥Îµ¥¨ìÀ禬¥X¨Ó ¥u³Ñ¤U82¡A¤S³Q¥´¦^쫬 |
|
|
·|û¡G¦h¦h10137435 µoªí®É¶¡:2021/1/5 ¤U¤È 12:59:07²Ä 465 ½g¦^À³
|
12¤ë21ªº«°T¦³Ãö¦X§@ªºÃ±¬ùª÷¦³¾÷·|¥h¦~©³«e¦¬¨ì? ¥»©P¤½¥¬À禬¥iª¾§_?! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/5 ¤W¤È 08:35:18²Ä 464 ½g¦^À³
|
OTC(«D³B¤è)¤îµhÃÄ¥«³õ(NSAIDSªü´µ¤ÇÆF + APAP +§½³¡³Â¾KÃĵ¥ÃĪ«)±N¦b2019¦~¬ð¯}190»õ¬ü¤¸! (¤£§t»Ý¥ÑÂå¥Í¶}¥ßªº³B¤è¤îµh¾¯) FMI¬ã¨s³ø§i...¹ï¤A酰®ò°ò×ô(APAP)¬O³Ì±`¥ÎªºOTC¤îµhÃĤ§¤@¡A¸ÓÃþÃĪ«¦bOTC¤îµhÃÄ¥«³õªº¦¬¤J¤¤¦û45¢Hªº¥÷ÃB¡C ¨ì2019¦~¡A¹ï¤A酰®ò°ò×ôÃĪ«¦bOTC¤îµhÃÄ¥«³õ¤¤ªº³Ì¤j¥÷ÃB±N«O«ù¦b87»õ¬ü¤¸¥H¤W(¥þ²y«D³B¤è¥«³õ)... www.globenewswire.com/news-release/2019/02/20/1738355/0/en/Over-the-Counter-Pain-Medication-Market-will-Exhibit-a-Steady-4-0-CAGR-through-2028-Future-Market-Insights.html |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/5 ¤W¤È 06:39:58²Ä 463 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/7/27 ¤U¤È 10:51:23²Ä 217 ½g¦^À³ www.sinewpharma.com/upload/userfiles/file/About%20us/About+Us.pdf SNP-810¡]µL¨x¬r©Ê¹ï¤AñQ®ò°ò×ô¡^ªºÁ{§É«e©MÁ{§É¬ã¨sµ²ªG ¦bSD¤j¹«¤¤¡Aµ¹¤©¹ï¤AñQ®ò°ò×ô¬Û·í©ó¨C¤Ñ¤HÃþ¨Ï¥Î¾¯¶q¬°77gªºSNP-810¡Aµ¹ÃÄ«á¡A¤j¹«¨x¥\¯à¤´µM«O«ù¥¿±`¡C 77g VS 4g(500mg*8Áû--¤AñQ®ò°ò×ôªº¦w¥þ¾¯¶q¬°4g/¤Ñ) ............................................................................................... ·|û¡GROGER588910148151 µoªí®É¶¡:2020/7/17 ¤U¤È 10:56:33²Ä 168 ½g¦^À³ AAPM 2018¦~·|ºK (SNP-810) ...Acetaminophen (AAP) is the leading worldwide cause of drug-induced acute liver failure (ALF) ... could maintain normal hepatic function even with AAP doses of 2000 mg/kg, demonstrating a protective index (LD50) of more than 4X. These CYP450 inhibitors (referred to as antidote, research code: SNP-810) reduced AAP-induced hepatotoxicity by lowering the levels of aspartate aminotransferase, alanine aminotransferase, histology activity index (HAI-score) and inhibition of NAPQI formation (as shown by AAP-Cys, a biomarker representing NAPQI) (p < 0.005). The survival was 100% (24/24) in a majority of antidote-treated groups, whereas the survival rate was 17% (2/12) in AAP-only group and 50% (6/12) in the NAC-treated group. ............................................................................................ ¦s¬¡²v: SNP-810(100%) VS AAP(APAP)17% VS NAC(AAP¸Ñ¬r¾¯)50% |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/5 ¤W¤È 06:11:44²Ä 462 ½g¦^À³
|
2020¦~3¤ë27¤é¤t´¶Ã±¸p¡m«D³B¤èÃÄ(¦w¥þ)¡A³Ð·s©M§ï²ªk®×¡n¡CÃĦw¥þ! Ãijзs! Ãħï²! ¡m¦w¥þ¡n+¡m³Ð·s¡nµL¨x¬rªºSNP-810¼öªù·m¤â! ......................................................................................... SNP-810ªº¯S©w¡u¤½»{¦w¥þ¡v¤§¦¨¤À:¥ÌÅS¾J+¤T´â½©¿} SNP-8 ¨t¦C¦¨¤À: ¦Û¼Æ¦ÊºØ [¬ü°êFDA®Öã]¡B[±`¥Î¥B¦w¥þ]¡B[«K©yt¾á±o°_]¡B[¤HÅé¥i¹¥Î¦w¥þ¤Æ¦Xª«]... ¨ä¤@¤é¦w¥þ¨Ï¥Î¾¯¶q¥i¹F 20 g/person ¥H¤W¡A¥B¦b 200mg/person¾¯¶q¤U§Y¥i§í¨î²v¹F 60-88%¡C ............................................................................................... ¥ÌÅS¾J¡A¬ü°êFDA«Øij¥Î¶q¬°¨C¤é¹¥Î¤£¶W¹L20g¡C ¤T´â½©¿}¤f·P¤W»P½©¿}¤ñ¸û±µªñ¡A¦]¦¹¬O³Ì±`¥Îªº²¢¨ý´À¥N«~¡A¥Ø«e¼sªx¹B¥Î©ó¶¼®Æ¡B¿}¼ß¡B¨Å»s«~¡BªGÂæ¡B»eÀ^µ¥¥[¤u¹ª«¤§¤¤¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/4 ¤U¤È 05:35:26²Ä 461 ½g¦^À³
|
1972¦~FDA¥l¶°¤F¤@²ÕÂå¥Í©M¬ì¾Ç®a¨Óµû¦ô¤îµhÃÄ(¥]¬A¹ï¤A酰®ò°ò×ô)..µ²ªGªá¤F48¦~©|¥¼¸Ñ¨M¨x¬r©Ê¡C Orz. ¨S·Q¨ì¨g¤HÁ`²Î¤t´¶¤jµ§¤@´§µ¹³o³õÀ¸²K¦â¤£¤Ö! 1. 2012¦~1¤ë24¤é ---®Ú¾Ú±`ÃÑ¡AFDA¤µ¤Ñ¤£·|§åãªü¥q¤ÇªL¡A§ó¤£¥Î»¡¤¹³\¨ä¦¨¬°«D³B¤èÃÄ(OTCÃĪ«)¡C ¹ï¤A酰®ò°ò×ô(APAP)¤]¬O¤@¼Ë¤£·|§åã¡]¦b¬ü°ê¡A¹L¶q¨Ï¥Î¬O¾ÉP¨x°IºÜªº¥Dnì¦]¡^ Analgesics have a spotty history of switching to OTC. According to common wisdom, the FDA would not approve aspirin today much less allow it to go OTC. The same could be said for acetaminophen (overdose of which is the leading cause of liver failure in the US) www.reutersevents.com/pharma/commercial/pharma-marketing-and-sales-when-make-rx-otc-switch 2. 1975¦~12¤ë13¤é(¨S¼g¿ù¦~¥÷1975) ^°êÂå¥ZLancet¦b1975¦~ªºªÀ½×:¦pªG¸ÓÃĪ«(APAP)¡§¤µ¤Ñ³Qµo²{¡A¥¦±N¤£·|³Q^°êºÊºÞ¾÷ºc§å㡨¡C ¸ÓÂø»xªº½s¿è©eû·|ºÙ¸ÓÃĪ«ªºªí±¦w¥þ©Ê¡§¨ã¦³´ÛÄF©Ê¡¨¡C¥LÌ«ü¥X¡A¡§¤£¶W¹L«Øijªº³Ì¤j¨C¤é¾¯¶q¡¨¥i¯à·|¤Þ°_¨x·l®`¡A¦Ó¹ï¤A酰®ò°ò×ô¤¤¬r¤w¸g¬O^°ê¨x°IºÜªº¡§³Ì±`¨£ì¦]¤§¤@¡¨¡C www.documentcloud.org/documents/760638-lancet-para-hepa.html#document/p3/a121151 (¶À¦â®Ø¤ºªº¤å¦r) PS:1956¦~¡A¸¯Äõ¯À¥v§J¡]GSK¡^ 500mg¤@¤ùªº¤AñQÓi×ôÃĤù¦b^°ê¹Ò¤º¤W¥«¾P°â¡A°Ó«~¦WPanadol¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/4 ¤U¤È 04:18:55²Ä 460 ½g¦^À³
|
J&JªºTylenolªºª÷ÄÁ¸nÅK¥¬m¦b2020.3.27³Q¤t´¶¥´¯}Åo! 2020¦~3¤ë27¤é¤t´¶Ã±¸p¡m«D³B¤èÃĦw¥þ¡A³Ð·s©M§ï²ªk®×¡n¡CÅýµL¨x¬rSNP-810§ó·m¤â¥[È! 1. 2013¦~9¤ë23¤é «OÅ@±j¥Íªº®õ¿Õ·n¿ú¾ð§K¨üºÊºÞªÌªº«I®`ycharts.com/analysis/story/protecting_jandjs_tylenol_cash_cow_from_regulators ¦b¶W¹L35¦~ªº®É¶¡¸Ì¡A±j¥Í¡]Johnson¡®Johnson¡^¡]JNJ¡^»P¬ü°ê¹«~ÃÄ«~ºÞ²z§½¡]FDA¡^ª§§n¤F®õ¿Õ¡]Tylenol¡^ªºÄµ§i...¹ê¬Iĵ§iªº [³\¦h©µ¿ð³£¥i¥HÂk¦]©ó±j¥Í¤½¥q¬°ªý¤î¦¬¤J«OÅ@©Ò±Ä¨úªºÁ|±¹¡C] ±j¥Í¦b¦UӮɴÁ¡§¦h¦¸¤Ï¹ï¦w¥þĵ§i¡A¾¯¶q¨î©M¦®¦b«OÅ@¸ÓÃĪ«¨Ï¥ÎªÌªº¨ä¥L±¹¬I¡¨¡C 2.§ó·s¡G2017¦~6¤ë14¤é쪩ªº¡G2014¦~3¤ë10¤é ®õ¿Õ¦³¦h¦MÀI¡HFDA¥¿¦b¼f¬d¨ä«D³B¤èÃijW«h Áp¨¹ºÊºÞ¾÷ºc«Å¥¬¡A¥ḺN¼f¬d«D³B¤èÃÄ¡]¨Ò¦p¹ï¤A酰®ò°ò×ôªº¬¡©Ê¦¨¤À¹ï¤A酰®ò°ò×ô¡^ªººÊºÞ¡C psmag.com/social-justice/dangerous-tylenol-fda-reviewing-rules-counter-drugs-76178 ¸Ó½Õ¬dªº«ÂI¬O¼³¼ö®§µhªº¬¡©Ê¦¨¤À¹ï¤A酰®ò°ò×ô¡A¸ÓÃĪ«ÄÝ©ó¸Ó¼f¬d½d³ò¤ºªºÃĪ«¡C ¥¿¦p§ÚÌ©Ò³ø¾Éªº¨º¼Ë¡A¾¨ºÞ¤w¸g¶i¦æ¤F40¦h¦~ªº¤u§@¡A¦ýFDA©|¥¼³Ì²×½T©w¦³Ãö¹ï¤A酰®ò°ò×ô¦w¥þ¨Ï¥Îªºªk³W¡A³o³¡¤À¬O¥Ñ©óÁcº¾ªº©x¹±Åé«Y¹ï«D³B¤èÃĪººÞ¨î©ÒP¡C 3.2020.4.12 ·s¥ßªk¥Í®Ä¡I¬ü国FDA«D处¤è药监ºÞ«¤j§ï²ûD¹õ www.shangyexinzhi.com/article/1676862.html |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/2 ¤U¤È 08:37:57²Ä 459 ½g¦^À³
|
ycharts.com/analysis/story/protecting_jandjs_tylenol_cash_cow_from_regulators ¼ÐÃD: «OÅ@±j¥ÍªºTylenol·n¿ú¾ð§K¨üºÊºÞªÌ(FDA)ªº«I®` .......................................................................................... ¦pªG³Q¹ï¤âGSK·m¨«µL¨x¬rªºSNP-810·|µo¥Í¤°»ò¨Æ? Tylenol·n¿ú¾ð¥²ËµLºÃ! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/2 ¤U¤È 08:23:58²Ä 458 ½g¦^À³
|
2013¦~9¤ë23¤é J&J¦b¹Á¸Õ¶}µoµL¨x¬r¦w¥þª©ªºAPAP¥¢±Ñ«á¤T½p¨ä¤f¡A§Y¨ÏFDA¯S§O¸ß°Ý¶}µo³oºØµL¨x¬rAPAPÃĪ«ªº¥i¦æ©Ê¡C ¨C¦~¦]¬°¹ï¤A酰®ò°ò×ôªº¦º¤`¤H¼Æ¬O[©Ò¦³¨ä¥LOTC¤îµhÃÄÁ`©M]ªº¨â¿¡C ycharts.com/analysis/story/protecting_jandjs_tylenol_cash_cow_from_regulators ......The healthcare giant did try to create a safer version, but after the initiative failed, J&J kept the effort confidential, even when the FDA specifically asked about the feasibility of developing such a drug,.. .............................................................................................. ÂùÀs·m¯]ªº²¼¶R¤F´N¤J®y¡A¤£·Q¬Ý¶X¦ÁÙ¯à°h²¼¡C |
|
|
·|û¡G¤p¦b10150798 µoªí®É¶¡:2021/1/2 ¤W¤È 09:02:25²Ä 457 ½g¦^À³
|
810±ÂÅv¤]¦n¡A610±ÂÅv¤]½}¡A¥u§Æ±æ±ÂÅv¯à»°§Ö¥X¨Ó¡A¥Ø«e810±ÂÅv¸ò610±ÂÅvþÃä¶i«×¤ñ¸û§Ö©O¡H |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/1 ¤U¤È 10:16:28²Ä 456 ½g¦^À³
|
ªYÄ£¹wpSNP-610¦b¤G´ÁÁ{§É«á±N·|¥H±ÂÅv(Áp¦XªvÀø)¬°¥Dn¥Ø¼Ð¡A¹w¦ô¦b2¡ã3¦~¤º´N¥i±æ¦³¦¨ªG®i²{¡C 2017¦Ü¤µ3¦~¥b¡A ¥[ªoÅo! ............................................................................................ 2017.7.27±M§ð¨x¯f»â°ìNASH¥«³õ¡GªYÄ£¥ÍÂå(¨Ó·½:¡m¸UÄ_¶g¥Z¡n 1239´Á) ... ¦¶Á`¤´«Ü¦³¦Û«Hªºªí¥Ü¦]¬°¾Ö¦³¿W¯S¾÷ÂàÅýSNP-610»P¨ä¥L¶i«×»â¥ýªºÃĪ«¨ã¦³¤¬¸ÉªºÀu¶Õ¡A²¦³º¨x¯fªºP¯f¾÷Âà½ÆÂø¡Aµ´¹ï¤£¬O¤@ÁûÃÄ¥i¥H¦Y¤U¾ãÓ¥«³õªº¡A¤j¼t·Qn¥þ±´x´¤NA SH¥«³õªº¸ÜSN P-610±N·|¬O¤@Áû«D±`¦³»ùȪºÃĪ«¡C¦Ó¦b¾P°âµ¦²¤¤W¡AªYÄ£¹wpSNP-610¦b¤G´ÁÁ{§É«á±N·|¥H±ÂÅv¬°¥Dn¥Ø¼Ð¡A¹w¦ô¦b2¡ã3¦~¤º´N¥i±æ¦³¦¨ªG®i²{¡C¥t¥~SNP-630«h¬OªYÄ£²£«~½u¤¤ªº²Ä¤G¥NÃĪ«¡A¤£¶È¬°¥þ·s¤Æ¦Xª«¦Ó¥B§ó¦³¦h«¾÷Âà¡A¥¼¨Ó¥Ø¼Ð§óÂê©w¥]¬A°sºë©Ê¨xª¢¤Î«D°sºë©Ê¨xª¢µ¥»â°ì¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/1 ¤U¤È 09:18:58²Ä 455 ½g¦^À³
|
1.SNP-610ªº¬ãµoµ¦²¤¡B¥Ø«e¶i®i¤Î¹w©w¦ó®É±ÂÅv¡H §Ú̥ѹê»Ú±ÂÅv¬¢°Óªº¹Lµ{¤Î¸gÅç¡A¯S§O±N·sÀø®Ä¤Î·s¦¨¥÷SNP-610¤Î630 [¦U¦³¨äµ¦²¤³W¹º] 2.2020¦~12¤ë29¤éªYÄ£¯×ªÕ¨xª¢·sÃÄSNP-610¨ú±o¬ü°ê±M§Q ..¦¨¥\¹F¦¨SNP-610¦b¯×ªÕ¨xª¢ªvÀø¤Wªº¥Ø¼Ð¡C[²{¥¿¿n·¥±À°Ê°ê»ÚÃļt¦X§@©Î±ÂÅvµ¥¨Æ©y¡C] .................................................................................... ·s¦¨¥÷SNP-610¤Î630 [¦U¦³¨äµ¦²¤³W¹º]---SNP-610Áp¦XªvÀø? SNP-630³æÃĪvÀø? |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/1 ¤U¤È 08:52:15²Ä 454 ½g¦^À³
|
2019.4.25 NASHÃĪ«¤jµÃGilead ¬ãµo³¡t³d¤H¬ù¿«¡P³Á§J«¢©_´Ë:§ÚÌ»{¬°¡A¹ïNASHªº¦³®ÄªvÀø³Ì²×±N»Ýn¤@ºØÁp¦X¤èªk....¡C finance.yahoo.com/news/gilead-reiterates-faith-nash-combination-141359862.html .......................................................................................... ·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/29 ¤U¤È 08:41:08²Ä 443 ½g¦^À³ Ó¤H¤jÁx²q´ú¦³°ê»ÚÃļt·Q±ÂÅvSNP-610§@Áp¦XÀøªk??? ........................................................................................... 3.2020/11/24-¡mNASH¡n¦N§Q¼w(Gilead ) ©M¿Õ©M¿Õ¼w(Novo Nordisk)Áp¦XÃĪ«²Õ¦X www.genetinfo.com/international-news/item/43459.html ............................................................................................ SNP-610³æ¿Wµo®i¤W¥«¥i»P¨ä¥L¦¨¤Àµo®i¦¨¬°½Æ¤è¡A¥H¶i¦æ½Æ¤èªvÀø¡A¦³¨ä¯S®í»ùÈ¡C |
|
|
·|û¡Gdk10140377 µoªí®É¶¡:2021/1/1 ¤U¤È 07:59:35²Ä 453 ½g¦^À³
|
99 ¸ô¹L |
|
|
·|û¡G¤p¦b10150798 µoªí®É¶¡:2021/1/1 ¤U¤È 02:58:35²Ä 452 ½g¦^À³
|
SNP-810±ÂÅvª÷¥i¯à³W¼Ò? ¤AñQÓi×ô¬O¥@¬É¤W·¥«nªº¤îµhÃĤ§¤@¡A¦ý¬O¦³¨x¬r©ÊP¦ºªº¯ÊÂI¡C§Ú̬O¥H·¥¥©§®ªº¤è¦¡¨Ó¸Ñ¨M60¦~¤jÃļt¤@ª½µLªk¸Ñ¨Mªº°ÝÃD¡C¥HÀ°§U¯f¤H´£¨Ñ§ó¦w¥þªºÃÄ«~¡A±ÂÅvª÷±N¬O¦b¤Ï¬M¦¹°^Ämªº»ùÈ¡A¤]±o¨ì°ê»Ú¤j¼tªº»{¥i¡C ©Ò¥HÂù¤è¹ï±ÂÅvª÷¤w¸g¦³¦@ÃѤF¶Ü¡H ¦X¤@¤]¬O¤G¤ëªìñq¦X§@¡A¤G¤ë©³¦¬ªºÄ³¬ùª÷¡A¥|¤ë¤½¥¬±ÂÅv¡A§Æ±æªYÄ£¤]¯à¨«¤@¼Ëªº¸ô¡A§ÚÁÙ¦í¦b130¼Ó¡A¦n·Qú ¦³¤H¤ñ§Ú§ó°ª¶Ü¡H |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/1 ¤W¤È 11:15:43²Ä 451 ½g¦^À³
|
SNP-630ȱo´Á«Ý!!! SNP-610Àu©ó°ê»Ú²{¦æ¥|®a¥ýµoªºNASHÃĪ«¡ASNP-630Àu©óSNP-610¡C SNP-630 ·|¤À¸Ñ¬° 3 Ó¬¡©Ê¥NÁª«(SNP-610¬O¨ä¤¤¤§¤@)¡A¨ä§@¥Î©ó NASH ¾÷Âà»P¥ÀÃĬۦü¡A±©¨ä(SNP-610)ÃIJz¬¡©Ê§¡§C©ó SNP-630¡C ................................................................................................................. ·|û¡GROGER588910148151 µoªí®É¶¡:2020/7/3 ¤W¤È 07:13:52²Ä 31 ½g¦^À³ ªYÄ£¨S¦³±ÂÅvñ¬ù«eÁÙ¬O§Ù·V°l°ª! ¦]¬°InterceptªºOCAµ´¹ï¬O¦º¦a³ÌÞªº1¤äÃĪ«¡A¦³NASH¬ð¯}©ÊÀøªk+¥[³t¼f§å¡A ©~µM¬O®â¦b³Ì«á¤@¨è¡A¦Ó¤£¬O¦b¤G´Á©Î¤T´Á! ............................................................................................................. SNP-610: Á{§É¤G´Á¸ÕÅç³Ì·sµ²ªG ¡A¸û°ê»Ú¬ã¨s¤¤¤§NASHÃĪ«§ó¦w¥þ¦³®Ä 18/43---ªA¥ÎSNP-610»P¨ä¥LÔ¿ïÃĪ«¦bÁ{§É2/3´ÁªºÀø®Ä¤ñ¸û: ALT 19/43---SNP-610»P¥@¬É¤W¬ãµo«eªuÃÄOcaliva (Intercept)*ªºÀø®Ä¤ñ¸û (©³¤U»¡ªº¥i±¤¦b¨xŦÅÖºû¤Æ¨S¤°µÛ¾¥!·N«ü¸òOcalivaªº¤ñ¸û¹Ïªí) ........................................................................................... ·|û¡GROGER588910148151 µoªí®É¶¡:2020/7/3 ¤W¤È 08:05:38²Ä 35 ½g¦^À³ 108/07/24 Bio-Asia¨È¬w¥Í§Þ¤j®iÁ|¿ì¤§¤½¥q®i±æ»¡©ú·| mops.twse.com.tw/nas/STR/663420190724M001.pdf Comparison of the Efficacy of Oral SNP-610 & Ocaliva (Intercept)* SNP-610 shows a greater reduction of ALT ¥i±¤¦b¨xŦÅÖºû¤Æ¨S¤°µÛ¾¥! ¦]¬°°²YOcalivaªºNASH¾AÀ³¯g§åã¡A·|¬O¦b¦ñ¦³¨xŦÅÖºû¤Æªº±wªÌ³o¶ô¡C ·|û¡GROGER588910148151 µoªí®É¶¡:2020/7/9 ¤W¤È 06:08:11²Ä 77 ½g¦^À³ www.sinewpharma.com/news_detail.php?nwno=30 .SNP-610¤w§¹¦¨²Ä¤@´ÁÁ{§É¹êÅç¡A¨Ã©ó¤HÅé¤G´ÁÁ{§É¸ÕÅçÃÒ©ú¦w¥þ¦³®Ä¡A¥BÀu©ó°ê»Ú²{¦æ¥|®a¥ýµoªºNASHÃĪ«¡C ¦w¥þ¦³®Ä¡A¥BÀu©ó°ê»Ú²{¦æ¥|®a¥ýµoªºNASHÃĪ«¡C ¦w¥þ¦³®Ä¡A¥BÀu©ó°ê»Ú²{¦æ¥|®a¥ýµoªºNASHÃĪ«¡C ¦w¥þ¦³®Ä¡A¥BÀu©ó°ê»Ú²{¦æ¥|®a¥ýµoªºNASHÃĪ«¡C ¹Ïªí¦b³o:mops.twse.com.tw/nas/STR/663420190724M001.pdf |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2021/1/1 ¤W¤È 10:59:49²Ä 450 ½g¦^À³
|
2020.12¤ë³Ì·s³Ì©P¥þ¸ê®Æ! static1.squarespace.com/static/5b5f666c9772ae3d286108fa/t/5fd8166c59305f0926a31c85/1607997042425/BB_WhitePaper+NASH_email+12_10B.pdf ²Ä6±i¹Ïªí: SNP-610--Active Likelihood of combination therapies: Due to the complexity of NASH, an effective treatment regimen is likely to be a combination approach, (Áp¦XÀøªkªº¥i¯à©Ê¡G¥Ñ©óNASHªº½ÆÂø©Ê¡A¦³®ÄªºªvÀø¤è®×¥i¯à¬O¤@ºØºî¦XªvÀø¤èªk) ................................................................................................ ·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/29 ¤U¤È 08:41:08²Ä 443 ½g¦^À³ ¬°°t¦X°ê»Ú¤jÃļt¤§¦X§@¡B§ÞÂà¡B±ÂÅv¤§»Ýn¡A¤w§¹¦¨²Ä¤G´ÁÁ{§É¸ÕÅ礧°ª¡B§C¨â¾¯¶q²Õ¦@ 36¦W¨ü¸ÕªÌ.. Ó¤H¤jÁx²q´ú¦³°ê»ÚÃļt·Q±ÂÅvSNP-610§@Áp¦XÀøªk??? ........................................................................................... ·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/15 ¤W¤È 08:19:50²Ä 395 ½g¦^À³ ¦]¬°³æ¥´¿W°«¤[§ð¤£¤U¡AÁp¦XªvÀøº¥º¥§Î¦¨¦@ÃÑ¡C SNP-610ªº¬ãµoµ¦²¤¡B¥Ø«e¶i®i¤Î¹w©w¦ó®É±ÂÅv¡H §Ú̥ѹê»Ú±ÂÅv¬¢°Óªº¹Lµ{¤Î¸gÅç¡A¯S§O±N·sÀø®Ä¤Î·s¦¨¥÷SNP-610¤Î630¦U¦³¨äµ¦²¤³W¹º ............................................................................................ SNP-610³æ¿Wµo®i¤W¥«¥i»P¨ä¥L¦¨¤Àµo®i¦¨¬°½Æ¤è¡A¥H¶i¦æ½Æ¤èªvÀø¡A¦³¨ä¯S®í»ùÈ¡CNASH¤§µo®i¡A¦U¤jÃļt§¡¦]»Ý¨x¬ï¨ë¦Ó¦¬®×¸ûºC¡A±`³y¦¨©µ«á¡C |
|
|
·|û¡G¤p¤å¤l10144877 µoªí®É¶¡:2021/1/1 ¤W¤È 06:14:17²Ä 449 ½g¦^À³
|
ªYÄ£°Ñ¥[2020¦~²Ä¤G©¡¥xÆWn¾ÇÁp¦X¾Ç³N¬ã°Q·| ¥»¤½¥q§ë½Z2020¦~²Ä¤G©¡¥xÆWÃľÇÁp¦X¾Ç³N¬ã°Q·|¡AºaÀò¾À³ø®i¥ÜÀu¨q½×¤å¼úª¬¡C |
|
|
·|û¡Gop123410143906 µoªí®É¶¡:2020/12/30 ¤U¤È 04:48:55²Ä 448 ½g¦^À³
|
R¤j:±z»~¸Ñ§Úªº·N«ä¡C ¦³300¤¸?¯u¬O´Á«Ý¡C ©êºò¡C |
|
|
·|û¡G¦h¦h10137435 µoªí®É¶¡:2020/12/30 ¤U¤È 04:32:42²Ä 447 ½g¦^À³
|
©ú¤Ñ¤¤¤Ñªk»¡ ¦³¤j¤j·|´£°ÝÃö©óªYÄ£ªº¬ÛÃö°ÝÃD?! |
|
|
·|û¡G½²ºû¤¯10143700 µoªí®É¶¡:2020/12/30 ¤U¤È 01:49:34²Ä 446 ½g¦^À³
|
·PÁ¦U¦ì¤j¤j´£¨Ñ±M·~¸ê°T¡A«D±`ÁÂÁ¡I¡IªYÄ£¬O«D±`¹Ú¤ÛªºªÑ²¼¡A©ñ¨ì2023¦~¡A5ÁûÃÄ¥þ¶}¥X¡B±ÂÅv¡A¤@Áû¥§¡8»õ¬üª÷¡q²qªº¡r¡A40»õ¬üª÷¡A¥x¹ô1200»õ¤¸¡A¤@ªÑ2400¤¸Àò§Q¡CY30¦~Åu§Q¡A¨C¦~ÁÈ80¤¸¡A¥»¯q¤ñ20¡AªÑ»ù¤W¬Ý1600¤¸¡C¬ü¹Ú¤£¤@©w¯à¦¨¯u¡A¦ý¬O¡A´Á«Ý300¤¸¥H¤W¤£¹L¤À¡AÓ¤H§ë¸êºâ½L¡A¤j®a°Ñ¦Ò¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/30 ¤W¤È 11:42:12²Ä 445 ½g¦^À³
|
·|û¡Gop123410143906 µoªí®É¶¡:2020/12/30 ¤W¤È 08:07:54²Ä 444 ½g¦^À³ R¤j: 1.§ë¸ê¥Í§Þ©Î¤W¥«Âd¤½¥q¡Aºn¬Ý¤½¥q(¸Û«H)¡A¦³¨Ç¤½¥q¦b¨p¶Ò¤W½æ°ª»ù¦ÑªÑ¡A¶R§C·sªÑ¡A¹ï¤pªÑªF«Ü¤£¦³µ½¡A¤pªÑªF´Nn¤p¤ß ............................................................................................... þ³ý¤£¶}´£þ³ý¡AÂW«¥Â¶ˤf! ¨º®aªºÄvª§ªÌ®³¨ì§Ö³t³q¹D¸ê®æ¡AªÑ»ù«e¨Ç¤é¤l³Ð5¦~°ª..... |
|
|
·|û¡Gop123410143906 µoªí®É¶¡:2020/12/30 ¤W¤È 08:07:54²Ä 444 ½g¦^À³
|
R¤j: 1.§ë¸ê¥Í§Þ©Î¤W¥«Âd¤½¥q¡Aºn¬Ý¤½¥q(¸Û«H)¡A¦³¨Ç¤½¥q¦b¨p¶Ò¤W½æ°ª»ù¦ÑªÑ¡A¶R§C·sªÑ¡A¹ï¤pªÑªF«Ü¤£¦³µ½¡A¤pªÑªF´Nn¤p¤ß¡C 2.ªYÄ£¦w¤ß©ñµÛµ¥-----¡C 3.¯¬¤j®a³£ÁÈ¿ú¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/29 ¤U¤È 08:41:08²Ä 443 ½g¦^À³
|
¬°°t¦X°ê»Ú¤jÃļt¤§¦X§@¡B§ÞÂà¡B±ÂÅv¤§»Ýn¡A¤w§¹¦¨²Ä¤G´ÁÁ{§É¸ÕÅ礧°ª¡B§C¨â¾¯¶q²Õ¦@ 36¦W¨ü¸ÕªÌ.. Ó¤H¤jÁx²q´ú¦³°ê»ÚÃļt·Q±ÂÅvSNP-610§@Áp¦XÀøªk??? ........................................................................................... ·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/15 ¤W¤È 08:19:50²Ä 395 ½g¦^À³ ¦]¬°³æ¥´¿W°«¤[§ð¤£¤U¡AÁp¦XªvÀøº¥º¥§Î¦¨¦@ÃÑ¡C [SNP-610³æ¿Wµo®i¤W¥«¥i»P¨ä¥L¦¨¤Àµo®i¦¨¬°½Æ¤è¡A¥H¶i¦æ½Æ¤èªvÀø¡A¦³¨ä¯S®í»ùÈ¡C] 1.2018/10/30-½÷·ç»P¿ÕµØ«Å¥¬±NÄâ¤â¬ãµo«D°sºë©Ê¨xª¢ªºÁp¦XÀøªk www.gbimonthly.com/2018/10/34667/ 2.2020/9/9-ºqþ÷ºX¤U¥þ资¤l¤½¥q¥Ì莱¨î药ÉOGalmed Pharmaceuticals¦@¦P«Å¥¬¡A双¤è关¤_联¦XTHR-ß¿E动剂ASC41 ©MSCD1§í¨î剂Aramcholªv疗«D°sºë©Ê¯×ªÕ©Ê¨xª¢¡]NASH¡^达¦¨¦X§@¬ã¨s xueqiu.com/9766314542/158951924 3.2020/11/24-¡mNASH¡n¦N§Q¼w(Gilead ) ©M¿Õ©M¿Õ¼w(Novo Nordisk)Áp¦XÃĪ«²Õ¦X www.genetinfo.com/international-news/item/43459.html ............................................................................................... SNP-610ªº¬ãµoµ¦²¤¡B¥Ø«e¶i®i¤Î¹w©w¦ó®É±ÂÅv¡H §Ú̥ѹê»Ú±ÂÅv¬¢°Óªº¹Lµ{¤Î¸gÅç¡A¯S§O±N·sÀø®Ä¤Î·s¦¨¥÷SNP-610¤Î630¦U¦³¨äµ¦²¤³W¹º ............................................................................................ SNP-610³æ¿Wµo®i¤W¥«¥i»P¨ä¥L¦¨¤Àµo®i¦¨¬°½Æ¤è¡A¥H¶i¦æ½Æ¤èªvÀø¡A¦³¨ä¯S®í»ùÈ¡CNASH¤§µo®i¡A¦U¤jÃļt§¡¦]»Ý¨x¬ï¨ë¦Ó¦¬®×¸ûºC¡A±`³y¦¨©µ«á¡C ............................................................................................. |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/29 ¤U¤È 08:32:10²Ä 442 ½g¦^À³
|
¥»¤½¥q¦P¨B¶}µo·s¦¨¤ÀSNP-630¬°¯×ªÕ¨x·sÃÄ¡A¤é«e¥ç¤w¨ú±o [¬ü°ê] »P«n«D±M§Q¡C .................................................................................... 2020.12.14ªYÄ£ºô¶§ó·s¤º®e:SNP-630 ©ú¦~Q1¥Ó½ÐTFDA IND---®É¶¡³o»ò±µªñ¡AIND¤£¦Ü©ó©µ´Á¤~¬O¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/29 ¤U¤È 08:12:55²Ä 441 ½g¦^À³
|
SNP-610¨ú±o¬ü°ê±M§Q: ¬°°t¦X°ê»Ú¤jÃļt¤§¦X§@¡B§ÞÂà¡B±ÂÅv¤§»Ýn¡A¤w§¹¦¨²Ä¤G´ÁÁ{§É¸ÕÅ礧°ª¡B§C¨â¾¯¶q²Õ¦@ 36¦W¨ü¸ÕªÌ¡A´Á¤¤¤ÀªRµ²ªGÅã¥Ü¡ASNP-610¦bÁ{§ÉÀø®Ä«ü¼Ð»P¥¼ªAÃÄ«e¤ñ¸û¡A§e²{·¥ÅãµÛªvÀø®ÄªG¡A¦¨¥\¹F¦¨SNP-610¦b¯×ªÕ¨xª¢ªvÀø¤Wªº¥Ø¼Ð¡C²{¥¿¿n·¥±À°Ê°ê»ÚÃļt¦X§@©Î±ÂÅvµ¥¨Æ©y¡C ................................................................................................ ¦n¨Æ³s²ø! |
|
|
·|û¡GRock00910149258 µoªí®É¶¡:2020/12/29 ¤U¤È 07:33:00²Ä 440 ½g¦^À³
|
¤é¡@¡@´Á¡G2020¦~12¤ë29¤é ¤½¥q¦WºÙ¡GªYÄ£(6634) ¥D¡@¡@¦®¡GªYÄ£¯×ªÕ¨xª¢·sÃÄSNP-610¨ú±o¬ü°ê±M§Q µo¨¥¤H¡G¦¶³Í¥Á »¡¡@¡@©ú¡G 1.¨Æ¹êµo¥Í¤é:109/12/29 2.¤½¥q¦WºÙ:ªYÄ£¥ÍÂåªÑ¥÷¦³¤½¥q 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q¡C 4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î¡C 5.µo¥Í½t¥Ñ: ¥»¤½¥q±µÀò©e¥ô±M§Q¨Æ°È©Ò³qª¾¡A¥»¤½¥q¯×ªÕ¨xª¢·sÃÄSNP-610¨ú±o¤@¶µ¬ü°ê±M§Q¡A ±M§Q¦WºÙ: ¡u¹w¨¾©ÎªvÀø¯×ªÕ¨x¡B«OÅ@¨x¥\¯à¡B©Î§ïµ½¯×ªÕ¨x¤Þ°_ªº¨x¯fÅÜ©Î¨ä ¥L¬ÛÃö¯f¯g¤§²Õ¦Xª«¤Î¤èªk(Methods and Compositions for Preventing or Treating Fatty Liver, Protecting Liver Function or Ameliorating Liver Diseases Caused by Fatty Liver or Other Associated Disorders)¡v¡C 6.¦]À³±¹¬I:¤£¾A¥Î¡C 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ: 1.¥»¤½¥q¯×ªÕ¨xª¢·sÃÄSNP-610°£¥»¦¸¬ü°ê±M§Q¤w®Öã¥~¡A¤¤µØ¥Á°ê±M§Q¤]¤w®Öã¡A ¥ç¤w¥Ó½Ð¤¤°ê¡B¤é¥»¤Î¼Ú·ù(¦@38·|û°ê)¡A¥Ø«e¥¿¿n·¥¼f®Ö¤¤¡C 2.¥»±M§Q¦³®Ä´Á©|¦³16¦~¡A³Ì¦h¥i©µªø¦Ü¤½¤¸2041¦~¡C 3.¥»±M§Q®Öã½d³ò¥]§t(comprising)¦hºØ¤w¦bÅ餺¸ÕÅç¤WÃÒ¹ê¥iªvÀø¯×ªÕ¨xª¢¥B ¨ã°ª«×¦w¥þ©Ê¤§¬¡©Ê¦¨¤À¡A¥iª½±µ§@¥Î©ó¨xŦ¡A°§C¨x¯×¨Ã§ïµ½¯×ªÕ¨xµoª¢¡C 4.¥»¤½¥qªø´Á±Mª`©ó¯×ªÕ¨xª¢ªvÀø»â°ì¡A¥»¤½¥q¯×ªÕ¨xª¢ªvÀø»â°ì©|¦³SNP-630¡C ¥»¤½¥q¦P¨B¶}µo·s¦¨¤ÀSNP-630¬°¯×ªÕ¨x·sÃÄ¡A¤é«e¥ç¤w¨ú±o¬ü°ê»P«n«D±M§Q; ¥ç¤w¥Ó½Ð¤¤°ê¡B¼Ú·ù(38Ó·|û°ê)¡B¤é¥»¡B¼Ú¨È±M§QÁp·ùµ¥14¦a°Ï±M§Q¡A¥@¬É ¦U°ê±M§Q¥¿¿n·¥¼f¬d¤¤¡C 5.«D°sºë©Ê¨xª¢(NASH)¤Î°sºë©Ê¨xª¢(ASH)¥«³õ³v¦~«ùÄòÂX¤j¡A¥þ²y¥«³õ«o¬OµLÃÄ ¥i¥H¨ÑÀ³¡C¾ÚGlobalData 2017¦~5¤ëªº³ø§i¹w´ú¡A¥]¬A¬ü°ê¡A¼Ú·ù¤¤j°ê®a¡]ªk°ê ¡A¼w°ê¡A¸q¤j§Q¡A¦è¯Z¤ú©M^°ê¡^©M¤é¥»ªºNASH¥«³õ¡A¦b¥¼¨Ó¤Q¦~ªº½Æ¦X¦~¼Wªø²v ¹F45¢H¡C¥t®Ú¾Ú¼w·N§Ó»È¦æ¤ÎEvaluate Pharmaªº¹w´ú¡A¥þ²yNASHÃĪ«ªº¥«³õ³W¼Ò¦b 2025¦~¤W¬Ý350»õ~400»õ¬ü¤¸¡CSNP-610¤wÀò¬ü°êFDA¤Î¥xÆWFDA®Öã³q¹L¶i¦æ¤G´ÁÁ{§É ¸ÕÅç¡C¬°°t¦X°ê»Ú¤jÃļt¤§¦X§@¡B§ÞÂà¡B±ÂÅv¤§»Ýn¡A¤w§¹¦¨²Ä¤G´ÁÁ{§É¸ÕÅ礧°ª¡B §C¨â¾¯¶q²Õ¦@ 36¦W¨ü¸ÕªÌ¡A´Á¤¤¤ÀªRµ²ªGÅã¥Ü¡ASNP-610¦bÁ{§ÉÀø®Ä«ü¼Ð»P¥¼ªAÃÄ«e ¤ñ¸û¡A§e²{·¥ÅãµÛªvÀø®ÄªG¡A¦¨¥\¹F¦¨SNP-610¦b¯×ªÕ¨xª¢ªvÀø¤Wªº¥Ø¼Ð¡C²{¥¿¿n·¥ ±À°Ê°ê»ÚÃļt¦X§@©Î±ÂÅvµ¥¨Æ©y¡C 6.·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¤@©w¯à¦¨¥\¡A¦¹µ¥¥i¯à¨Ï§ë¸ê±Á{·ÀI¡A §ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/29 ¤W¤È 10:07:03²Ä 439 ½g¦^À³
|
«e¨Ç¤é¤l¤U¶^¡A¦]«H©À¤Q¨¬¡A«ùªÑ¼W¥[¤@¨Ç¡C ªñ¤é©Ò¶K¸ê®Æ³£¬O¼ÆÓ¤ë«e¶K¹L¡A½Ð¦Û¦æµûÂ_§ë¸ê»ù¦ì¡A«¥¤£¬Oµu½u¾Þ§@¯à¤â¡A¤j³¡¦ì§ë¸ê¶g´Á³£¬Û·íªø®É¶¡¡C ¦Ñ¸Ü¤@¥y:±ÂÅvª÷«¥¤ß¸Ì¤]¨S©³! |
|
|
·|û¡Gop123410143906 µoªí®É¶¡:2020/12/29 ¤W¤È 09:10:58²Ä 438 ½g¦^À³
|
R¤j:¦n¥Í§ÞªÑ¥i¥H¤W¤Ñ? ´^·¥Í§Þ´N«Ü?? ¯¬¤j®a³£ÁÈ¿ú¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/29 ¤W¤È 08:56:42²Ä 437 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/27 ¤W¤È 09:53:25²Ä 424 ½g¦^À³ ¬°¤°»ò2017¦~¬ü°êÃĪ«±M®a»¡:®õ¿Õ¡]Tylenol,APAP)¬O¡§¨´¤µ¬°¤î³Ì¦MÀIªºÃĪ«??? ¬°¤°»ò¬ü°êÂå¾Ç±M®aWilliam M. Lee, M.D»¡¦pªG¨S¦³¸Ñ¬r¾¯(N-¤AñQ¥b¯Ö®ò»ÄNAC¡^¡A¹ï¤A酰®ò°ò×ô(APAP)¥i¯à¦´N³Q§¹¥þ¸T¤î¤F??? ¤d¨¥¸U»y¤£¦p¤@±i¹Ïªí²³æ©öÀ´! FDA¸ê®Æ²Ä7¶ www.fda.gov/media/87626/download ALF«æ©Ê¨x¥\¯à°IºÜ:¹ï¤A酰®ò°ò×ô(APAP)¤ñ¨Ò46% ¤W¥«ÃĪ«¤ñ¨Ò11% (¤W¥«ÃĪ«:¥Ñ1,036ºØFDA§å㪺ÃĪ«²Õ¦¨) Why So Much Trouble with Acetaminophen??? ............................................................................................... FDA¹ïAPAP¨x¬r©Ê«ÜÀYµh!!! GSK»PJ&JÂùÀs·m¯]¡A½Ö®a¥¢§Q ½Ö®aAPAP¥«³õ´N³Q¹ï¤â¦Y±¼¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/29 ¤W¤È 08:46:25²Ä 436 ½g¦^À³
|
1. 2020.12.7·s»D ¬ü°êªÍ¬ì±M®aDr. Len Horovitz»¡:¤j¦h¼Æª`®gCOVID-19¬Ì]ªº°Æ§@¥Î¥i¥H¥Î®õ¿Õ¡]Tylenol,APAP)¨ÓªvÀø¡C www.usatoday.com/story/news/health/2020/12/04/covid-vaccine-side-effects-fatigue- aches-normal/3813934001/ .............................................................................................. 2. 2020.3.19 ·s»D J&Jªº®õ¿Õ¡]Tylenol,APAP)¦]¬°·s«a¯f¬r»Ý¨D¼É¼W2~4¿¡A¨Ñ¤£À³¨D²£¯à24¤p®É¥þ¶}¡C www.reuters.com/article/us-health-coronavirus-johnson-johnson/jjs-tylenol-production-at-maximum-capacity-as-coronavirus-boosts-demand-idUSKBN2162FU |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/28 ¤U¤È 06:20:51²Ä 435 ½g¦^À³
|
ªÑªF¤H¼Æ±q3084(7/24)-1952(12/25)=´î¤Ö1132¤H ½Ð°Ý¶}ª©¥D±zÁÙ«ù¦³ªYÄ£¶Ü? |
|
|
·|û¡Gop123410143906 µoªí®É¶¡:2020/12/28 ¤U¤È 06:17:05²Ä 434 ½g¦^À³
|
ÁÂÁÂR¤j:©ê¨cµ¥¶}µP¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/28 ¤U¤È 06:14:15²Ä 433 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/25 ¤W¤È 11:55:50²Ä 419 ½g¦^À³ 109/12/21 ªYÄ£»P°ê»ÚÃļtñqSNP-810¬ãµo¦X§@¨óij µo¨¥¤H¡G¦¶³Í¥Á ¤@¡B¥»¤½¥qSNP-810·sÃÄ»P°ê»ÚÃļtñq·sÃĬãµo¦X§@¨óij¡A¶i¦æÀø®Ä½T»{µ¥¬ÛÃö¹êÅç¡A°ê»ÚÃļt¨Ì¾Ú¥»¦X§@¨óij±N¤ä¥I¥»¤½¥q¤@©wª÷ÃB¤§Ã±¬ùª÷¤Î¨½µ{¸Oª÷¡C ................................................................................................. ¤w§¹¦¨¤§ SNP-810 Á{§É¸ÕÅçµ²ªG¡A¦U¶µÃİʾǰѼƻP Panadol®¬Û¦ü¡C ¤½¥qºô¶:SNP-810¤w¦V¥xÆWTFDA¥Ó½Ð¾Ç¦WÃij\¥iÃÒ! ©ê¨cµ¥Â½µP!!! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/28 ¤U¤È 05:28:04²Ä 432 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/7/10 ¤U¤È 01:20:11²Ä 102 ½g¦^À³ ..©Ò¥HSNP-810À˪þ»P¹ï·ÓÃÄ«~(ì¼tÃÄ´¶®³¯k)ÃÄ«~¥ÍÅé¬Ûµ¥©Ê¼Æ¾Ú§Y¥i¥Ó½Ð¾Ç¦WÃÄÃÄÃÒ¡A¤£¥Î§@P3¡C ¦Ü©ó¼Ï¯Ã¸ÕÅç¡]pivotal studies¡^¡AÓ¤H²q´úÀ³¸Ó¬O¦³¤Gӥتº(¯u¥¿ì¦]ÁÙ¬O±o°Ý¤½¥q): ¹êÃÒSafeTynadol®(SNP-810)ªº¦w¥þ©Ê¤ñPanadol®§óÀu²§(¦]¬°n¥Ó½ÐFDA¬ð¯}©ÊªvÀø¡A¨S¦³Á{§É¼Æ¾Ú¤f»¡µL¾Ì) ----¥Ó½Ðקï¥é³æ¤º®e(µL¨x¬r©Ê¡A¥]¸ËµL»Ý¥[µùĵ»y¡A¥i´£°ª¤AñQÓi×ô¾¯¶q¡A¤£¨ü325mg¼W¶iÀø®Ä.... ¥Ó½Ðקï¥é³æ¤º®e(µL¨x¬r©Ê¡A¥]¸ËµL»Ý¥[µùĵ»y¡A¥i´£°ª¤AñQÓi×ô¾¯¶q¡A¤£¨ü325mg¼W¶iÀø®Ä.... ¥Ó½Ðקï¥é³æ¤º®e(µL¨x¬r©Ê¡A¥]¸ËµL»Ý¥[µùĵ»y¡A¥i´£°ª¤AñQÓi×ô¾¯¶q¡A¤£¨ü325mg¼W¶iÀø®Ä.... ........................................................................................... ¤w§¹¦¨¤§ SNP-810 Á{§É¸ÕÅçµ²ªG¡A¦U¶µÃİʾǰѼƻP Panadol®¬Û¦ü¡C ¤½¥qºô¶:SNP-810¤w¦V¥xÆWTFDA¥Ó½Ð¾Ç¦WÃij\¥iÃÒ!!! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/28 ¤U¤È 02:18:27²Ä 431 ½g¦^À³
|
SNP-810(APAP 325mg+SNP-820)¥þ±¨ú¥N¨ã¨x¬r©ÊªºAPAP¥«³õ SNP-810(APAP 500mg~1000mg©Î§ó°ª+SNP-820)·m¦^³QNSAIDªü´µ¤ÇÆF,COX-2§í¨î¾¯OpioidsÃþ«I»kªº¥«³õ |
|
|
·|û¡Gop123410143906 µoªí®É¶¡:2020/12/28 ¤U¤È 01:18:24²Ä 430 ½g¦^À³
|
Æg°Õ¡I |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/28 ¤W¤È 06:34:59²Ä 429 ½g¦^À³
|
4128¤¤¤Ñ109/12/31 15:00 ½u¤Wªk»¡·|:»¡©ú¥»¤½¥q¸gÀçÁZ®Ä¡BÀç¹B²{ªp¤Î¥¼¨Ó®i±æµ¥¡C³sµ²ºô§}reurl.cc/OqZ7O9 ---------------------------------------------------------------------------------------- ¤£¹H«O±Kì«h¤U¯à³zº|¨º¨Ç®ø®§??? |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/27 ¤U¤È 01:33:05²Ä 428 ½g¦^À³
|
SNP-810°£¤F¯à¥þ±¨ú¥N¦³¨x¬r©ÊªºAPAP¡A ·íAPAP¦¨¤À§t¶q¶W¹L325mg(500mg¬Æ¦Ü1000mg§ó¦³¤îµh®ÄªG)ªºSNP-810¤]®Öã¤W¥«¡A ´N¥i¥H·m¦^³Q¨ä¥LÃþ¤îµhÃĪ««I»kªº¼s¤j¥«³õ¡]NSAID, COX-2 §í¨î¾¯¡BOpioidsÃþ¤îµhÃÄ¥«³õ¡^ PS:¦]¬°APAP¨ã¦³¨x¬r©Ê¡A¤~³QFDA±j¨î±N§t¶q¥Ñ1000mg¤U׬°500mg»P325mg ¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/27 ¤W¤È 10:37:53²Ä 427 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/7/17 ¤U¤È 11:05:42²Ä 169 ½g¦^À³ §Ú¤£¬OÃį«¤]¤£¬OªÑ¯«¡A¦w¦wÀRÀRµ¥«Ý¶W¯Å¤j¤ù¤Wºt!!! SNP-8 ¨t¦C¦¨¤À: ¦Û¼Æ¦ÊºØ [¬ü°êFDA®Öã]¡B[±`¥Î¥B¦w¥þ]¡B[«K©yt¾á±o°_]¡B[¤HÅé¥i¹¥Î¦w¥þ¤Æ¦Xª«]¤¤¡AÀ³ ¥ÎÃĪ«¬ÛÃö¥NÁȕÀ CYP450 Åé¥~§í¨î¾¯¿z¿ï¥¥x¡A¬D¿ï¥X¼ÆºØ AAP¬r©Ê¥NÁª««n»Ã¯À§í¨î¾¯ HUYPS02¡BHUYPS04 §¡¬°·¥¦w¥þ¤§¤Æ¦Xª«¡A¨ä¤@¤é¦w¥þ¨Ï¥Î¾¯¶q¥i¹F 20 g/person ¥H¤W¡A¥B¦b 200mg/person ¾¯¶q¤U§Y¥i§í¨î²v¹F 60-88%¡C ............................................................................................ SNP-810n¥þ±¨ú¥N¥«³õ¤W«Ü«K©y¦ý¦³¨x¬r©ÊªºAPAP¡A¤W¥««á°â»ù¤]¬OÃöÁä¡C ¥ÌÅS¾J©M¤T´â½©¿}§¹¥þ²Å¦X:[¬ü°êFDA®Öã]¡B[±`¥Î¥B¦w¥þ]¡B[«K©yt¾á±o°_]¡B[¤HÅé¥i¹¥Î¦w¥þ¤Æ¦Xª«] |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/27 ¤W¤È 10:23:48²Ä 426 ½g¦^À³
|
¦¶³Í¥Á»¡¡AªYÄ£©Ò¶}µoªºSNP-810¡A¬O°ò©ó¤AñQÓi×ô¦A¥[¤W¯S©w¡u¤½»{¦w¥þ¡v¤§¦¨¤À¡A¥iªýÂ_¨xŦ¬r©Ê¦¨¤Àªº¥Í¦¨¡A¯à¿n·¥§ïµ½ÃÄ«~¬r©Ê«o¤£¼vÅT¨äÀø®Ä¡A¦]¦¹¡A°ê»Ú¤jÃļt¬Ý¨ì¤F³o¶µ§Q°ò¡A¦³·NÄâ¤âªYÄ£¡A§ÞÂহ¶µ§Þ³N¡C ¯S©w¡u¤½»{¦w¥þ¡v¤§¦¨¤À¦pªG¬O¥ÌÅS¾J©M¤T´â½©¿}³oÃþ¡A¤£¥u¦w¥þ¡A»ù®æÁÙ¬Û·í«K©y! |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/27 ¤W¤È 10:16:06²Ä 425 ½g¦^À³
|
SNP-810±M§Q New hepatotoxicity-free pharmaceutical composition containing acetaminophen drugs patents.google.com/patent/US20170172950A1/en ¨ä¤¤¥ÌÅS¾J©M¤T´â½©¿}ªº²Õ¦XÅã¥Ü¥X³Ì¨Îªº«OÅ@®ÄªG ............................................................................................. ¦pªG¯u¬O³oºØ«O°·¹«~°t¤è? ªA¥Î¹L¶q°Æ§@¥ÎÀ³¸Ó´N¬OÅé«öt¤É! D-Mannitol (¢Ò¡Ð¥ÌÅS¾J)¬O¤@ºØ¥Õ¦âµ²´¹©TÅé¡AÄÝ©ó¿}¾JÃþ¡A¨ã²¢¨ý¡C 1.²¢«×¬ù¬O½©¿}ªº¤@¥b¥B¼ö¶q¸û§C¡A¤f·P²M²n¡C2.¦³²æ¤ô¾¯©M´î»´²Õ´¤ô¸~ªº§@¥Î¡C 3.¥i§@¬°¹«~¤¤¥Î§@²¢¨ý¾¯¡B½Õ¨ý¾¯¡B´î¿}¨¾ÂH¡F¦bÃÄ«~À³¥Î½d³ò¡BªvµÇ§Q§¿ÃÄ¡C 1991¦~¥[®³¤j²v¥ý§åã¨Ï¥Î½©¿}¯À(¤T´â½©¿})¡A¬ü°ê¹«~ÃÄ«~ºÊ·þºÞ²z§½1998¦~§åã¨ä°µ¬°¹«~²K¥[¾¯¨Ï¥Î¡A¥xÆW½Ã¥Í¸p«h©ó2001¦~°_¤½§i¥i¥H¨Ï¥Î¡C¦Ü©ó°w¹ï½©¿}¯Àªº·ÀIµû¦ô¡A¥]§tU.S. FDA¡B¥@¬É½Ã¥Í²Õ´¤§JECFA¡B¼Ú·ùEUµ¥¶i¦æ¹L¤@¦Ê¦h¦¸°Êª«¤Î¤HÅé¸ÕÅç¡AºI¦Ü¥Ø«e¬°¤î¡A¤p°Êª«¸ÕÅç¨ÃµL¤Æ¾ÇPÀù©ÊªºÃÒ¾Ú¡A¥B¥¼µo²{µo¨|¬r©Ê¡B¥ÀÅé¬r©Ê¡BFL¬r©Ê¥H¤ÎL¨à¬r©Ê¡AU.S. FDA®Ú¾Ú¨¬°÷ªº°Êª«¸ÕÅç¨Ã°µ¥X½©¿}¯À¤£·|³y¦¨¤HÃþ§K¬Ì¬r©Ê¤§µ²½×¡A¤é«e¦@¦³35Ó°ê®a®Ö㽩¿}¯Àªº¨Ï¥Î¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/27 ¤W¤È 09:53:25²Ä 424 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/22 ¤U¤È 08:25:07²Ä 408 ½g¦^À³ ¬ü°êÃĪ«±M®a»¡:®õ¿Õ¡]Tylenol,APAP)¬O¡§¨´¤µ¬°¤î³Ì¦MÀIªºÃĪ«! ¤@¥¹¥X²{§ó¦w¥þÃĪ«SNP-810¡AFDA¤£µL¥i¯à±N¥u§t[¤AñQÓi×ô]¦¨¤ÀªºÃĪ«±j¨î¤U¥«¡A ³oÓ¼s¤j¥«³õ·|Åܦ¨¦³¦h¤j??? ............................................................................................. ¬°¤°»ò2017¦~¬ü°êÃĪ«±M®a»¡:®õ¿Õ¡]Tylenol,APAP)¬O¡§¨´¤µ¬°¤î³Ì¦MÀIªºÃĪ«??? ¬°¤°»ò¬ü°êÂå¾Ç±M®aWilliam M. Lee, M.D»¡¦pªG¨S¦³¸Ñ¬r¾¯(N-¤AñQ¥b¯Ö®ò»ÄNAC¡^¡A¹ï¤A酰®ò°ò×ô(APAP)¥i¯à¦´N³Q§¹¥þ¸T¤î¤F??? ¤d¨¥¸U»y¤£¦p¤@±i¹Ïªí²³æ©öÀ´! FDA¸ê®Æ²Ä7¶ www.fda.gov/media/87626/download ALF«æ©Ê¨x¥\¯à°IºÜ:¹ï¤A酰®ò°ò×ô(APAP)¤ñ¨Ò46% ¤W¥«ÃĪ«¤ñ¨Ò11% (¤W¥«ÃĪ«:¥Ñ1,036ºØFDA§å㪺ÃĪ«²Õ¦¨) Why So Much Trouble with Acetaminophen??? |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/26 ¤W¤È 07:15:49²Ä 423 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/22 ¤W¤È 10:41:09²Ä 404 ½g¦^À³ ...... ¨ì¤W¶gªÑªF¤H¼Æ±q°ªÂI¤Ö¤F1059¤H ¤µ¤Ñ¤S¦³¦h¤Ö¤H´±¶R¦^??? ........................................................................................... §ë¸ê¤HÀ~¯}Áx!¥»¶g¤H¼ÆÄò´î¶^¯}2000¤H(ªÑªF¤H¼Æ±q°ªÂI¤Ö¤F1/3)¡C |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/26 ¤W¤È 06:11:45²Ä 422 ½g¦^À³
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/23 ¤W¤È 09:09:55²Ä 413 ½g¦^À³ ±ÂÅvª÷«¥¤ß¸Ì¤]¨S©³!±ÂÅvª÷«¥¤ß¸Ì¤]¨S©³!±ÂÅvª÷«¥¤ß¸Ì¤]¨S©³! ...................................................................................... ³z¦²á²á«¥¤ß²z¨S©³ªº¥D¦]¦³3ÂI: 1.ªYÄ£¦~³øºô¶»P»¡©ú·|¦³±ø¦CNASHÃĪ«(SNP-610)ªº±ÂÅv¦æ±¡¡A¦ý¨S¦³SNP-810ªº¡C 2.¥Í§Þ³ß³s¨Ó ¦Aªï¦Ê»õ±ÂÅv®×¹Ïªí¤¤ªºSNP-810±ÂÅv»ùÈ:[µû¦ô¤¤] money.udn.com/money/story/10161/4651212 3.«¥´¿¥h¹q¤½¥q¸ß°Ý¨Ç¨Æ±¡.... ¥Ñ¤W¬ã§P¡AªYÄ£°ª¼h«Ü¥i¯à¤£ª¾¹D¦³2014¦~Mallinckrodt¥H13»õ¬ü¤¸¦¬ÁÊCadenceªº°ê»Ú¦æ±¡¥i°Ñ¦Ò¡C |
|
|
·|û¡Gop123410143906 µoªí®É¶¡:2020/12/25 ¤U¤È 07:30:59²Ä 421 ½g¦^À³
|
¤w¸gñ©w(¤@³¾¦b¤â)¦w¤ßµ¥«Ý¡C ³Ó(¥¼¨M©w=¤Q³¾¦bªL)¡C¯¬¤j®a³£ÁÈ¿ú¡C |
|
|
·|û¡G¦h¦h10137435 µoªí®É¶¡:2020/12/25 ¤U¤È 05:47:16²Ä 420 ½g¦^À³
|
¤£´¦ÅS¦X¬ù±ø¤å¤Î¬ãµo¾÷±K¤§¤º®e¡A¥]¬A¡GÀø®Ä°t¤è¡B¸ÕÅç³]p¡Bñ¬ù¦X§@¹ï¶H¡Bµ¹¥I»ùª÷¤§ª÷ÃBµ¥ ®É¶¡¥i¥H±µÅS? ¤½¥q¬°¦ó¤£±µÅS»Ýn¦X§@ªº®É¶¡,¦X¤@¬O¨âӤ뤣¨ì´Nµo¥Í±ÂÅv~ ªYÄ£2Ó¤ë,2©u,©Î§ó¤[??? |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/25 ¤W¤È 11:55:50²Ä 419 ½g¦^À³
|
Y¤¤¤Ñ¶°¹Î¦³¦@¥Îªº±ÂÅv½Í§P¯Z©³¡A¨º2®a¨«¦P¤@¼Ò¦¡¾÷²v´N°ª¡C ºK¤@¬q¦bDr.Allenªº¤å³¹¡A¸Ì±¦³¬q¸Ü»¡±o¤£¿ù : ¡u°µ§ë¸ê¡A¬J»Ýn¦³³¥¤ß¤]»Ýn¦³@¤ß¡F¯à°÷©Ó¨ü±o¦í©µ¿ðº¡¨¬¡A¤~¬O¦X¾Aªº§ë¸ê¤H¡v §C»ù¶Rªº©ê¨c´N¬O! ............................................................................................ 2020-02-11 17:39¸gÀÙ¤é³ø °OªÌ³¯®ÑÂ{¡þ§Y®É³ø¾É ¦X¤@¤ÎÃö«Y¥ø·~ ¦@¦P»P°ê»ÚÃļtñ·sÃĬãµo¦X§@³Æ§Ñ¿ý ¦X¤@(4743)¤µ(11)¤é¤½§i¤ÎÃö«Y¥ø·~-¤¤¤Ñ(¤W®ü)¥Íª«¬ì§Þ¦³¤½¥q ¦@¦P»P°ê»ÚÃļtñq·sÃĬãµo¦X§@³Æ§Ñ¿ý¡C ¦X¤@ªí¥Ü¡A¦X¤@¤ÎÃö«Y¥ø·~¡Ð¤¤¤Ñ(¤W®ü)¥Íª«¬ì§Þ¦³¤½¥q¦@¦P»P°ê»ÚÃļtñq·sÃĬãµo¦X§@³Æ§Ñ¿ý¡A¶i¦æ«áÄò¦X§@»P±ÂÅv¦X¬ùij©w¨Æ©y¡A°ê»ÚÃļt±N¨Ì¾Ú³Æ§Ñ¿ý¤ä¥I¥»¤½¥q¤@©wª÷ÃBij¬ùª÷¡A©ó½T»{¦¬¨ì¸Ó¶µÄ³¬ùª÷®É¡A±N¦A¦æ¤½§i¡A³Æ§Ñ¿ý¸Ô²Ó¤º®e°ò©óÂù¤è«O±K¬ù©w¼È¤£´¦ÅS¡C ........................................................................................ 109/12/21 ªYÄ£»P°ê»ÚÃļtñqSNP-810¬ãµo¦X§@¨óij µo¨¥¤H¡G¦¶³Í¥Á 5.µo¥Í½t¥Ñ: ¤@¡B¥»¤½¥qSNP-810·sÃÄ»P°ê»ÚÃļtñq·sÃĬãµo¦X§@¨óij¡A¶i¦æÀø®Ä½T»{µ¥¬ÛÃö¹êÅç¡A°ê»ÚÃļt¨Ì¾Ú¥»¦X§@¨óij±N¤ä¥I¥»¤½¥q¤@©wª÷ÃB¤§Ã±¬ùª÷¤Î¨½µ{¸Oª÷¡C¥Ø«e°ò©ó¹ï¤èn¨D¤§«O±K¬ù©w¡A¤£´¦ÅS¦X¬ù±ø¤å¤Î¬ãµo¾÷±K¤§¤º®e¡A¥]¬A¡GÀø®Ä°t¤è¡B¸ÕÅç³]p¡Bñ¬ù¦X§@¹ï¶H¡Bµ¹¥I»ùª÷¤§ª÷ÃBµ¥¡C ¤G¡B«S¦X§@§¹¦¨¡AÂù¤è°ò©ó¦X§@¨óij¡A¦A¨ó°Ó«áÄòÂX¤j¦X§@µ¥¬ÛÃö¨Æ©y¡A©¡®É±N¥t¦æ¤½§i¡C |
|
|
·|û¡Gop123410143906 µoªí®É¶¡:2020/12/25 ¤W¤È 09:15:21²Ä 418 ½g¦^À³
|
R¤j:Æg°Õ¡I |
|
|
·|û¡Gmeetav10144056 µoªí®É¶¡:2020/12/24 ¤U¤È 12:25:45²Ä 417 ½g¦^À³
|
ªYÄ£SNP-810±ÂÅv¡A·~¬É²±¶Ç¦³¨â®a¤½¥q°Ñ»P¡A¥]¬A¥þ²y«e¤Q¤jÃļt¤¤ªºG¤½¥q»PJ¤½¥q¡C¹ï¦¹¡AªYÄ£µo¨¥Åé¨tªí¥Ü¡AÂù¤èñ¦³«O±K¨ó©w¡A¤£µû½×¥~¬É¶Ç¨¥¡C ¥Í§Þ·~¤º¤H¤h¤ÀªR¡AªYÄ£ªºSNP-810±ÂÅv®×¡A»P°ê»Ú¤j¼t¬¢½Í¤@¦~¦³¾l¡A±ÂÅvª÷ÃB«h¥i¯à¦A¼g¥xÆW·sÃĬö¿ý¡A¬O§_¬D¾Ô¦X¤@ªº5.3»õ¬ü¤¸¡AȱoÆ[¹î¡C ¨Ó¯Â¬Ý«e°ªªº¾Çªø¯à¤£¯à¸Ñ®M¡I¨ì©³¦h¼F®`¡H G or J or? |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/23 ¤U¤È 11:00:03²Ä 416 ½g¦^À³
|
SNP-810µL¨x¬r©ÊAPAP(§Þ³N§t¶q°ª) VS. º¤äAPAP[ÀR¯ßª`®g¾¯](§Þ³N§t¶q§C) SNP-810°ê»ÚÃļt±ÂÅvª÷(¥u¦YªG¤l)? VS. 13»õ¬ü¤¸¶R³Wöæ(Cadence¤½¥q¥u¦³³o¤äÃĪ«®Öã¤W¥«¡AÁÙ¬O¸ò¨ä¥LÃļt¶R¤Jªº) «¥¦¤U¦nÂ÷¤âµ¥Â½©³µP! .......................................................................................... ·|û¡GROGER588910148151 µoªí®É¶¡:2020/9/2 ¤W¤È 11:04:43²Ä 334 ½g¦^À³ 2014.02.11 Mallinckrodt13亿¬ü¤¸¦¬购Cadence¥H获±o镇µh药Ofirmev(º¤ä¹ï¤A酰®ò°ò×ôÀR¯ßª`®g¾¯) www.xinyaohui.com/news/201402/12/1193.html cn.reuters.com/article/cadence-offer-idCNL3N0LG33Q20140211 ---------------------------------------------------------------------------- SNP-810¬O²Ä1¤äµL¨x¬r©Ê¹ï¤A酰®ò°ò×ô·sÃÄ¡A¸Ñ¨M¤Fªñ40¦~¨Ó¹ï¤A酰®ò°ò×ôªº¨x¬r©Ê¡A ¸Ó¦³¦h¤Ö»ùÈ??? |
|
|
·|û¡GROGER588910148151 µoªí®É¶¡:2020/12/23 ¤U¤È 10:39:12²Ä 415 ½g¦^À³
|
¤@¥¹¦w¥þµL¨x¬rSNP-810®Öã¤W¥«¡A¥un±ÂÅvÃļt¹BÄw±cØò¤@µf¡AÄ~2009«áFDA¦A¦¸ªí¨M³q¹Lacetaminophen¤îµhÃĦb¬ü°ê¤U¥«¾÷²v¦³¦h¤j? ....................................................................................... ·|û¡GROGER588910148151 µoªí®É¶¡:2020/7/10 ¤U¤È 10:48:35²Ä 108 ½g¦^À³ 2009/07/02 09:22´¶®³¯kacetaminophen¤îµhÃÄ ¦b¬ü°ê®£¤U¥« ¹«~º[ÃĪ«ºÞ²z§½(FDA)©eû·|ªº±M®a¥H20²¼¹ï17²¼¤ä«ù¸Ó¨M©w¡C city.udn.com/54543/3508510 ¥@¬É¤é³ø¢¬¬üÁpªÀ°¨¨½Äõ¦{¨È¹F´´1¤é¹q¡j 2009.07.01 09:04 pm ¬F©²±M®a30¤éªí¥Ü¡A¥]¬AVicodin©MPercocetµ¥§t¦³´¶®³¯k(acetaminophen)»P³Â¾K¾¯ªº³B¤èÃÄÀ³¸Ó¤U¥«¡A¦]ªA¥Î¹L¶q¥i¯à¾ÉP¦º¤`¡C¹«~º[ÃĪ«ºÞ²z§½(FDA)©eû·|ªº±M®a¥H20²¼¹ï17²¼¤ä«ù¸Ó¨M©w¡C ´¶®³¯k¬O¬ü°ê¨Ï¥Î³Ì¼sªº¤îµhÃĪ«¡A³\¦h¯f¤H¦]¬°´¶®³¯k¤ñ¸û¤£¶ËG¡A©Ò¥HÁקKªA¥Î¥i¯à¾ÉPG¼ìºÅªºibuprofen©Îaspirin(ªü´µ¤ÇÆF)¡A¦Ó¿ï¥Î´¶®³¯k¡C¹Ãħ½ªí¥Ü¡A¾¨ºÞ¦h¦~¨Ó¶i¦æ±Ð¨|«Å¾É¡AªA¥Î´¶®³¯k¹L¶q¬O³y¦¨¨x°IºÜªº¥Dnì¦]¡A¾ÉP¨C¦~¦³5¸U6000¤H¶i¤J«æ¶E«Ç¡C´¶®³¯k³y¦¨ªº60%¦º¤`»P³B¤èÃĪ«¦³Ãö¡C ¤£¹L³\¦h±M®a¤]¤Ï¹ï§â³oÃþ¤îµhÃÄ¥þ±ºM¬[¡A¦]¬°¦¹ºØ²£«~³Q¼sªx¥Î¨Ó±±¨îÄY«ºC©Ê¯kµh¡C ¹Ãħ½±M®a¥H36²¼¹ï1²¼¨M©w¡A¦pªG¸ÓÃþÃÄ«~¤£¤U¥«¡A¸ÓÃþÃÄ«~ªº¼ÐÅÒ¤WÀ³¸Ó¥H¶Â²°¤l(black box)¼Ð¥Ü¡Aĵ§i¸ÓÃþÃÄ«~ªA¥Î¹L¶qªº¦MÀI¡C¶Â²°¤l¬O³ÌÄY«ªº¦w¥þĵ§i¡C®Ú¾Ú¹Ãħ½ªº¼Æ¾Ú¡A¥h¦~¶}¨ã2»õ±i´¶®³¯k³B¤è¡C ¹Ãħ½±M®a¤]¥H21²¼¹ï16²¼¨M©w¡A¤ä«ù°§C¤£»Ý³B¤èªº´¶®³¯k¦¨ÃĨC¤é³Ì°ªªA¥Î¶q¡C ¥Ø«eªº¨C¤é³Ì°ª¥Î¶q¬°¥|§J¡A©Î¬O¤K²ÉExtra Strength Tylenol¡C¸Ó²Õ±M®a¨S¦³´£¥X´À¥N©Êªº³Ì°ªªA¥Î¶q¡C´¶®³¯k¬O³\¦h¥«°â¤îµhÃĦ¨ÃĪº¥Dn¦¨¤À¡A³o¨Ç¤îµhÃÄ¥]¬ATylenol¡BExcedrin©M¨ä¥L¤îµhÃÄ¡C ¸Ó²Õ±M®a¤]¥H24²¼¹ï13²¼ÃÙ¦¨°§C³æ¦¸ªA¥Î³Ì°ª¶q¨ì650²@§J(650mg)¡C¥Ø«e³Ì°ª³æ¦¸ªA¥Î¶q¬°1000mg©Î¨â²ÉExtra Strength Tylenol¡C¹Ãħ½±M®a¦b¥t¤@¶µªí¨M¤¤¡A¨M©w1000mgªºªA¥Î¶q¡A¥²¶·¥ÑÂå®v¶}¨ã³B¤è¡C |
|
|
·|û¡GRock00910149258 µoªí®É¶¡:2020/12/23 ¤U¤È 07:21:39²Ä 414 ½g¦^À³
|
ªYÄ£¡G ¤µ¤Ñ¸gÀÙ¤é³ø³ø¾É¤¤ ¥t¦³¤@¬q¸Üȱoª`·N¡G ¥Í§Þ·~¤º¤H¤h¤ÀªR¡AªYÄ£SNP-810±ÂÅv®×¡A»P°ê»Ú¤j¼t¬¢½Í¤@¦~¦³¾l¡A±ÂÅvª÷ÃB¥i¯à¦A¼g¥xÆW·sÃÄ°O¿ý¡A¬O§_¬D¾Ô¦X¤@ªº5.3 »õ¬ü¤¸¡AȱoÆ[¹î¡C ¡K.¡K ¦pªG¤Wz¤ÀªR¦¨¯u¡A¦X¤@ªÑ¥»35»õ¡AªYÄ£¤~5»õ¡C §A»¡ªYÄ£ªÑ»ù·|¤£·|º¦¨ì¤Ñ¤W¥h¡C ⋯ ¤µ¤Ñªì¥H¨Ó¡A¥«³õ¤@ª½¶Ç»¡¡AªYÄ£ªº±ÂÅvª÷¡A5»õ¬ü¤¸°_¸õ¡I ¤¤¤Ñ丶¦X¤@¬OªYÄ£¤jªÑªF¡A¦ÑÁó¤Õ©ú¥ý¥Íªº¿ï¾Ü§ë¸ê¼Ðªº¤Î²´¥ú丶®æ§½¡A¯uªº¬O¥O¤H´Ü¨Ø¡I |
|
|
|